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Abstract
Whereas most G-protein-coupled receptors (GPCRs) are monomeric in 
structure, y-Aminobutyric acid type B (GABAb) receptors are heterodimers of 
two seven transmembrane protein subunits, GABAB(i) and GABAB(2>. GABAb 
receptor function is dependent upon the co-expression of both these proteins 
which, when individually expressed, are devoid of receptor activity.
Desensitisation of cell surface receptors allows tissues to rapidly adjust 
their response to agonist. A conserved mechanism ensures that GPCR 
signalling is closely followed by desensitisation. This entails the 
phosphorylation of activated receptors enabling interaction with arrestin 
proteins and subsequent internalisation. It is not known if heterodimeric 
GABAb receptors employ this method of desensitisation. Data presented here 
result from experiments to determine whether GABAb receptor cell surface 
stability is controlled in a similar manner to that of other GPCRs. Also 
documented is the study of a putative interaction between the protein kinase 
AMPK and the GABAB(i) subunit.
Initial whole cell labelling studies demonstrated that both GABAB(i) and 
GABAB(2) are basally phosphorylated. Dissimilar to other GPCRs, agonist did 
not increase levels of phosphorylation and this remained true upon 
overexpression of G protein receptor kinases. Because GABAb receptors 
lacked the internalisation promoting increase in phosphorylation upon agonist, 
it was predicted that they might have enhanced surface stability. This was 
confirmed in heterologous systems where GABAb receptors did not 
demonstrably internalise after agonist application even when arrestins were 
overexpressed.
GABAb receptors in cultured cortical neurones showed a similar lack of 
internalisation in response to agonist. Biotinylation of neuronal surface 
receptors demonstrated that GABAb receptors reside for an unusually long 
time at the plasma membrane. Chronic agonist decreased the surface receptor 
half-life, but this did not correlate with an increase in internalised receptor. 
Interestingly, chronic agonist did not significantly reduce total receptor protein 
levels, suggesting GABAb receptors may not downregulate. Protein kinase A
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(PKA) stimulation, both exogenously and through intracellular pathways, 
counteracted the agonist-induced degradation and demonstrated that this 
particular kinase can control GABAb receptor surface numbers. Protection 
from degradation was correlated with increased phosphorylation at serine 892 
within GABAB(2)i a residue previously demonstrated to be a PKA substrate.
Subsequent experiments were carried out to identify kinases capable of 
phosphorylating GABAB(i)a Affinity purification assays isolated a kinase from 
brain able to interact with and phosphorytate a twenty amino acid stretch of the 
carboxy-terminal domain of GABAB(i). Yeast two-hybrid studies identified the 
catalytic a1 subunit of AMPK as a putative interacting protein with GABAB(1). 
AMPK was found to phosphorylate GABAB(i) at serines 917 and 923 within the 
carboxy-terminal domain. Phosphorylation of serine 917 was further confirmed 
with a phospho-specific antibody raised to this residue. a1 AMPK affinity 
purifies with GABAB(1) carboxy-terminal domain GST fusion proteins and also 
co-immunoprecipitates with GABAb receptors from brain. Preliminary 
investigations indicate that AMPK activation increases surface GABAb receptor 
levels in cortical neurones and may affect the protein protein interactions of
g a b aB(1).
The results presented in this thesis suggest GABAs receptors are highly 
stable at the neuronal surface. The activation of PKA and AMPK may be 
mechanisms by which neurones are able to regulate plasma membrane GABAb 
receptors.
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CHAPTER ONE
1.1 The neurone is dedicated to receiving and delivering signals
Of crucial importance to the physiology of multicellular organisms is intercellular 
signalling. In the central nervous system (CNS) neurones are morphologically and 
functionally dedicated to delivering and receiving signals, termed neurotransmission. 
Neurotransmission contains both chemical and electrical components with much of 
the electrical communication via gap junctions. Chemical synaptic transmission is far 
more diverse, both in the type and in the nature of delivery of the chemical signal. 
The amount and identity of neurotransmitter released by pre-synaptic neurones and 
the class and number of receptors present post-synaptically help determine the 
manner of the response. In addition, this response is modulated by rates of 
neurotransmitter uptake and degradation. The effect of transmission on the post- 
synaptic neurone is to change the membrane potential and alter the probability of 
action potential firing. Hyperpolarising signals are therefore inhibitory, moving the 
membrane potential away from the spike threshold for action potentials; whilst 
excitatory signals will depolarise and cause action potential firing.
1.2 Y~Amino-Butyric Acid (GABA) is the major inhibitory neurotransmitter in 
brain
The first neurotransmitter reported to have an inhibitory action was GABA, and its 
discovery opened up the new field of inhibitory neurotransmission. GABA was initially 
isolated from brain tissue in 1950 independently by both Jorge Awapara and Eugene 
Roberts, who also demonstrated its synthesis from glutamic acid (Awapara et al., 
1950; Roberts & Frankel 1950). For a chemical to be classified as a neurotransmitter 
it is accepted that it should be demonstrable that it is synthesised, stored, and 
released from neurones. A site of action should also exist in tandem with a 
mechanism of removal from that site.
The inhibitory action of GABA was first demonstrated in the crayfish where the 
exogenous application of a substance from mammalian brain extracts, termed 'Factor 
P, mimicked the effect of stimulating inhibitory axons at the neuromuscular junction 
(Elliot et al., 1956). This substance was identified as GABA (Bazemore et al., 1957)
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and was observed to be present at high concentrations in crayfish inhibitory axons, 
but virtually undetectable in excitatory motor fibres (Kravitz et al., 1963). It became 
appreciated that GABA application had generally inhibitory effects in both vertebrates 
and invertebrates, and that these effects were matched by changes in ion 
conductance similar to those observed under inhibitory nerve activation (Kuffler & 
Edwards 1958; Kuffler 1960). It was subsequently shown that GABA was released 
from the inhibitory axon in a calcium dependent manner (Otsuka et al., 1966).
GABA is synthesised through de-carboxylation of the amino-acid L-glutamate by 
the enzyme glutamic acid decarboxylase (GAD). GAD exists as two major isoforms 
GAD 65 and 67, which differ in their kinetics, sensitivity to the presence of co-factor 
pyridoxal 5-phosphate and cellular localisation (Martin & Rimvall, 1993). Synthesis 
occurs in the cytosol of inhibitory neurones from where GABA is loaded into vesicles 
ready for release by vesicular neurotransmitter transporter (VGATs) (Fon & Edwards 
2001).
It has become apparent that most classical neurotransmitters, including GABA, 
have both rapid and modulatory effects. This is achieved through activity at two 
different classes of receptors; ionotropic and metabotropic receptors, lonotropic 
receptors are responsible for the fast effects of neutrotransmitters, whilst the slower 
action is through metabotropic receptors.
1.3 The ionotropic GABA response
The ionotropic GABA response was the foremost to be characterised and is 
elicited through GABAa receptors (Macdonald & Olsen 1994). GABAa receptors were 
the first GABA receptors to be cloned (Schofield etal., 1987). This revealed that they 
belong to the ligand gated ion channel superfamily of receptors, homologous to 
nicotinic acetylcholine receptors, glycine receptors and 5 -HT3 receptors amongst 
others. GABAa receptors are hetero-oligomers of five subunits, each with four 
transmembrane domains, a large extracellular N-terminus and an intracellular 
carboxy-terminal tail (Macdonald & Olsen 1994) The pentameric nature of the 
GABAa receptor leaves a central pore lined by the second transmembrane domain of 
each subunit. The division between each subunit forms extracellular clefts that in 
conjunction with the N-terminal domain that are thcught to form ligand binding sites.
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Agonist binding allosterically alters the structure of the receptor, allowing the 
selective flow of anions through the central pore (Macdonald & Olsen 1994). This 
selectivity is dictated by the amino-acid composition of the second transmembrane 
domain of each subunit. The pore of the GABAa receptor is permeable to Cl‘ ions 
and, to a lesser extent, HCO3' ions (Bormann et al., 1987; Kaila 1994). In the mature 
neurone the extracellular concentration of Cl- ions is approximately 120mM while 
intracellularly the concentration is 7mM. Upon activation of GABAa receptors, chloride 
ions flow down the concentration gradient, hyperpolarising the neurone. The 
exception to this is seen in embryonic neurones where the chloride gradient is 
reversed, resulting in excitation through GABAa activity.
A large number of different GABAa receptor subunits are expressed and are 
grouped according to sequence homology into a(1-6),p(1-3),Y(1-3),8,e,7i and 0 
subunits (Sieghart & Sperk 2002). Additional variability is also provided by the 
existence of alternate splice variants of certain subunits. The existence of so many 
subunits is probably a product of genetic duplication throughout evolutionary history. 
Although a huge number of receptors are theoretically possible due to different 
subunit permutations, this does not appear to be the case; and instead certain 
subunit combinations are favoured (McKernan & Whiting 1996). However, there is 
Still considerable variability in GABAa receptor composition, leading to heterogeneity 
in GABAa expression patterns, targeting and pharmacology.
GABAa receptor mediated inhibition is fast, i.e. it is rapidly activated and 
inactivated. GABAa receptor pharmacology is complex, receptors having a Hill 
coefficient of 2 for GABA indicating the presence of 2 GABA binding sites, both of 
which must be occupied for maximal response. The extracellular surface of GABAa 
receptors also provides other ligand binding sites including ethanol, benzodiazepines, 
barbiturates and endogenous neurosteroids. Benzodiazepines act as allosteric 
modulators enhancing the GABA induced current by increasing the frequency of 
channel opening, but not acting as agonists in their own right (Study & Barker 1981). 
At low concentrations barbiturates also enhance GABA induced current, probably by 
increasing the duration of channel opening, whilst at high concentrations barbiturates 
act as agonists. Ethanol and neurosteroids such as 5-a-pregnanolone again enhance 
GABA mediated current through the receptor by allosterically modulating its structure.
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GABAa receptors are inhibited by bicuculline, although sensitivity to other antagonists 
such as to picrotoxin is modified by receptor subunit composition. The variable 
composition of each receptor can also dictate differential targeting of the receptor 
within a neurone, with receptors containing y subunit being targeted to the synapse 
whilst others are targeted to extrasynaptic regions. Because different neurones 
express different subunits, areas of the brain can become pharmacologically distinct.
GABA also activates another class of ionotropic receptors that are closely related 
to GABAa receptors and are termed GABAC receptors. GABAC receptors are 
pharmacologically distinct from GABAa receptors, being insensitive to bicuculline and 
activated by the selective agonist c/s-4-aminocrotonic acid (CACA). GABAC receptors 
are also stimulated by the GABAa agonist muscimol and are actually more sensitive 
to GABA, although they desensitise more slowly and show no modulation by 
benzodiazepines or neurosteroids (Bormann and Feigenspan, 1995). GABAC are 
believed to be structurally similar to GABAa receptors but are composed of novel 
subunits designated p1 and p2 in either a homo- or heteropentameric manner.
GABAc expression in the brain is limited probably to p2 subunits with most GABA c 
receptors being found in the retina especially in bipolar cells (Bormann & Feigenspan, 
1995).
1.4 The metabotropic GABA response
1.4.1 Discovery of GABAb receptors
Much of the early work characterising the inhibitory action of GABA utilised the 
drug bicuculline, which antagonised the effect of GABA application. Resistance to 
bicuculline antagonism though was described (Straughan etai, 1971), demonstrating 
that bicuculline was not a universal GABA receptor antagonist. This bicuculline 
insensitive GABA response appeared to be especially prominent in sympathetic 
nerve terminals, where it decreased evoked neurotransmitter release (Bowery & 
Hudson 1979, Brown & Higgins 1979).
Crucial to deducing the nature of the bicuculline insensitive GABA response was 
the drug (-)P-p-chlorophenyl-GABA (baclofen). Baclofen was initially conceived as a 
lipophilic gabamimetic, and indeed it proved to have an inhibitory quality (Mott &
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Lewis 1994). However, the inhibitory effect of baclofen was also bicuculline 
insensitive (Curtis et al., 1974). Moreover, baclofen was inactive at sites that had 
been previously characterised as bicuculline sensitive, yet was as effective as GABA 
in reducing neurotransmitter release. These inconsistencies meant that it was 
generally considered that baclofen did not act at GABA receptors. In 1980 Bowery 
and co-workers demonstrated the presence in the CNS of a receptor to baclofen 
(Bowery et al., 1980). They determined that baclofen diminished the evoked release 
of radiolabelled neurotransmitter from cortical and cerebellar slices, an effect that 
was mimicked by GABA. This led them to propose that both GABA and baclofen may 
indeed act at the same site to inhibit neurotransmitter release (Bowery et al., 1980). 
Evidence to support this hypothesis was produced the following year with the 
demonstration that baclofen could displace tritiated GABA from rat brain membranes 
(Hill & Bowery 1981). Previous groups had shown that, at best, baclofen could only 
weakly displace tritiated GABA (Galli et al., 1979; Horng et al., 1979), however Hill 
and Bowery showed that upon the inclusion of divalent cations in the binding 
solutions a much larger pool of GABA could be displaced. Indeed, GABAb receptor 
binding was the first to be described that required the presence of physiological 
concentrations of divalent cations (Hill & Bowery 1981). Because the classical GABA 
agonist isoguvacine could not displace baclofen, the isoguvacine binding site was 
termed the GABAa receptor, whilst the novel GABA and baclofen binding site was 
designated the GABAb receptor (Hill & Bowery 1981).
1.4.2 GABAb receptors couple to heterotrimeric G-proteins
Further studies identified a large number of differences, apart from agonist and 
antagonist sensitivity, between GABAa and GABAb receptors. The most salient 
observation was that GTP potently inhibits GABAb receptor binding (Hill et al., 1984; 
Asano et al., 1985). This inhibition is due to a reduction in receptor affinity for agonist 
and not receptor binding capacity. Sensitivity to GTP was GABAb specific with no 
effect of nucleotides at GABAa receptors; and the effect was confined to GTP, with 
other nucleotides such as ATP having no effect (Hill et al., 1984; Asano et al., 1985). 
Sensitivity to GTP had been previously demonstrated with several other receptors 
including those for dopamine (Freedman et al., 1981), adrenergic receptors
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(U’Prichard & Snyder, 1978) and opiate receptors (Pert & Taylor, 1980). These 
receptors couple to G proteins, and because GTP sensitivity is a hallmark of G 
protein coupled receptors (GPCRs), it suggested that GABAb receptors belong to this 
class of receptor. Further evidence that GABAb receptors are indeed GPCRs was the 
effect of solubilisation on GABAb receptor binding. In contrast to GABAa receptors, 
where solubilisation has little effect upon agonist binding, it was noted that 
solubilisation prevents GABAb receptor binding. This supported the notion that 
GABAb receptors couple to G proteins, with detergents that disrupt the receptor:G 
protein interaction removing agonist binding. Also demonstrated was the ability of the 
inhibitory G protein inactivator, pertussis toxin, to decrease GABAb receptor binding 
in brain membranes (Asano et al., 1985), indicating that GABAb receptors couple to 
inhibitory G proteins. Finally, it was shown that baclofen enhances GTPase activity in 
brain membrane preparations, with this enhancement greatest in areas with the 
highest concentration of GABAb receptors (Hill et al., 1989; Bowery et al., 1989). This 
indicated that GABAb receptor activation stimulated GDPiGTP exchange, a property 
of GPCRs.
1.5 G Protein-Coupled Receptors (GPCR’s)
1.5.1 G proteins act as signal transducers
Unlike ionotropic receptors, which are also the effectors of agonist activity, 
GPCRs utilise a transducer, a G protein, to couple to effector proteins. G proteins are 
named after their ability to bind guanine nucleotides, specifically GTP and GDP. They 
have an inherent GTPase activity, catalysing the hydrolysis of GTP to GDP. Binding 
of GTP to a G protein switches it ‘on’ and it is able to couple to effectors. The period 
of coupling is dictatated by the rate of GTP hydrolysis; with hydrolysis terminating 
effector coupling and leaving the G-protein GDP bound. This rate can be modulated 
by a host of other proteins including regulators of G-protein signalling proteins 
(RGS’s) and GTP exchange factors (GEF’s) (De Vries et al., 2000; Ross & Wilkie 
2000). Early purification studies of G-proteins that couple to GPCR’s elucidated that 
they are composed of three independent proteins an a, a p and a y subunit (Gilman 
1987). The a subunit binds guanine nucleotides and possesses GTPase activity. The
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activated receptor acts as a GEF to the a subunit, allosterically modulating the G- 
protein to exchange bound GDP for GTP and so switching it ‘on’. Reciprocally, the 
activated G protein reduces the affinity of the receptor for agonist, promoting ligand 
removal. This is why a high concentration of GTP can prevent GPCR agonist binding, 
because by shifting the equilibrium towards GTP bound G-proteins it also shifts the 
GPCR agonist affinity in a negative direction.
1.5.2 Structural analysis elucidates mechanisms of G-protein action
Crystallisation studies of the heterotrimeric G-proteins have shed further light on 
their ability to link the GPCR to effector molecules (Lambright et al., 1996). The a 
subunit is composed of three domains: a Ras-like GTPase domain, a helical domain 
and an N-terminal helix projecting away from the rest of the protein. The N-terminus 
is subject to myristoylation aiding the membranous localisation of the a subunit. The 
GTPase and helical domains form a cleft where guanine nucleotide binding occurs. In 
a GDP bound state the a subunit binds to the p subunit over two distinct interfaces 
called the ‘switch I* and ‘switch IT regions (Lambright et al., 1996). The y phosphate of 
GTP is capable of interacting with residues unaffected by GDP and in doing so 
causes a confirmational change that removes the switch I and II regions from close 
proximity to the p subunit, thus dissociating the complex (Lambright et al., 1996).
In contrast to the more flexible a subunit, the p and y subunits form a tightly 
associated rigid unit. The p subunit is a canonical water filled ‘propeller* with seven 
blades and an approximate seven-fold symmetry (Sondek et al., 1996). The y subunit 
partially encircles the p subunit with the N-termini of each subunit forming parallel 
coiled coils. Post-translational farnesylation of the y subunit N-terminus aids 
membranous localisation of the complex. Each blade of the p propeller is a WD 
repeat motif of approximately 40 amino-acids terminating in a tryptophan-aspartate 
dipeptide. The y subunit does not appear to directly interact with the a subunit, the 
interaction of the py complex being mediated by amino-acids at one end of the 
p propeller. The py subunit is also able to interact with the receptor, probably playing 
a role in the receptor catalysed GTP exchange. Dissociation of the Py subunit upon 
GDP-GTP exchange in the a subunit reveals residues at the end of the propeller that
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mediate interaction with the switch I and II regions of the a subunit. These residues 
are implicated in effector coupling and so the py complex is activated.
Both the a and Py subunits of the G-protein are capable of coupling to effectors. 
However, it is the a subunit that determines the activity of the heterotrimer with 
nucleotide exchange promoting a structural reorganisation. In contrast there is little 
change in the Py subunit on nucleotide exchange, its activity being solely regulated by 
the confirmation of the a subunit. Binding of the a subunit negatively regulates py 
activity not only by masking important amino-acids responsible for effector coupling 
but also by restricting the degrees of freedom of the complex, thus making other 
interactions impossible. The precise extent to which the heterotrimeric G protein 
physically dissociates upon activation remains controversial (Klein et al., 2000), but it 
is clear that to activate effectors some form of detachment occurs.
1.5.3 Heterotrimeric G-proteins couple to a large array of effector proteins
In contrast to the rapid action of an ionotropic receptor, where agonist binding 
elicits an almost immediate effect through the receptor, the activation of a GPCR is 
slow. Agonist binding enhances receptor affinity for G proteins, which in turn, bind 
receptors and exchange GDP for GTP leading to dissociation of G protein subunits. 
Only then can effectors be activated. Although this may appear to be an inefficient 
process, it is quite the reverse. Because one given GPCR can couple to more than 
type of G-protein it allows a receptor to have multiple effects and these can be either 
temporally and spatially separated or concurrent. Signalling through G-proteins also 
has other advantages including a multiplicative effect where a small signal can give a 
large response due to the ability of the receptor to couple to several orders of 
magnitude higher number of G-proteins. GPCR signalling can act over a longer time 
frame than ionotropic signalling, due to the property whereby it elicits an 
accumulation of metabolites which continue to exert an effect after cessation of 
receptor activity.
1.5.4 GPCRs exhibit a seven-helical transmembrane domain structure
The sequencing of the light sensitive GPCR rhodopsin allowed the first analysis 
of a GPCR structure (Hargrave et al., 1983; Ovchinnikov 1982; Nathans & Hogness
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1983). This showed seven hydrophobic stretches of amino acids that were putative 
a-helical transmembrane (TM) domains, connected by hydrophilic loops with a 
proposed extradiscal N-terminal domain and intracellular C-terminus. After the 
cloning of the p2 adrenergic receptor which showed a remarkably similar composition 
(Dixon et al., 1986), it became apparent that this structure may be common to all 
GPCRs. The solving of the crystal structure of rhodopsin has further elucidated this 
arrangement; demonstrating a 7TM collection of a helices joined by variable length 
loops arranged, when viewed from outside the cell, in an anti-clockwise manner 
(Palczewski et al., 2000).
The importance of GPCRs within an organisms signalling repertoire is illustrated 
by the number of receptors within the genome; with 5% of c.elegans genome 
dedicated to ~1100 receptors (Bargmann 1998). Within vertebrates a similar number 
of different GPCRs exist, and are involved in processes as diverse as taste and 
olfacation to regulation of neuronal activity, reflecting the evolutionary effectiveness 
of such a signalling mechanism.
GPCRs can be subdivided along the lines of sequence similarity into families A,B 
and C. Family members tend to share over 25% sequence identity across their 
transmembrane domains as well as possessing other highly conserved familial 
characteristics (Bockaert & Pin 1999). Between the three families there is very little 
sequence similarity with possession of predicted 7TM domains being the only 
common feature (Bockaert & Pin 1999; Pierce etal., 2002).
Family A contains the archetypal GPCRs rhodopsin, and p adrenergic receptors, 
along with receptors to dopamine and the muscarinic acetylcholine receptors. Other 
GPCRs belonging to family A include all of the olfactory receptors (~200), making it 
by far the largest class of GPCR. Family A GPCRs characteristically possess a small 
N-terminal extracellular domain and a large third intracellular loop, with variable 
length intracellular carboxy-terminal domains. The majority of family A receptors are 
activated by small ligands. These are believed to fit into pockets created on the 
extracellular surface deep between the transmembrane domains. Ligand binding 
alters receptor confirmation, rearranging transmembrane domains 6 and 3 amongst 
other movements (Ballesteros et al., 2001; Farahbakhsh et al., 1995). This 
movement is transmitted to the intracellular side of the receptor and is thought to
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unmask G protein binding sites, allowing the catalysis of G protein guanine 
nucleotide exchange. Mutational analysis of several family A members supports this 
theory, with mutations of the proposed ligand binding sites able to remove agonist 
sensitivity. Mutations of putative binding sites can also cause constitutive receptor 
activity if they place receptors in a state analogous to that adopted when ligand is 
bound (Bockaert & Pin 1999; Pierce et al., 2002).
Family B is much smaller and consists of receptors sensitive to peptides such as 
the secretin receptor and the vasoactive peptide receptor. It appears that all 
members of family B couple to G-proteins to positively regulate adenylyl cyclase. Like 
family A the transmembrane domains of family B receptors are believed to be 
involved in ligand binding, as are extracellular the loops. The comparative bulk of 
peptides to ligands of family A means that the ligand binding site is probably not so 
deeply buried within the transmembrane domains of the receptor, and there is also 
evidence to support a role for the N-terminus of certain family B receptors in ligand 
binding.
When metabotropic glutamate receptors (mGluRs) were initially cloned 
(Houamed et al., 1991; Masu et al., 1991) it was apparent that they were very 
dissimilar to previously cloned GPCRs and they were proposed to belong to a 
separate GPCR family (Nakanishi 1994), which became family C. Family C receptors 
are the most phylogenetically disparate group of GPCRs. Several other family C 
receptors have been identified in addition to mGluRs including taste receptors (TiRs), 
putative pheromone receptors, calcium sensing receptors and also GABAb receptors 
(Bockaert & Pin 1999). Whereas most GPCR’s are 400-500 amino-acids in length 
and typically have molecular weights in the region of 50-60kDa, family C receptors 
are much larger with molecular weights often well over 100kDa. The seven 
transmembrane domains are found towards the end of family C sequences due to the 
large (often in excess of 500 amino-acids) N-terminal extracellular domain (NTED) 
(fig.1). Another feature of the NTED common to family C receptors is the presence of 
a region showing homology to bacterial periplasmic binding proteins (PBPs), first 
described in mGluRs (O’Hara et al., 1993). PBPs are involved in the transport of 
amino-acids and ions across bacterial membranes and their role in family C
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receptors is thought to be analogous to this in that they bind the amino-acid or ionic 
ligands required for receptor activation. This characteristic of family C GPCRs 
appears to have evolved through the gene fusion of a primordial amino-acid-binding 
protein and an ancestral 7TM receptor (Nakanishi 1994). Within the mGluRs the 
amino-acid binding area shows a high degree of similarity to that found in the 
ionotropic glutamate AMPA and NMDA receptors (O’Hara et al., 1993). Between the 
amino-acid binding domain and the first transmembrane domain lies a stretch of 70 
amino-acids containing 9 highly conserved cysteine residues, reminiscent of those 
found in transmembrane tyrosine kinase receptors (Aaronson 1991). This cysteine 
rich region is thought to be important in ligand binding interactions and is lacking in 
GABAb receptors. The intracellular loops of family C receptors are small in 
comparison to those of other GPCRs- often less than 10 amino-acids in length whilst 
the intracellular carboxy-terminal domains are of moderate length, being normally 
100 amino-acids.
1.5.5 GPCRs share a conserved desensitisation mechanism
Evolution preserves successful mechanisms, and as organisms become more 
complex, these systems are employed over and again. Organisms need to be able to 
receive and transduce signals and GPCRs are an efficient solution to this, as 
evidenced by their phylogenetic conservation. In a similar manner a conserved 
system has developed and is utilised by a wide variety of GPCRs to ‘switch off 
receptor activity i.e. mediate desensitisation.
The primary step in GPCR desensitisation is phosphorylation. This can be 
mediated by classical second messenger activated kinases such as PKA and PKC 
(so called heterologous desensitisation), or by specific G protein receptor kinases 
(GRKs) (homologous desensitisation). GRKs belong to a gene family encoding 7 
kinases (GRKs 1-7), and they specifically phosphorylate G protein coupled receptors 
(Pitcher et al., 1998). Importantly, GPCRs that are in an active confirmation are far 
more amenable to GRK phosphorylation, allowing GRKs to preferential ‘label’ 
activated receptors. In addition to this the agonist occupied receptors potently 
stimulate GRK activity (Pitcher et al., 1998). GRKs themselves are subject to 
palmitoylation, keeping them in close proximity to the membrane, and are able to
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directly interact with G protein (3y subunits (Pitcher et al., 1992) which is important for 
their activation. GPCRs that are substrates for GRKs usually have multiple serine 
and threonine residues in regions responsible for coupling to G proteins, usually the 
second and third intracellular loops in conjunction with the carboxy-terminal 
intracellular domain. Phosphorylation of these residues may promote uncoupling from 
G proteins, but more importantly, greatly enhances the affinity of GPCRs for 
arrestins. These are a class of protein belonging to a gene family containing four 
different isoforms (visual arrestin, cone arrestin, arrestins 2 & 3 (formerly p-arrestin 1 
& 2)) that when bound to phosphorylated GPCRs prevent G protein coupling (Pierce 
et al., 2002; Luttrell & Lefkowitz 2002). The tertiary step in GPCR desensitisation is 
the internalisation of the GPCR into clathrin-coated vesicles. Arrestins are crucial to 
this step, acting as bridging molecules between adaptin proteins (hetero-oligomeric 
protein complexes involved in the intracellular trafficking of proteins) and 
phosphorylated GPCRs.
The process of vesicle formation from surface membranes is too complex to be 
covered in depth here, but briefly involves the formation of clathrin-coated pits around 
the molecules to be endocytosed. Adaptin 2 (AP2) is thought to be the main adaptin 
involved in endocytosis, and assists the formation of clathrin coated pits by binding 
both clathrin and arrestins. Clathrin structure is such that as oligomers of clathrin 
build-up they cause curvature of the membrane and subsequent invagination. The 
final step in vesicle formation is the separation of this invaginated pit from the rest of 
the membrane. The GTPase dynamin, in tandem with other proteins of the 
endocytotic machinery such as ampiphysin, is central to this step and catalyses the 
‘pinching’ of vesicle necks causing vesicle formation.
GPCR endocytosis can rapidly alter the number of receptors at the surface, 
thereby causing a desensitisation of the response. Complexed GPCR arrestin 
molecules can also form intracellular scaffolds that mediate a variety of downstream 
actions. Once a GPCR has been endocytosed, it can be dephosphorylated by 
specific phosphatases (Pitcher et al., 1995) and recycled to the surface membrane, 
or it can be degraded via late endosomes and lysosomes. It is now thought that not 
all GPCR endocytosis occurs in an arrestin and clathrin dependent manner. GPCR 
endocytosis can also occur into caveolae, although this appears to be somewhat
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Figure 1: Illustration of the multiple steps in GPCR desensitisation
1. Agonist binding activates receptors which in turn catalyse GTP:GDP exchange 
within heterotrimeric G proteins.
2. Dissociation of heterotrimeric G protein subunits allows coupling to effector 
proteins. GRKs are able to interact with activated receptors which reciprocally 
elicit GRK activity.
3. GRK phosphorylation of multiple residues within the intracellular loops 
and carboxy-terminal intracellular domain of the GPCR promotes binding to 
arrestin proteins.
4. Arrestins sterically prohibit further G protein coupling and facilitate 
internalisation into clathrin coated pits.
5. Internalised GPCRs are dephosphorylated by GPCR specific phosphatases 
causing arrestin dissociation from followed by recycling to the membrane. 
Alternatively, receptors are trafficked to late endosomes and lysosomes for 
degradation.
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receptor and cell type specific. It is thought that the caveloae mechanism of GPCR 
endocytosis is secondary to that mediated through the arrestin pathway, which under 
physiological conditions predominates (Ferguson 2001).
1.5.6 Post-translational modifications of GPCRs
GPCRs are subject to a number of important post-translational modifications that 
help to maximise receptor coupling efficiency, and tailor receptor activity to specific 
cellular demands. The phosphorylation of GPCRs is most closely associated with 
desensitisation mechanisms, as covered above. Other roles for phosphorylation of 
GPCRs have also been uncovered outside this context. Notable illustrations of 
alternative roles of phosphorylation include the ability of phosphorylation of the |32 
adrenergic receptor at residue ser216 to switch coupling from Gs G proteins, to which 
they normally efficiently couple, to Gj G proteins (Daaka et al., 1997). It has also been 
shown that PKA phosphorylation of GABAb receptors can paradoxically delay the 
onset of desensitisation (Couve et al., 2001). Phosphorylation is able to promote 
changes in the intermolecular interactions of GPCRs. One such example is observed 
in the interactions of mGluR7 which binds directly to active calmodulin or G protein j3y 
subunits in a mutually exclusive manner via residues in its intracellular carboxy- 
terminal domain. The binding of (3y subunits renders mGluR7 unable to couple to 
Ca2+ channels, but this ability is restored in the presence of activated calmodulin. 
Phosphorylation of ser862 within mGluR7 prevents these interactions and alters 
mGluR7 activity, permitting coupling to Ca2+ channels (El Far & Betz 2002).
Post-translational palmitoylation of specific cysteine residues within many GPCR 
intracellular carboxy-terminal domains increases the hydrophobicity of this region, 
and has been proposed to allow the formation of a fourth intracellular loop. 
Preventing the palmitoylation of |32-adrenergic receptors through mutagenesis of the 
putative palmitoylation site leads to an uncoupled GPCR (O’Dowd et al., 1989). The 
observation that the majority of GPCRs have conserved cysteine residues within or at 
the end of their carboxy-terminal intracellular domain (GABAb receptors included) 
means that this may be a highly conserved modification amongst GPCRs to enhance 
coupling and perhaps modulate targeting.
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Post-translational glycosylation is almost universal amongst GPCRs, and indeed 
the presence of immature glycol groups can be used as a marker of retention within 
the endoplasmic reticulum (ER) and is also used to trigger ER associated 
degradation. The precise functions of GPCR glycosylation are poorly understood, but 
glycosylation may play a role in receptor folding and targeting, and also mediating 
interactions on the extracellular surface of GPCRs.
1.5.7 Monomeric or polymeric?
The ‘classical’ view of GPCRs describes them as monomeric entities that contain 
all the necessary information within their structure to correctly traffick and couple to G 
proteins. The tenet that GPCRs function solely as monomers has never been 
conclusively proved though; and data is accruing that challenges the monomeric 
dogma. It transpires that certain GPCRs require the presence of accessory 
molecules to confer activity, whilst others form dimers or higher order structures 
(Bouvier 2001).
The first evidence that a GPCR may require an accessory protein to mediate 
activity concerned the calcitonin-receptor-like receptor (CRLR). CRLR was initially 
proposed to be the calcitonin gene related peptide receptor (CGRP) (Njuki et al.,
1993) but appeared inactive in heterologous systems. It was subsequently 
discovered that activity was conferred upon the co-expression of a protein called 
RAMP (receptor-activity-modifying protein) (McLatchie et al., 1998). RAMP was a 
member of what emerged to be a family of 3, single transmembrane domain proteins 
(RAMP1-3) which showed no resemblance to GPCRs. CRLR became the CGRP 
(calcitonin gene-related peptide) upon the co-expression of RAMP 1, and the 
adrenomedullin receptor when co-expressed with RAMP2 (McLatchie etal., 1998).
The possibility that GPCRs may form dimeric or even oligomeric structures was 
entertained in the early days of GPCR research, when ligand binding studies of |32 
adrenergic receptors demonstrated co-operativity, i.e. the ability of the presence of 
one ligand to alter the receptor affinity for the second (Limbird & Lefkowitz 1976). It 
has since been shown that certain receptors, including the p2 adrenergic and 
muscarinic receptors, can be immunoprecipitated as homodimers from transfected 
cell lines (Herbert et al., 1996; Zeng et al., 1999). Endogenously expressed
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adenosine Ai receptor and dopamine receptors have also been observed to form 
dimers (Ciruela et al., 1995; Ng et al., 1996) and it is now accepted that dimerisation
may play a role in GPCR activity. Heterodimerisation between different GPCR
subtypes has been proposed as a mechanism whereby novel receptors with altered 
pharmacology may be formed, an example being the heterodimerisation of 8 and k 
opioid receptors (Jordan & Devi 1999). Mechanistically it has been argued that the 
formation of a dimer may allow more efficient coupling to G proteins (Bouvier x); and 
the idea of ‘rafts’ of GPCRs complexing with conveniently juxtapositioned effectors is 
appealing. Whether oligomerisation is a universal feature of GPCR structure is 
contentious, indeed, the crystal structure of rhodopsin does not necessarily support it 
forming dimers (Palczewski et al., 2000). It is more probable that dimerisation is a 
property that has evolved within some GPCR members as receptors have diverged. 
In family C GPCRs dimerisation is obligate though, and this was first shown with the 
advent of the heterodimeric GABAb receptors, which is covered in greater detail 
below.
1.6 GABAb receptor molecular biology
1.6.1 Cloning reveals similarities to mGluR receptors
The cloning of the p2 adrenergic receptor signified the beginning of a period in 
which receptors to most major neurotransmitters and hormones were rapidly 
identified. This was due in part to the relative sequence similarities of receptors, 
allowing the use of degenerate primers to clone putative receptors, and also new 
bioinformatic techniques. Although purification from bovine brain of a putative GABAb 
receptor with an Mr 80kDa was reported in 1993 (Nakayasu et al., 1993), no amino- 
acid sequence was divulged. Indeed GABAb receptors remained elusive until 1997 
(Kaupmann et al., 1997), 11 years after the cloning of the p2 adrenergic receptor. 
This resistance to cloning was attributable partly to the dearth of ligands that retained 
high affinity for the receptor under solubilising conditions, and also to the lack of cell 
lines expressing large amounts of receptor protein.
Antagonists, unlike agonists, can bind to receptors independently of G-protein 
coupling, allowing antagonist binding to crude membrane preparations. To clone
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GABA b the novel high affinity radiolabelled GABAb antagonists [125l] CGP64213 and 
[125l] CGP71872 were designed. These antagonists blocked both the pre and 
postsynaptic GABAb response and had dissociation constants of 1 .OnM (Kaupmann 
et al., 1997). [125l] CGP71872 is a photoaffinity ligand, covalently binding proteins 
upon exposure to UV light. Brain membranes were incubated with [125l] CGP71872, 
washed thoroughly and then exposed to UV light. The membrane preparation was 
then analysed using SDS-PAGE. Using this technique two specific bands of 
approximately 100kDa and 130kDa were radiolabelled, indicating the antagonist 
bound two separate proteins. Subsequent to this a brain cDNA library was 
transfected into COS cells which were screened for expression of proteins that would 
bind the antagonist. Using this technique a clone encoding a 960 amino-acid protein 
was isolated, designated GABABR1a (NC-IUPHAR now designates GABAb receptors 
GABAB(X,y) where X= subunit and Y = splice variant -  this nomenclature is adhered to 
throughout the rest of this thesis). The cDNA for a second 844 amino-acid receptor, 
GABAB(ib), was isolated by screening a cDNA library with GABAB(ia) cDNA. GABAB(ia) 
and GABAB(1b) are identical except at the N-terminus with the first 144 amino-acids of 
GABAB(ia) replaced with 18 different residues in GABAB(i b), indicating that they are 
alternate splice variants of the same gene. Sequence analysis predicted a 7TM 
GPCR like structure for GABAB(1a) and GABAB(1b); with their size and large NTED 
(accounting for over 50% of each protein), placing them in GPCR family C. Similar to 
other family C GPCRs, GABAB(ia) and GABAB(ib) possess domains with homology to 
bacterial periplasmic binding proteins (also known as Leucine Isoleucine Valine 
Binding Proteins (LIVBP’s)) in the extracellular N-terminus. It should be noted 
however that the amino-acid sequence identity of GABAB(ia) and GABAB(ib) with 
members of the mGluR family is comparatively low with mGluR receptors retaining a 
similar identity to iontropic glutamate receptor subunits. All mGluRs share 21 highly 
conserved cysteine residues, including the N-terminal cysteine rich domain, that are 
considered a hallmark of the receptor, but these are mostly missing in GABAb 
receptors. GABAB(i) showed weak similarities to naturetic peptide receptor, selectins 
and complement receptor type I (Kaupmann et al., 1997).
When expressed in recombinant systems GABAB(1a) and GABAB(ib) yielded 
proteins of Mr 130kDa and 100kDa respectively, identical to the Mr of the proteins
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photoaffinity labelled with [125l] C G P 71872 in brain membranes. GABAB(ia) and 
GABAB(ib) also bound antagonists with similar affinities to native proteins, and both 
were shown to negatively regulate adenylyl cyclase upon exposure to GABA or 
baclofen in stably transfected HEK cells (Kaupmann et al., 1997). This was strong 
evidence that the proteins responsible for the metabotropic GABA response had 
been identified. Anomalous to this supposition was that the agonist affinity of 
heterologously expressed proteins was 100-150 fold lower than in native systems, 
and adenylyl cyclase regulation was weak (Kaupmann et al., 1997).
1.6.2 GABAb receptors are heterodimeric in nature
Although initially described as functional (Kaupmann et al., 1997), it became 
apparent that the pharmacology of the cloned GABAb receptor did not match that of 
native GABAb receptors. Recombinant expression of tagged GABAB(1) in a variety of 
cell lines failed to demonstrate the surface trafficking of functional receptor with all 
receptor intracellularly retained within the endoplasmic reticulum (ER) (Couve et al.,
1998). ER retention is a common property of proteins that form part of multimeric 
complexes and prevents the inappropriate surface trafficking of unassembled 
subunits (Teasdale & Jackson 1996). In an acute prediction, it was suggested that 
GABAB(i) contained an ER retention element and that additional information, such as 
the co-expression of another protein, would be needed to allow the surface trafficking 
of functional receptors in a recombinant system (Couve et al., 1998).
The form of this additional information was indeed another protein; termed GABAb 
R2 (GABAB(2)) it had a 7TM topology and was concurrently identified by several 
groups (Jones et al., 1998; Kaupmann et al., 1998; White et al., 1998; Kuner et al.,
1999). They demonstrated that only upon co-expression with GABAB(2) could 
GABAB(i) form a functional receptor with similar pharmacological properties to native 
receptors. This discovery redefined the GPCR paradigm because in essence it 
demonstrated that GABAb receptors were composed of two individual subunits. 
Moreover, succeeding analysis of GABAb receptor elicited closure of Ca2+ channels 
in sympathetic neurones verified that coupling was only possible upon coexpression 
of both subunits (Fillipov et al., 2000). Some groups observed that whilst GABAB(2) 
alone could couple to adenylyl cyclase (Martin et al., 1999; Kuner et al., 1999), the
32
TM l-VII
a)
100 200 300 400 500 600 700 800 900
4 -
100 200 900300 400 600 700 800
(32-adrenergic
400300200100
N- terminal Venus Fly Trap Modules
Transmembrane domains
GABA0(2)
GABAb<i )
Figure 2 GABAb receptor structure
a) Kyte-Doolittle hydropathicity indices of both GABAb receptor subunits 
aligned along their transmembrane domains. Highlighted in red are the putative 
coiled coils within each subunit, important for mediating interactions between 
the intracellular carboxy-terminal domains. Also shown for comparison is the (32 
adrenergic receptor, a family A GPCR. Note the far larger N-terminal domains of 
the family C GABAb subunits, whilst the (32 adrenergic receptor shows a much 
larger 3rd intracellular loop.
b) Cartoon of the proposed topology of the heterodimeric GABAb receptor. 
Interactions between the two subunits occur within the extracellular N-terminal 
domains, transmembrane domains and intracellular carboxy-terminal located 
coiled coils. The N-terminal domains are thought to be composed of venus fly­
trap modules, with ligand binding within the groove. GABAb<2) is basally 
phosphorylated at serine 892.
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co-expression of GABAB(i) was required to couple to potassium channels (Kuner et 
al., 1999). Since these initial findings, further thorough investigations support the 
concept that only heterodimeric receptors are able to couple to G-proteins and thus 
activate effectors.
The two subunits interact with each other through putative coiled coil domains 
found in their intracellular carboxy-terminal domains, and additionally in unmapped 
regions, probably the transmembrane domains (Calver et al., 2001; Galvez et al.,
2001). The interaction between the two subunits is of extremely high affinity, and the 
receptor is immunoprecipitated as a heterodimer from native tissue (Kaupmann et al., 
1998; Benke et al., 1999). Native receptors were further shown to be heterodimers of 
GABAB(i) and GABAb(2), with the formation of homodimers of either subunit precluded 
(Benke et al., 1999). Double immunolabelling of thalamocortical neurones has shown 
that >95% dendrites immunoreactive for GABAB(i) are also immunoreactive for 
GABAb(2) (Kulik etal., 2002).
1.6.3 Splice variants
Multiple splice variants of GABAb(i ) have been discovered, along with those 
initially reported GABAB(i a) and GABAB(ib). As mentioned earlier, GABAB(ia) and 
GABAB(ib) differ in their N-terminal domains. Specifically, GABAB(ia) possesses a pair 
of tandem complement protein modules (‘sushi’ domains) N-terminal to the region 
with homology to bacterial amino acid binding proteins (Hawrot et al., 1998). 
Complement protein modules are usually (although not exclusively) found in proteins 
associated with the complement, clotting and immune systems, and so appear out of 
place in a receptor for neurotransmitters. Complement protein modules are involved 
in mediating protein protein interactions, although N-terminal complement modules 
are often associated with ligand recognition (Hawrot et al., 1998). Expression of the 
splice variants GABAB(ia) and GABAB(ib) is regionally and developmental^ differential 
(Fritschy et al., 1999). Western blotting with splice variant specific antibodies for 
GABAB(ia) and GABAB(ib) demonstrates that between P0 and P10 GABAsoa) is 
predominant. At P10 both splice variants are expressed in equal amounts, and total 
GABAb(i) expression is greatest. In the adult GABAB(ib) is expressed at roughly twice 
GABAB(ia) concentration, whilst total GABAB(i) expression is halved (Fritschy et al.,
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1999). Within the CNS the distribution of GABAB(ia)is markedly dissimilar to that of 
GABAB(ib) with certain brain regions containing exclusively one splice variant 
(Fritschy et al., 1999) (covered in greater detail in section 1.7.1).
Another splice variant, GABAB(1C), is also encoded in the human GABAB(i) gene. 
GABAB(ic) possesses only the first complement domain and, like GABAB(ia), is 
preferentially expressed in foetal tissue (Calver et al., 2002); hinting at a possible 
developmental role of the complement modules within GABAb receptors. Further 
splice variants of GABAB(i) are thought to exist in rats, including GABAB(iC) (which 
confusingly is a different splice variant to human GABAB(iC)), GABAB(id), and 
GABAB(ie). Rat GABAB(ic) contains an insertion prior to the fifth transmembrane 
domain, GABAB(id) encodes a truncated receptor missing half of the intracellular 
carboxy-terminal domain (Calver et al., 2002) and GABAB(1e) only encodes the NTED 
(Schwarz et al., 2000). Studies show that expression of mRNA transcript GABAB(1e)is 
much greater in the periphery, where levels of expression of other splice variants are 
low; however when co-expressed with GABAB(2), GABAB(ie) is unable to couple to G 
proteins (Schwarz et al., 2000). Other splice variants (GABAB(if), GABAB(ig)) have also 
been identified (Wei et al., 2001). However, there have been no demonstrations of 
endogenous protein expression of any of these splice variants and only rat GABAB(iC) 
has been shown to be able to form a functional GABAb receptor. Until it can be 
shown that these splice variants are translated their relevance remains open to 
query.
Studies of GABAb(2) initially reported three splice variants (Ng et al., 1999), but 
subsequent analysis of GABAB(2) gene structure has shown that splice variants are 
not encoded (Martin et al., 2001), and that the initial supposed splice variants were 
artefactual.
1.6.4 Further insights into GABAb molecular biology
Supervening the finding that functional GABAb receptors are heterodimeric, a 
range of studies has elucidated why activity is dependent upon heterodimerisation. 
They have also added weight to the notion that exclusively heterodimeric receptors 
are active. Primarily, GABAB(d is inactive when expressed alone because it is 
retained within the ER (Couve et al., 1998). This retention can be attributed to the
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presence of an RSR(R) motif within the intracellular carboxy-terminal domain at 
amino acids 922-925 (Margeta-Mitrovic et al., 2000; Calver et al., 2001; Pagano et 
al., 2001). This motif is found in other multimeric protein complexes that require 
assembly within the ER prior to export, such as K Atp  channels, and prevents the 
surface expression of unassembled subunits (Margeta-Mitrovic et al., 2000). Thus, 
the co-expression of GABAB(2) is required to mask this ER retention motif and allow 
passage of the combined receptor through the secretory pathway.
Inactivity of GABAB(i) in the absence of GABAB(2) is not solely attributable to ER 
retention. Substitution of an arginine for an alanine within the RSR motif can relieve 
ER retention of GABAB(d, with the mutant subunit migrating to the cell surface. This 
mutant though is incapable of activating GABAb effector proteins (Margeta-Mitrovic et 
al., 2000; Pagano et al., 2001), demonstrating that GABAB(i) is not just a functional 
GPCR that happens to be ER retained. It was subsequently demonstrated that 
although the NTED of GABAB(i) contains all the structural information necessary and 
sufficient for agonist binding (Malitshek et al., 1999); GABAB(d is lacking key 
residues in the second intracellular loop that are critical for coupling to G proteins and 
are conserved amongst mGluRs (Robbins et al., 2001). Tellingly, these residues are 
also present in the second intracellular loop of GABAB(2), and it was consequently 
proven that GABAB(2) is the subunit that couples to G proteins (Robbins et al., 2001; 
Galvez etal., 2001).
As mentioned earlier, GABAb receptors, in common with other family C GPCRs, 
possess a large NTED with homology to bacterial periplasmic binding proteins. Three 
dimensional molecular modelling, and crystallisation studies of these regions reveal a 
structure akin to venus flytraps (fig. 2) and the regions are sometimes referred to as 
venus flytrap modules (VFTMs) (Galvez et al., 1999). Agonist is purported to bind 
within the groove created by each lobe, and upon binding brings amino acids of 
either lobe into close proximity, thus activating the receptor (Kunishima et al., 2000; 
Galvez et al., 1999; Galvez et al., 2000). Because GABAB(2) can traffick to the surface 
in the absence of GABAB(1) and it also contains residues responsible for G protein 
coupling, the possibility that GABAB(2) may form an active receptor when expressed 
alone is more plausible. GABAB(2) is missing key determinants though that manifest in 
it lacking activity. Although GABAB(2), like GABAB(i), possesses an N-terminal VFTM,
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a number of residues vital to GABA binding within the VFTM of GABAB(i) are absent 
within the VFTM of GABAB(2) (Kniazeff et al., 2002). This accordingly leaves 
GABAB(2) unable to bind either agonist or antagonist when expressed alone (Kniazeff 
et al., 2002). In spite of the inability of GABAB(2) to bind ligand, the VFTM within this 
subunit is not vestigial. In fact, deletion of the NTED of GABAB(2) results in the 
removal of GABAb receptor activity, as do certain point mutations within the VFTM of 
GABAB(2) (Kniazeff et al., 2002). One possibility is that GABAB(2) binds an altogether 
different ligand to GABAB(i), conferring activity upon itself and perhaps altering the 
pharmacology of the complete receptor. Studies of the evolutionary conservation of 
amino acids reveal that those critical for ligand binding within mGluR receptors and 
GABAB(i) are conserved between species as distant as Caenorhabditls elegans and 
Homo Sapiens (Kniazeff et al., 2002). Evolutionary pressure has maintained certain 
amino acids at key positions within these receptors so that the ligand binding 
characteristics are preserved, thus maintaining receptor activity. There appears to be 
no such conservation of amino acids within the VFTMs in GABAB(2) however. This 
argues against the existence of a natural ligand for this site and so non-specific 
mutations over time are permitted, whilst receptor activity remains unaffected 
(Kniazeff et al., 2002).
Because mRNA and protein expression patterns for individual subunits do not 
show perfect overlap (Billinton et al., 2000; Calver et al., 2000) the case is still open 
for roles of monomeric subunits. The possibility of dimerisation with other GPCRs has 
been proposed (Sullivan et al., 2000); and monomeric surface trafficking could be 
dependent upon non 7TM proteins similar to RAMPs. This does appear to be 
increasingly unlikely though, with neurones from mice that have had the intracellular 
carboxy-terminal domain of GABAB(2) genetically ablated showing no surface 
expression of GABAB(ia) (unpublished observation), arguing against the existence of 
other proteins capable of trafficking GABAB(ia). Furthermore, genetic ablation of 
GABAB(i) massively reduces expression levels of GABAB(2), although mRNA levels 
are unchanged (Prosser et al., 2001, Schuler et al., 2001). This infers that the 
presence of GABAB(1), or a protein associated with GABAB(i) is required to stabilise 
GABAB(2) protein levels.
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A comprehensive model of GABAb receptor activation now exists. Primarily, 
agonist binds within the VFTM of GABAB(d, causing the closure of the VFTM, and 
also confirmational changes within the VFTM of GABAB(2), probably through direct 
physical interactions. This change in structure; which when one considers the 
sequence of the two subunits, involves the majority of the receptor complex, is 
propagated through the transmembrane domains. This activates the G protein 
through specific residues within the intracellular loops of GABAB(2), but probably also 
involving other determinants within GABAB(d intracellular domains, and hence allows 
receptor-effector coupling. Because efficient GABAb coupling is dependent upon 
allosteric interactions between all major domains within the two subunits (Galvez et 
al., 2001), it can be deduced that the two subunits have evolved together so as to co­
operatively produce the metabotropic GABA response.
1.6.5 GABAb interactions
To search for other possible GABAb subunits several groups have utilised yeast 
two-hybrid screens of brain cDNA libraries using both the N and Carboxy terminals of 
GABAB(1) and GABAB(2) as bait proteins. In parallel to yeast two-hybrid screens a 
bioinformatics approach consisting of mining expressed sequence transcripts (ESTs) 
for sequences with homology to GABAB(d or GABAB(2) has been employed. Both 
these techniques have thus far failed to identify any further mammalian members of 
the GABAb subunit family. It is therefore likely that the GABAb family consists of only 
two subunits (although interestingly Drosophila possesses a third member with equal 
homology to GABAB(i) and GABABB(2) (Calver et al., 2002)).
A by product of the search for other receptors however has been the identification 
of a large number of potential binding partners to GABAB(1) and GABAB(2). Amongst 
these are proteins from the 14-3-3 family of signalling molecules that have been 
shown to interact with the intracellular carboxy-terminal domain of GABAB(i) (Couve 
et al., 2001). The putative interaction site overlaps amino acids 905-927, a stretch 
running from the second half of the coiled coil domain to just past the ER retention 
motif. The precise function of the interaction between 14-3-3 and GABAB(d remains 
unknown, but may it be involved with signalling or scaffolding events (Couve et al., 
2001; El Far & Betz 2002). Recently it has been demonstrated that the binding of 14-
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3-3 overcomes the ER retention of homomeric channels such as the KCNK3 
potassium channel (O’Kelly et al., 2002). Misfolded or ER resident proteins that 
escape the ER are efficiently retrieved by COPI-coated vesicles for retrograde 
transport due to the presence of dibasic ER retention motifs interacting with COPI 
proteins, such as (3-COP. 14-3-3 binding can mask these sequences and therefore 
prevent recognition by the COPI complex, allowing forward transport. 14-3-3 binding 
stabilises and enhances the surface expression of both homomers of a4 subunit and, 
interestingly, heteromeric a4(32 neuronal nicotinic acetylcholine receptors (Jeanclos 
et al., 2001). It has been suggested that 14-3-3 binding could act as a general 
mechanism to allow the escape from the ER of proteins retained, and that this 
function of 14-3-3 may also apply to heteromeric complexes. So whereas previously 
it was believed that the masking of the ER retention sequence alone by other 
proteins in a complex was enough to elicit the ER escape, it maybe that the 
additional binding of 14-3-3 molecules are also required to facilitate this process by 
helping prevent |3-COP recognition. Whether 14-3-3 plays such a role in the 
trafficking of the GABAb complex is not known, however it is tempting to speculate 
that the overlap of the ER retention sequence and the 14-3-3 binding region are not 
purely coincidental.
Other proteins that interact with GABAb have been identified and include the 
transcription factor ATF4 (CREB2) which has been shown to interact with GABAB(i) 
(Nehring et al., 2000; White et al., 2000; Vernon et al., 2001). The interaction occurs 
between the leucine zipper region of ATF4 and the coiled coil of GABAB(i). 
Complexed GABAB(i) and ATF4 co-immunoprecipitate from transfected cells, but only 
when GABAB(2) is not expressed, demonstrating that GABAB(i) and ATF4 binding is 
mutually exclusive with respect to GABAB(2). Baclofen application has been shown to 
induce trafficking of ATF4, although the direction of this trafficking is unresolved with 
one group reporting trafficking into the nucleus (White et al., 2000), whilst others 
detecting nuclear exit of ATF4 (Vernon et al., 2000). It should be noted that this 
trafficking is unlikely to be due to baclofen causing a direct structural reorganistion of 
the GABAB(i):ATF4 complex because baclofen is unable to activate' the monomeric 
receptor. A more probable occurrence is that baclofen triggers other signals e.g. 
altered intracellular metabolite levels which can then result in ATF4 trafficking.
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Several other proteins have been reported to interact with GABAB(2) including the 
multiple PDZ domain protein MUPP-1 and N-ethylmaleimide-sensitive factor (NSF) 
(Calver et al., 2002). These interactions however only occur in the absence of 
GABAB(i), and so are probably not involved in the regulation of the complete 
heterodimeric receptor. Thus far only one protein (apart from heterotrimeric G 
proteins) has been implicated in altering the function of the dimer and this is PKA. 
PKA phosphorylates the carboxy-terminal intracellular domain of GABAb(2) and is also 
able to associate with fusion proteins of this region from brain lysates (Couve et al.,
2001). Although this interaction has not been demonstrated to be direct, and indeed 
could involve kinase-anchoring proteins, it is of relevance to the heterodimer. This is 
because PKA activation can slow the desensitisation of receptors by phosphorylating 
serine 892 in the carboxy-intracellular domain of GABAB(2) (Couve et al., 2001). 
Heterodimerisation is obligate to receptor activity, and therefore this phosphorylation 
occurs at the complete receptor. Apart from the interaction with PKA, all other 
reported GABAs receptor interactions involve the coiled coil domains of either 
subunit. The region implicated in PKA phosphorylation is considerably downstream of 
the coiled coil within GABAb(2), and this is probably why the interaction can occur in 
the dimerised receptor.
1.7 Anatomical studies of GABAb distribution
1.7.1 Receptor distribution within the brain
Initial descriptions of the distribution of GABAs receptors within the CNS relied 
upon the use of radiolabelled agonists, usually tritiated GABA in the presence of 
isoguvacine to block GABAa binding sites (Mott & Lewis 1994). In most regions of the 
brain GABAa receptors predominate in concentration over GABAs, with GABAa 
receptors accounting for 70-80% of overall GABA binding sites (Wilkin et al., 1981; 
Chu et al., 1990). However the molecular layer of the cerebellum (Wilkin et al., 1981), 
specific thalamic nuclei and the interpeduncular nucleus of the brainstem show much 
greater concentrations of GABAb, with GABAb receptors representing up to 90% of 
GABA binding sites (Chu et al., 1990). The highest absolute concentrations of GABAb 
binding sites are seen in the frontal cortex, olfactory bulb, superficial grey of the
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superior colliculus and molecular layer of the cerebellum (Chu et al., 1990; Mott & 
Lewis 1994). Areas with intermediate levels of binding include the amygdala and 
certain thalamic nuclei whilst lower levels are observed in the hippocampus, 
hypothalamus, substantia nigra and neostriatum. Within the hippocampus the 
dendritic layer shows the most prominent binding, indicative of preferential GABAb 
receptor targeting to dendrites as opposed to somatic layers (Mott & Lewis 1994). 
Unfortunately radioligand binding is of low resolution and has several caveats. These 
include variable concentrations of endogenous GTP that could alter receptor 
sensitivity to radiolabelled agonist, and varying concentrations of endogenous GABA 
which could displace radiolabelled agonist. In fact the number of GABAb antagonist 
binding sites in crude brain membranes is approximately 3-fold the number of GABAb 
agonist binding sites (Bittiger et al., 1992), reflecting the variable agonist affinity of 
receptors. This quantative difference is of no concern in whole brain radioligand 
binding assays if there is an equal distribution of different affinity receptors, but if 
certain regions of the brain contain more receptors in a low affinity state then the 
results could be misleading.
GABAb receptor cloning has enabled mRNA in situ hybridisation studies to be 
performed. This, in conjunction with the design of subunit and splice variant specific 
antibodies, has allowed for a very accurate map of receptor localisation.
Most data from in situ hybridisation studies supports previous radioligand binding 
assays. Initial studies of GABAB(i) mRNA transcript localisation denoted the presence 
of high levels in all cerebral cortical layers, the hippocampal pyramidal cell layers, the 
granular cell layer of the dentate gyrus and in the basal ganglia. In addition high 
levels of expression were noted in the cerebellum, especially in the Purkinje cell layer 
and at moderate levels in the granular layer (Kaupmann et al., 1997) supporting the 
earlier conclusions from radiolabelled agonist. Studies using antibodies to either 
GABAB(ia) or GABAB(ib) show expression patterns similar to those observed with 
mRNA transcripts. Intriguingly though, there is a sharp contrast in the distribution 
patterns of GABAB(ia) and GABAB(ib) within certain areas of the brain (Fritschy et al.,
1999). This is most noticeable within the striatum where GABAB(ia) is moderately 
expressed, whilst GABAB(ib) is virtually absent. Discrepancies are also noted in the 
hippocampus, with the CA3 region containing exclusively GABAB(ib) whilst the CA1
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layer stains for both GABAB(ia) and GABAB(ib), but in a highly delineated manner, with 
GABAB(1a) in the pyramidal cell layer and GABAB(i b) in the stratum lacunosum 
pyrimidale (Fritschy eta!., 1999). Within the cerebellum immunostaining for GABABis 
particularly strong, with GABAB(ib) selectively present in Purkinje cells and lower 
levels of GABAB(ia) in granule cells. The level of GABAb expression within the 
molecular layer of the cerebellum is not uniform but consists of intensely stained 
bands of Purkinje cells forming a regular striped appearance. This staining is 
coincident to that seen with the protein zebrin, and positively correlates with 
metabolic activity, hinting that GABAb expression maybe regulated according to 
metabolic demands (Fritschy et al., 1999). Analysis of the class of neurones 
immunoreactive for GABAb demonstrates very high staining in monoaminergic and 
cholinergic neurones within the CNS, but much lower levels within the GABAergic 
neurones (Margeta-Mitrovic et al., 1999). This supports the important role of GABAb 
receptors in regulating noradrenergic transmission, although questions the 
importance of GABAb as an autoreceptor (Margeta-Mitrovic et al., 1999).
Macroscopic staining of brain sections with a GABAB(2) specific antibody 
demonstrates a very similar pattern of expression to that observed with GABAB(i) 
specific antibodies. Nonetheless, certain fields poorly overlap with GABAB(i) staining 
and these included the striatum, nucleus accumbens, olfactory tubercle and the 
hypothalamus where the staining for GABAB(2) was much lower (Kulik et al., 2002). 
Studies of the neocortex have also demonstrated the existence of interneurones 
discretely staining for GABAB(1) and not GABAB(2) (L6pez-Bendito et al., 2002). A 
common theme emerging from studies of the expression of either subunit in the brain 
is that most regions immunopositive for GABAb stain for both subunits, but if there is 
a discrepancy then it is GABAB(2) which is not expressed. This leaves certain areas 
expressing either exclusively or much higher levels of GABAB(d. Neurones staining 
for exclusively GABAB{1) show highest immunoreactivity in the cell body and lack 
electrophysiologically recordable GABAb responses (Lopez-Bendito et al., 2002). 
During development it appears that GABAB(i) is primarily expressed, with GABAB(2) 
co-expression, which would allow functional receptors, occurring later (L6pez-Bendito 
et al., 2002). It maybe that GABAB(i) serves an alternative role in certain cells such 
as acting as an anchoring molecule. Another possibility is that GABAB(i } is expressed
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in these cells and is retained in the ER, but in certain circumstances, e.g. after 
neuronal insult, GABAB(2) expression is upregulated allowing the rapid formation of 
functional receptors. The reason behind the discrepancies in expression profiles 
requires further studies to elucidate.
1.7.2 Subcellular receptor distribution
Withinin the cerebellum Purkinje cells show by far the highest immunoreactivity 
for GABAb, with much lower levels of staining noted in granule cell somata (Fritschy 
et al, 1999). Electron microscopy analysis of Purkinje cell staining show that GABAb 
is predominantly located along the dendritic trees and cell bodies. GABAb staining 
was conspicuously absent from dendrites apposed to GAD-positive puncta, indicating 
a lack of GABAb localisation at GABAergic synapses, at least in the cerebellum 
(Fritschy et a l, 1999). Ultrastructural localisation of GABAB(i) within Purkinje 
dendrites shows weak labelling in the dendritic shaft, but intense labelling within 
dendritic spines that make asymmetric (i.e. excitatory) synapses with parallel fibre 
and climbing fibre terminals. This staining was extrasynaptic or perisynaptic and 
maximal ~240nm from the edge of the synapse (Kulik et a l, 2002), with pre and 
postsynaptic densities on the whole immunonegative for GABAb (Fritschy et al., 
1999; Kulik et al, 2002). Staining of GABAB(2) showed a similar ultrastructural 
localisation within the cerebellum to that of GABAB(i) (Kulik et al, 2002). Therefore it 
appears that within the cerebellum GABAb receptors are preferentially expressed in 
Purkinje cells where they accumulate peri and extrasynaptically in spines making 
excitatory synapses, and are restricted from the pre and postsynaptic densities.
Studies of the ventrobasal thalamus show GABAb localisation is also 
extrasynaptic here. GABAb receptors in this region were preferentially located 
extrasynaptic to GABAergic synapses as opposed to glutamergic synapses in a ratio 
of 2:1 (Kulik et al, 2002). Presynaptic staining of GABAb was not observed on either 
glutamergic or GABAergic terminals indicating that it neither functions as an auto or 
heteroreceptor in this region (Kulik et al, 2002). Common to both regions is the 
extrasynaptic targeting of GABAb receptors, but the lack of GABAb receptors at 
GABAergic synapses in the cerebellum is not replicated in neurones from the 
ventrobasal thalamus. Overall, it appears GABAb receptors are extrasynaptically
targeted, preferentially In dendritic spines. Presynaptic targeting and the class of 
synapse that GABAb receptors appose is probably specific to different neuronal 
types.
1.8 GABAb receptor function
1.8.1 Physioiogical roles
As previously mentioned, initial appraisals of the GABAb response indicated that it 
could be inhibited by pre-treating tissue with pertussis toxin (Asano et al., 1985; 
Ohmori et al., 1990). Pertussis toxin specifically inactivates the Gj/0 class of G 
proteins. Activation of this class of G proteins triggers inhibitory effectors, primarily 
the closure of Ca2+ channels, inhibition of adenylyl cyclase and the opening of 
potassium channels (Mott & Lewis 1994) and it is through these effector pathways 
that GABAb elicits its actions.
The earliest studies of what would resolve to be GABAb activity implicated the 
bicuculline insensitive GABA response in the inhibition of noradrenergic transmitter 
release (Bowery & Hudson 1979). This effect exemplifies the role of GABAb receptors 
at the presynaptic terminal where activation of receptors coupling to G0 G proteins 
causes the closure of voltage sensitive Ca2+ channels (Mott & Lewis 1994). The G 
protein educed closure of Ca2+ channels involves a direct interaction between 
liberated (3y subunits and the channels (Ikeda 1996). This presynaptic activity of 
GABAb receptors is of crucial importance both at GABAergic neurones and also at 
neurones carrying other classes of neurotransmitter. At the GABAergic neurone it is 
critical to inhibit further release of GABA, with the GABAb receptor acting as an 
autoreceptor. Stimulation of inhibitory interneurones elicits GABA release and an 
I PSP that quickly starts to diminish in magnitude as the stimulation is repeated (Mott 
& Lewis 1994). Further studies showed that this reduction in IPSP size could be 
blocked by GABAb antagonists (Davies et al., 1990)). It is now recognised that the 
rapid reduction of IPSP is caused by GABA activation of GABAb autoreceptors on 
interneurones which inhibit presynaptic calcium influx and subsequent GABA release. 
The reduction in GABA release consequences in decreased postsynaptic GABAa 
receptor activity, and means that macroscopically this GABAb action is excitatory.
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GABAb autoreceptors are thought to be important in the induction of long term 
potentiation (LTP) because the reduction in GABAa activity permits depolarisation of 
the postsynaptic membrane great enough to relieve the Mg2+ block on NMDA 
receptors and allow LTP (Davies et al., 1991).
The inhibition of adenylyl cyclase through GABAb activation confers a modulatory 
role upon the receptor. It permits the fine tuning of individual neuronal responses by 
reducing the intracellular concentration of cAMP and therefore PKA activity. PKA 
phosphorylation can significantly effect the activity of many classes of ion channels 
and so even minor changes in the level of PKA activity can have profound effects on 
neuronal firing. GABAb receptor inhibition of adenylyl cyclase has also recently been 
revealed to play an unexpected role in the control of neurotransmitter release. 
Presynaptic vesicles containing neurotransmitter are replenished in a manner 
dependent upon both local Ca2+ and cAMP concentrations. As well as the inhibiton of 
Ca2+ influx covered above, it appears that the activation of GABAb receptors at 
presynaptic terminals causes a dip in local concentrations of cAMP, so that vesicles 
upstream of those released are less amenable to liberation (Sakaba & Neher 2003). 
This demonstrates dual complementary functions of GABAb activation at the 
presynaptic terminal utilising two different effector systems.
As stated, GABAb activity normally negatively regulates adenylyl cyclase, 
however a wealth of evidence also exists to support a paradoxical role for GABAb 
receptors in the control of cAMP concentration. It transpires that when co-activated 
with Gs G protein coupling receptors which positively regulate adenylyl cyclase, such 
as the p adrenergic receptors, the liberated Py subunit from Gj class of G proteins can 
synergistically enhance the action of the GaS subunit. This can trigger an 
accumulation of cAMP far greater than that elicited by the activation of a Gs coupled 
GPCR alone (Karbon et al., 1984; Karbon & Enna 1989). This property of GABAb 
receptor coupling allows a form of the learning event associated coincidence 
detection in neuronal circuits such that when two different classes of receptor on a 
neurone are stimulated through different transmitters the effect is far greater than that 
when either receptor is stimulated singularly.
The other major effect of GABAb receptors is observed postsynaptically, and is 
described as the late inhibitory postsynaptic potential (IPSP). Orthodromic stimulation
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in the hippocampus primarily elicits a glutamergic excitatory postsynaptic potential, 
which is followed by a biphasic GABAergic IPSP. The early component of the IPSP is 
maximal 10-20ms after stimulation and is caused by increased membrane 
permeability to Cl" ions through GABAa receptors (IPSPA) (Mott & Lewis 1994). The 
second slow component is bicuculline insensitive, peaks 130-200ms after stimulation, 
and lasts for 0.4-1.5s (Mott & Lewis 1994; Calver et al., 2002). The slow component 
of the GABA mediated IPSP (IPSPB) is due to GABAb receptor activity and is 
inhibited by the GABAb antagonist phaclofen (Dutar & Nicoll 1988(a)) and can be 
replicated by baclofen application. IPSPB is caused by increased membrane 
permeability to K+ ions and can be blocked by application of ions known to block K+ 
channels activity such as extracellular Ba2+ and intracellular Cs2+ (Gahwiler & Brown 
1985). The increase in membrane permeability allows K+ ion efflux down an 
intracellular to extracellular concentration gradient which produces hyperpolarisation 
of the membrane. This action of GABAb receptors is elicited through the py subunit 
activation of G protein coupled inwardly rectifying potassium channels (GIRKs) 
(Wickman & Clapham 1995). The coupling of GABAb receptors to GIRKs is thought 
to be entirely postsynaptic (Luscher et al., 1997; Couve et al., 2000; Calver et al.,
2002). Mice lacking a GIRK channel subunit (GIRK2) are unable to form GIRKs and 
in these mice the IPSPB is absent, although there is no change in presynaptic GABAb 
properties (Luscher et al., 1997).
One aspect of IPSPB that should be mentioned is that it is dependent upon 
multiple stimuli, and indeed is only evoked by relatively strong repetitive stimulations 
(Newberry & Nicoll 1984; Dutar & Nicoll 1988(b)). If neurones are treated with a 
GABA uptake inhibitor such as the anticonvulsant Tiagibine the requirement for 
strong stimuli is removed and IPSPB is greatly enhanced (Thompson & Gahwiler 
1992). Analysis of the ultrastructural localisation of GABAb receptors demonstrates 
the vast majority of both pre and postsynaptic receptors are found extrasynaptically 
(see above). GABA uptake mechanisms operate to minimise the duration that 
released GABA resides within the synapse, preventing extrasynaptic GABA spillover 
and corresponding GABAb activation. Only when strong stimuli elicit more GABA than 
can be efficiently taken up are the GABAs receptors activated, and this can be 
mimicked by GABA uptake inhibitors. Physiologically, it is has been demonstrated
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that certain synchronised firing patterns of interneurones, such as those observed in 
hippocampal theta rhythm activate GABAb receptors through GABA spillover 
(Scanziani 2000; Couve et al., 2000; Calver et al., 2002). GABAb activity is of crucial 
importance in keeping the rhythm at a certain frequency, and blockade of GABAb 
receptors can dramatically increase the frequency of oscillations (Scanziani 2000).
GABAa receptor-mediated I PSPs can change the membrane conductance by 90- 
140nS, whereas IPSPB only causes an increase of between 13-19nS (Calver et al.,
2002). Thus, it would appear that the IPSPB is minor in comparison to IPSPA; 
however because the duration of IPSPB is much greater it can have a profound effect 
upon the membrane potential causing peak membrane hyperpolarisation of 
approximately ~10-20mV. IPSPB is relatively ineffective in preventing strong 
depolarising signals, but significantly reduces the probability of weak synaptic inputs 
eliciting action potential firing. This quality of the postsynaptic GABAb response can 
help maintain the Mg2+ block of NMDA receptors and has the effect of enhancing the 
signal to noise ratio (Calver et al., 2002).
Although GABA is an inhibitory neurotransmitter and GABAb couples to effectors 
that are inhibitory in nature; the precise role of GABAb receptors has not been easy to 
elucidate. GABAb receptor activation could be excitatory if inhibiting GABA release 
directly by acting as an autoreceptor. Likewise, GABAb activity at glutamergic 
neurones may also be excitatory if they are stimulating GABAergic interneurones. 
Pharmacological studies have been used to try and identify the physiological roles of 
GABAb receptors. These have produced conflicting results, with some studies 
demonstrating that application of baclofen is proconvulsant (Mott et al., 1989) and 
thus suggesting activation can be excitatory; whilst other studies propose GABAb 
activity is anticonvulsant (Morrisett et al., 1993). Mice have recently been generated 
lacking the GABAB(1) subunit and these lack all baclofen mediated GABAb responses 
(Proser et al., 2001; Schuler et al., 2001). This has not only supported previous work 
showing that the GABAb response depends upon heterodimer formation, but has also 
provided a compelling insight into the physiological role of GABAb receptors within 
the whole organism. Mice deficient in GABAB(i) subunit lack both pre and 
postsynaptic GABAb activity, and so lack the baclofen inhibition in neurotransmitter 
release, as well as the slow GABAergic IPSP. Phenotypically these mice are prone
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to developing intractable tonic-clonic seizures that can be triggered by very slight 
stimuli (Proser et al., 2001; Schuler et al., 2001). This suggests that the loss of the 
inhibitory tone provided by GABAb action leaves neurones closer to the threshold 
needed for triggering seizures. Other phenotypic traits include increased locomotor 
activity and also reduced pain thresholds. This implies that GABAb receptor activity 
has a basal negative effect on pathways in the brain important for controlling these 
events. Although these traits are most probably due to the lack of GABAb responses, 
it is impossible to discount any effect caused by the absence of GABAb receptors 
throughout development. To strictly differentiate between developmental and 
physiological roles of the receptor requires the generation of inducible GABAb 
receptor knockout animals.
1.8.2 Pharmacological Heterogeneity
Early studies of GABAb receptors proposed a number of pharmacologically 
distinguishable subtypes mediating different actions of GABAb receptors in different 
localisations (Bonanno & Raiteri 1993). The most prominent finding was a purported 
difference in the sensitivity to the antagonist phaclofen between presynaptic and 
postsynaptic receptors (Dutar & Nicoll 1988(b)). Studies analysing the GABAb 
mediated inhibition of neurotransmitter release in synaptosomal preparations 
disclosed variations in the antagonism of this effect by phaclofen dependent upon the 
neurotransmitter release antagonised (Bonnano 1989). It has since been highlighted 
that phaclofen is a comparatively poor antagonist alongside newer antagonists and is 
typically used at concentrations of 1 mM to exact GABAb antagonism (Mott & Lewis
1994). At these concentrations phaclofen has non-specific effects at GABAa 
receptors and may also act as a partial agonist at GABAb receptors (Stirling et al., 
1989). This leaves much of the work based solely upon this drug open to question.
Pharmacologically it would be beneficial to separate the GABAb presynaptic 
response from the postsynaptic response. Differences in sensitivity to both agonists 
and antagonists are easily attributable to the existence of different subtypes. 
However, the absence of alternative subunits and the results from knocking out the 
GABAB(i) subunit suggest that one type of receptor is responsible for mediating both 
responses. Differential pharmacology can also be explained in varying accessibility to
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drugs in different neuronal populations, and disparity in the ratios of receptor to G 
protein. Post-translational modifications may also affect the sensitivities to agonist 
and antagonist, and it is also likely that the configuration of the receptor in terms of its 
molecular interactions with other proteins, both extracellularly and intracellularly 
influences pharmacology.
1.9 Pathological roles
Dysfunction of the response mediated by GABAb receptors is associated with 
several pathological conditions. Because GABAb receptors provide an important 
inhibitory tone over neuronal firing, it is probable that they are involved in the 
pathogenesis of epilepsy, a disease characterised by paroxysmal neuronal 
depolarisation. Indeed, as mentioned above, the main phenotype of mice lacking 
GABAs receptors is a reduced seizure threshold and a tendency to develop 
generalised intractable tonic clonic seizures (Proser et al., 2001; Schuler et al., 
2001). Pharmaceutical preparations used in the clinical treatment of epilepsy do not 
directly target GABAs receptors but certain anticonvulsants which increase synaptic 
and extrasynaptic concentrations of GABA such as GABA uptake inhibitors will 
increase GABAb receptor activity. It is likely that an element of the therapeutic effect 
of GABA uptake inhibitors is mediated through enhanced GABAb receptor activity. 
GABAb receptors are also implicated in a very different form of epilepsy known as 
absence seizures. Absence seizures consist of periods of non-convulsive inactivity 
and inattentiveness due to dysfunctional thalamo-cortical circuitry. GABAb receptor 
activity is critical in the maintenance of seizures in animal models of absence seizure 
(Hosford et al., 1992), and baclofen application can provoke these seizures (Vergnes 
et al., 1997). It is therefore possible that drugs antagonising the GABAb response 
may have a therapeutic role in the treatment of absence seizures.
In humans as well as other animals a sudden loud sound normally elicits a startle 
response. The response is reduced if it follows a weaker prepulse and this is known 
as prepulse inhibition. Schizophrenics have consistently been shown to have 
deficiencies in their prepulse inhibition, with subsequent auditory stimuli havhg a 
similar startling effect to the initial stimulation (Braff & Geyer 1978). An interesting 
observation of heterozygote GABAb receptor knockout mice was that they show an
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increase in their prepulse inhibition so that they respond even less to a second 
startling sound than wild type mice (Proser et al., 2001). An indication as to the 
effectiveness of an antipsychotic compound is its ability to enhance this prepulse 
inhibiton (Hunter et al., 2000), and the observation that effectively reducing the 
GABAb receptor response may have a similar effect indicates that GABAb receptors 
may play a role in either the aetiology of schizophrenia and/or the clinical 
effectiveness of certain antipsychotics.
GABAb receptor activation has been demonstrated to decrease the amount of 
glutamate and the peptides substance P and CGRP (Kangrga eta!., 1991; Malcangio 
& Bowery 1993, 1995) released in the dorsal horn of the spinal cord. These 
neurotransmitters all have excitatory effects within the dorsal horn and are important 
in the transmission of acute and chronic pain. In animal models baclofen has been 
demonstrated to have analgesic actions (Hammond et al., 1993) and baclofen 
appears an, albeit rarely employed, useful adjunct treatment in such conditions as 
trigeminal neuralgia (Couve et al., 2000).
Experiments conducted with GAB As receptor antagonists that are able to cross 
the blood brain barrier indicate that antagonism of GABAb receptors is associated 
with enhanced learning behaviour (Mondadori et al., 1993, 1996 a,b), whilst baclofen 
treatment limits learning behaviours (DeSousa et al., 1994). The treatment with 
GABAb receptor antagonists may lower the threshold for LTP, and this is of clinical 
relevance because it indicates that GABAb receptor antagonists may be used as 
cognitive enhancing drugs in those with dementia.
GABAb receptor agonists can alter the response of animal and human subjects to 
drugs of abuse. Baclofen has been demonstrated to reduce the self-administration of 
cocaine, alcohol and opiates and also reduce cocaine cravings in abusers of this 
substance (Roberts & Andrews 1997; Addolorato et al., 2000; Xi & Stein 1999; Ling 
et al., 1998). This anti-abusive potential of GABAb agonists maybe related to a 
reduction in dopamine release in the ventral tegmental area of the nucleus 
accumbens (Kalivas & Duffy 1995). It is also of interest to note it has been recently 
demonstrated that chronic cocaine administration can cause elevated levels of 
extracellular GABA in this area of the brain, and this has been linked to a cocaine 
induced dysfunction of GABAb receptor activity (Xi et al., 2003). GABAb receptor
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dysfunction may also be involved in the aetiology of depression, and it is likely that 
many of the antidepressant treatments in current use have considerable downstream 
effects upon GABAb receptors (Couve et ai, 2000).
Although there are a large number of neuropharmacological areas where drugs 
that act at GABAb receptors may be of some benefit, currently only one condition is 
regularly treated by a drug that directly acts at GABAb receptors and this is the 
therapeutic use of baclofen in the treatment of spasticity (Meythaler 1999). Spasticity 
is a highly debilitating condition characterised by an increase in muscle tone in the 
limbs and is often secondary to cerebrovascular accidents which damage the 
descending inhibition. Treatment with baclofen, usually intrathecally, is highly 
effective in relieving spasticity and can be continued for years without apparent loss 
in efficacy (Meythaler 2001).
1.10 Aims of this thesis:
Our insight into the structure and function of GABAb receptors has greatly 
increased over the last few years. It is still unclear however whether the receptor 
behaves in a similar manner to other GPCRs in terms of desensitisation and 
internalisation responses. Also unexplored are the effects that interactions with other 
proteins have upon receptor activity. In this thesis I propose to:
1) Study the effect application of agonist has upon the phosphorylation state and 
surface stability of GABAb receptors in heterologous and native systems.
2) Examine the phosphorylation of GABAB(i)and identify kinases able to mediate 
phosphorylation of this subunit.
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CHAPTER 2 Materials and Methods
2.1 Materials
All chemicals were purchased from Sigma (Dorset, UK) unless otherwise stated, and 
all restriction enzymes were purchased from New England Biolabs. All tissue culture 
reagents, unless otherwise stated, were from GibcoBRL Lifetechnologies. Baclofen 
and Br-cAMP were purchased from Sigma. Oligonucleotides were synthesised by 
Cruachem (Edin, UK), and MWG-Biotech (Germany). Imject maleimide-coupled 
mcKLH, EZ Link Sulfo-NHS-SS Biotin, EZ Link Sulfo-NHS Biotin and UltraLink 
NeutrAvidin beads were purchased from Pierce (Rockford, IL). GRK2 was purified 
from Sf9 insect cells. The PKA catalytic subunit was purchased from Promega 
(Southampton, UK). Radionucleotides and Hybond nitrocellulose membranes were 
purchased from Amersham Pharmacia (Buckinghamshire, UK). Peptides and 
phospho-peptides for purification of phospho-specific antibodies were synthesised by 
the Rockefeller institute (NY, USA). Primers were synthesised by MWG-Biotech 
(Ger.). A Biorad phosphorimager was used for data capture and quantification 
(Hertfordshire, UK).
2.2 Molecular Biology
Most of the techniques described can be found in Sambrook et al. (1989).
2.2.1 DNA constructs
Rat G A B A B(ia) and GABAB(2) subunit cDNAs were expressed in the mammalian 
expression vector pRK5 (Couve et al 1998; Couve et al 2002). GABAB(ia)Was tagged 
with 9E10 epitope (EQKLISEEDL) between amino acids 4 and 5 as described 
previously (Couve et al 1998), whilst GABAB(2) was N-terminally tagged with the flag 
epitope (Couve et al 2002). The GST fusion protein vectors pGEX-CR1 (CR1, 
containing the carboxyl terminal domain of GABAB(i)), truncations of the carboxyl 
terminal domain of GABAB(1) (81-8) and pGEX-CR2 (CR2, containing the carboxyl 
terminal domain of GABAB(2)) have been described previously (Couve et al 1998; 
Couve et al 2002). The cDNAs for THRH, arrestin 2-EGFP and arrestin 3-EGFP have
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been described previously (Scott et al 2002). All DNA manipulations and fidelity of 
DNA constructs were verified by DNA sequencing.
2.2.2 Bacterial strains
Subcloning and PCR were performed using the E.Coli strains XLIBIue (F’::Tn 10 
proA+B+laclq D (lacZ)M15/recA1 end A1 gyrA9($Nalr) thi hsdR17(rK-mK+) supE44 
rel 1 lac).
Production of GST-fusion proteins was performed using the E.Coli strain BL21 (F- 
ompT [Ion} hsdSB{rg- mg- an E.Coli B strain) with DE3, a prophage carrying the T7
RNA polymerase gene (Studier et al 1990).
2.2.3 Growth media and agar plates
Bacteria were grown in Luria-Bertani medium (LB). For plasmids encoding ampicillin 
resistance, ampicillin was added to a concentration of 100mg/ml. For growth of BL21 
bacteria, chloramphenicol was added to a concentration of 34mg/ml.
For plates, agar was added to 15g/l. All growth was carried out at 37°C.
2.2.4 Preparation of electrocompetent bacterial cells.
Cells were streaked onto an LB agar plate lacking selective antibiotics. A single 
colony was then used to inoculate 10 mis of LB which was then incubated at 37°C 
overnight. The overnight culture was added to 11 of LB and grown to an absorbance 
at OD600 of 0.6. Bacteria were centrifuged at 4000 rpm for 10mins and then washed 
in 500ml sterile, ice-cold water. The bacteria were centrifuged again, washed in 
25mls ice-cold glycerol, re-centrifuged and finally resuspended in 2.5ml 10% glycerol. 
Aliquots of 90pl were stored at -80eC.
2.2.5 Transformation of bacteria with plasmid DNA
20-30pl of electrocompetent bacteria with the DNA of interest were added to a 0.2cm 
electroporation cuvette on ice. A Biorad genepulser was then used to give a single 
pulse with the settings of 2.5KV, 200Q and 25pF. Following this the bacteria were 
resuspended in 500pl of LB and incubated at 37°C for 1 hour before plating onto LB- 
agar plates containing the appropriate antibiotics and incubating overnight at 37#C.
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2.2.6 Ethanol precipitation of DNA
To precipitate DNA from an aqueous solution, 0.1 volumes of 3M Sodium Acetate pH
5.2 was added to the solution followed by two volumes of 100% ethanol. After 
incubation of the solution at -20°C for at least 10mins followed by centrifugation at 
13,000 rpm for 10 mins, the DNA pellet was washed with 70% ethanol and dried at 
room temperature. For the precipitation of small amounts of DNA, such as ligations, 
1pl of glycogen (1 mg/ml) was added before addition of Sodium Acetate and ethanol.
2.2.7 Phenol/chloroform extraction
A 1:1 mixture of Phenol and Chloroform equilibrated with Tris pH 8.0, 
Phenol/Chloroform (p/c), was obtained from Camlabs. Extraction of DNA samples in 
a volume of 50-500ml was carried out by vortexing with an equal volume of p/c in a 
microfuge tube followed by centifugation at full speed for 5 min. The aqueous phase 
was then transferred to a new microfuge tube and the process repeated with 
chloroform to remove any traces of phenol. Finally the DNA in the aqueous phase 
was precipitated with ethanol.
2.2.8 Agarose gel electrophoresis of DNA
See Sambrook et al. (1989) chapter 6.
Briefly, 1% agarose gels were prepared by dissolving agarose in 1xTAE by heating in 
a microwave. After cooling, ethidium bromide was added to the solution to a 
concentration of 100ng/ml and the gel pored. 10x loading buffer consisting of 0.25% 
bromophenol blue, 0.25% xylene cyanol FF and 15% Ficoll-400 was added to 
samples prior to loading on gel and DNA was resolved at 100 Volts. DNA was 
visualized by placing the gel on a UV transilluminator.
2.2.9 Restriction digestion of DNA, plasmid inserts and PCR products
10pg of plasmid DNA or 20pl of PCR product was digested in a final volume of a 
100pl with 5pl each of the appropriate restriction enzyme(s) and 10pl buffer at 37°C 
for 2 hours or overnight. In the case of single digests of vector DNA self-ligation of 
the vector was inhibited by adding 1ml of shrimp alkaline phosphatase (Amersham) 
to the reaction mixture after digestion followed by a further incubation at 37°C for 30
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min. Digested DNA was purified by agarose gel electrophoresis followed by 
extraction of the band from the agarose gel using Qiagen gel purification kits.
2.2.10 Polymerase Chain Reaction (PCR)
PCR was carried out using either Taq polymerase (Promega) or Pfu polymerase 
(Stratagene) in a final concentration of: 1x the appropriate buffer supplied by the 
manufacturer, 0.25 mM aNTPs and 1pM forward and reverse primers. Amplification 
was caried out with 30 cycles of: denaturation at 948C for 30s, annealing at 52-56°C 
(depending on the primer melting temperature) for 45s and extension at 72°C for 1 to 
2 mins (depending on length of expected product).
2.2.11 Ligations.
A rough estimate of the relative concentrations of vector and insert was made based 
on the intensity of bands on an agarose gel. Three different insert:vector ratios were 
used; approximately 2:1, 5:1 and 10:1. A control with no insert was also carried out. 
The reaction mixture was as follows: 
vector 
insert
1pl 10mM ATP (pH 7.5)
1pl NEB T4 DNA Ligase Buffer 
1pl NEB T4 DNA Ligase 
H2 O to a final volume of 10pl
The reaction mixture was then incubated overnight at 16°C. Following incubation, 1pl 
glycogen was added and the reaction mix ethanol precipitated. The pellet was then 
resuspended in 10pl water, and this was electroporated into XL-1Blue bacteria as 
described. Mini-Preps (see next section) were carried out if an enhancement of more 
than two-fold from the control was seen from the numbers of colonies on the plates. 
Mini-Preps were screened for successful ligation by restriction digestion, using the 
same enzymes which were used to prepare the fragments before ligation.
Plasmids containing inserts were sequenced to verify the correct insertion of the 
ligation product and in the case of PCR inserts for fidelity of the amplification.
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2.2.12 Mini-preparation of plasmid DNA (mini-preps)
Alkaline lysis method: 3ml of bacterial culture was centrifuged at 3500rpm for 5min in 
a bench-top centrifuge. The medium was removed and the bacteria resuspended in 
100pl of solution I. To this was added 200pl solution II (made fresh on the day of use), 
and mixed by inverting several times. After 5min, 150pl solution III was added. After 
mixing (not vortexing), and leaving on ice for 10min, the tubes were centrifuged at full 
speed in a bench-top microfuge for 10min. The supernatant was then removed to a 
fresh tube, and ethanol precipitated, followed by centrifugation at full speed for 10min. 
The pellet was washed in 1ml 70% ethanol, dried, and resuspended in 50pl water to 
which 1 pi RNAse was added.
2.2.13 DNA sequencing
Sequencing was carried out using the automated services provided by either MWG- 
Biotech (Germany) or Cytomyx (UK).
2.2.14 Site directed mutagenesis
This was carried out according to the protocol of the Stratgene ‘Quikchange’ kit 
Briefly, primers complementary to sequence to be mutated were designed containing 
the mutated residues approximately in the middle of the primer, the primer length 
being between 25 and 50 base pairs. PCR reactions were carried out using Pfu 
‘turbo’ as follows:
30 sec 95°C (1st cycle - 1min)
45 sec 54°C
2 min 72°C for every kb in plasmid to be mutagensied 
12-18 cycles
PCR products were then digested with Dpnl to remove all methylated, non- 
mutagenised backbone DNA.
Products were then transformed into super-competent XL-1B cells using heat shock 
at 42°C for 45sec followed by ice for 2min. Cells were then incubated at 37#C for 
30min in LB and plated as normal.
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For ease of selection of mutagenised constructs, primers were designed containing 
silent mutations that inserted restriction sites- usually Pstl. This allowed for mini-prep 
and digestion and prevented sequencing of false- positives. Prior to mutagenesis it 
was checked that codon usage would not be significantly altered by introduction of 
silent mutations.
2.2.15 Maxi-preparation of plasmid DNA by caesium chloride banding
This was carried out as described in Sambrook eta! (Sambrook et al 1989).
11 of bacterial culture in LB ampicillin grown overnight at 37#C was centrifuged at
4,000 rpm for 15 mins. The bacterial pellet was resuspended in 10ml Solution I, to 
which 20ml Solution II was added and mixed thoroughly. 15ml Solution III was then 
added and the mixture left on ice for 5min. It was then centrifuged for 10min at 4,000 
rpm. The supernatant was removed and added to an equal volume of isopropanol, 
followed by centrifugation for 10min at 4,000rpm. The pellet was resuspended in 6ml 
10X TE to which was added 6g CsCI and 100pl 10mg/ml Ethidium Bromide. This was 
centrifuged at 100,000 rpm overnight in a Beckman TLN100 ultracentrifuge rotor. 
Centrifugation promoted formation of DNA bands that were extracted using a 5ml 
syringe and wide-bore hypodermic needle. Ethidium bromide was removed from the 
DNA by butanol extraction with water saturated butanol a sufficient number of times 
to remove all ethidium bromide colouring. DNA was precipitated by adding 2 volumes 
of ethanol and centrifuged at 4,000rpm for 5min. The DNA pellet was then 
resuspended in 1ml 10X TE followed by 2X phenol/chloroform extraction and 1X 
chloroform extraction. The DNA was again precipitated by adding 2 volumes of 
ethanol and centrifuged at 4,000rpm for 5min. and finally resuspended in TE to a 
concentration of 1 mg/ml. The DNA concentration was determined by reading the 
absorbance at 260nm.
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2.2.15 List of oligonucleotides used
To manufacture site directed mutants the following oligonucleotides were employed: 
GABAB(ia) S909A
5' GAG GAG CGC GTC GAT GAA CTG CGC CAT CAG CTG  CAG TCT  
3' AGA CTG CAG CTG ATG GCG CAG TTC TGC GAC GCG CTC  
GABAB(ia) S917A
5' GAA CTG CGC CAT CAG CTG CAG GCT CGG CAG CAA CTC CGC
3' GCG GAG TTG CTG CCG AGC CTG CAG CTG ATG GCG CAG TTC
GABAB(ia) S917D
5' GAA CTG CGC CAT CAG CTG CAG GAC CGG CAG CAA CTC CGC
3' GCG GAG TTG CTG CCG AGC CTG CAG CTG ATG GCG CAG TTC
58
GABAe(ia) S923A
5' TC T  CGG CAG CAA CTC CGC GCA CGG CG C CAC CCC CCA ACA  
3' TG T TGG GGG GTG GCG CCG TGA GCG GAG TTG  CTG CCG AGA  
GABAe(ia) S923D
5' TC T  CGG CAG CAA CTC CGC GAC CGG CG C CAC CCC CCA ACA  
3' TG T TGG GGG GTG GCG CCG GTC GCG GAG TTG  CTG  CCG  AGA
GABAB(ia) 929'STOP
5’ CG G  CGC CAC CCC CCA TGA TGA CCA GAT  
3’ ATC TGG TCA TCA TGG GGG GTG GCG CCG
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2.3 Cell Biology
2.3.1 Antibodies
The rabbit anti-GABAB(ia) antibody was raised against a 15 amino acid peptide from 
the amino terminus GABAB(ia) of 2.5 pg/ml purified according to protocol below. The 
pan anti a-AMPK antibody was a gift from David Carling (Imperial College, UK). 
Secondary antibodies were from Molecular Probes and Jackson and used at 1:400. 
Monoclonal FLAG and VSV antibodies were obtained from Sigma (Dorset, UK). The 
anti-myc (9E10) antibody was obtained from 9E10 hybridoma cells (Connolly et al., 
1996) and used post- protein A purification. The polyclonal anti-myc antibody was 
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The guinea-pig anti 
GABAbR1 and GABAbR2 antibodies and the rabbit anti GluR1 antibody were 
purchased from Chemicon International (Harrow, UK). The GABAa(33 antibody was 
used as described previously (Kittler etal., 2000). The EEA1 antibody was purchased 
from BD Biosciences (Palo Alto, CA). The rabbit anti-GABABR2-P-Ser892 (UCL71) 
has been described previously (Couve et al.t 2002). The secondary anti-mouse, anti­
rabbit and anti-guinea pig antibodies conjugated to Cy5, Texas Red (TR) and 
fluorescein isothiocyanate (FITC) were purchased from Jackson Immuno Research 
Laboratories (West Grove, PA). The secondary anti-rabbit antibody conjugated to 
[125l] was purchased from Amersham Pharmacia Biotech (Buckinghamshire, UK).
2.3.2 Cell line culture
COS-7 cells were most routinely used for transiently expressing proteins of interest. 
They were grown at 37°C with 5% CO2  in Dulbecco's Modified Eagle Medium 
(DMEM) supplemented with 1 mM Glutamine and 10% Foetal Calf Serum.
2.3.3 Transient transfection of COS cells
Two dishes seeded at 2X106 cells/10cm dish of cells in exponential growth at 30-50% 
confluence were used per transfection. Cells were trypsinised from the dish and 
washed once in 50ml DMEM. After centrifugation at 1,000rpm for 2min, the cells were 
washed once in 10ml Optimem (Gibco), and then resuspended in 0.5ml optimem. 
Cells were transfected by electroporation (400V, infinite resistance, 125-pF Bio-Rad 
Gene Electropulser II) with up to 20pg of DNA using equimolar ratios of expression
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constructs unless otherwise stated. Cells were used 36-48h after transfection. For 
immunofluorescence studies cells were plated onto poly-L-lysine (10pg/ml) -coated 
coverslips and analyzed 36-48h after transfection.
2.3.4 Preparation of low density hippocampal cultures
Low density cultures of hippocampal neurones were prepared as described 
previously (Goslin and Banker, 1991) on poly-L-lysine coated (1 mg/ml) glass 
coverslips over a glial feeder layer. Briefly, from embryonic day 18 (E18) rats 
hippocampi were dissected in 1x hepes buffered (10 mM) HBSS under a dissecting 
microscope. Hippocampi were trypsinised for 15 min in IxHBSS with 0.25% trypsin 
followed by 3x5 min washes in IxHBSS. After the final wash, hippocampi were 
triturated in 1ml IxHBSS with 2 fire polished pasteur pipettes (5 passes each), the 
second pipette having a 60-70% diameter of the first. The number of live cells was 
then counted in trypan blue and cells were plated on polylysine treated (1 mg/ml) 
coverslips at a density of 2600-10000 cells cm2 in attachment medium. After allowing 
the cells to attach for 4 hours or overnight the attachment media was replaced with 
maintenance media. Half the medium was changed every 7 days.
2.3.5 Preparation cortical neuronal cultures
Cultures of hippocampal neurones were prepared as described previously (Goslin 
and Banker, 1991) on poly-L-lysine coated (1 mg/ml) 5 or 10 cm plates. Embryonic 
day 18 (E18) rat cortices were dissected in 1x hepes buffered (10 mM) HBSS under 
a dissecting microscope. Hippocampi were trypsinised for 15 min in IxHBSS with 
0.25% trypsin followed by 3x5 min washes in IxHBSS. After the final wash, cortices 
were triturated by multiple passaging into and out of a 10ml plastic pipette until 
completely broken up. The number of live cells was then counted in trypan blue and 
cells were plated on polylysine treated (1 mg/ml) coverslips at a density of 2600- 
10000 cells cm2 in attachment medium. After allowing the cells to attach for 4 hours 
or overnight the attachment media was replaced with maintenance media. The 
neurones were kept for no longer than 7 days.
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2.3.6 Imaging
Transfected cells were plated onto 6 cm dishes containing 10 mg/ml poly-L-lysine 
coated 13 mm coverslips. Cells were washed twice with PBS, fixed for 10 min in 4% 
paraformaldehyde and blocked for 10 min in immunofluorescence solution (0.25 % 
BSA, 10% horse serum in PBS). Cells were permeabilised in immunofluorescence 
solution containing 0.5% NP-40 for 10 min at RT and blocked for another 10 min in 
immunofluorescence solution containing 0.1% NP-40. Samples were incubated 
sequentially with primary and secondary antibodies for 1 h at RT in blocking solution. 
Coverslips were examined using a confocal microscope (MRC1000, Bio-Rad).
2.4 Biochemistry
2.4.1 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE)
3X SDS PAGE sample buffer (80mM Tris-HCI pH6.8, 100mM DTT, 10% glycerol, 
2%SDS and 0.1% bromophenol blue) was added to samples before loading.
Separating gels were made up as follows:
Tris-HCI pH 8.8 1.5M 7.5 ml
Water + PROTOGEL (30% acrylamide) (National Diagnostics) 26.6ml
(relative amounts of water and acrylamide depended upon the size of proteins to be
resolved)
10% SDS 0.3 ml
10% Ammonium Persulphate 0.3 ml 
N.N.N’.N’-tetramethyl-ethylene diamine (TEMED) 12pl
Stacking gels were prepared as follows:
Tris-HCI pH 6.8 1.25M 1.25 ml 
Water 6.8 ml 
PROTOGEL 1.7 ml 
SDS 10% 100pl
10% Ammonium Persulphate 100pl 
TEMED 10pl
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Gels were run in 1X PAGE Buffer until the dye front reached the bottom of the gel. If 
proteins were to be visualised directly, they were fixed and stained with 1% 
Coomassie Blue in 10% acetic acid/20% methanol and destained in 10% acetic 
acid/20% methanol. If proteins were to be visualised by western blotting, proteins in 
the PAGE gel were transferred to a nitrocellulose membrane as described below.
2.4.2 Transfer of SDS-PAGE gels
The SDS-PAGE gel was placed against a pre-wetted Hybond nitrocellulose 
membrane (Amersham) with three pieces of Whatman 3mm filter paper on each side, 
and the completed "sandwich" placed in a BioRad transfer apparatus cassette. This 
procedure was carried out with all components submerged in transfer buffer. Transfer 
was carried out in a BioRad transfer apparatus with 1X Transfer Buffer at 350mA for 
2h. After transfer the filter was stained using 0.1% Ponceau S in 5% acetic acid, and 
the positions of protein lanes and molecular weight markers marked with a ball-point 
pen. Excess Ponceau S was washed away with water.
2.4.3 Western blotting
Following transfer the filter was blocked with 4% marvel milk in 0.05% Tween-20 in 
PBS for 1h. Antibodies were diluted to the appropriate concentration in blocking 
buffer and applied to the filter in a sealed plastic bag overnight with agitation at 4°C. 
Excess antibody was washed off with 4% marvel milk and 0.05% Tween-20 in PBS 
( 5 X 5  min). Secondary antibodies either conjugated to Horseradish Peroxidase or 
125l were added for 1h at room temperature prior to being washed off with 4% marvel 
milk in 0.05% Tween-20 in PBS (4 X 10 min) followed by 2X 5 min with 0.05% 
Tween-20 in PBS. HRP conjugated anti-mouse and anti-rabbit secondary antibodies 
for Western blotting were from Jackson and used at 1:5000 and detected by 
application of Super Signal Chemiluminescent substrate (Pierce). Immunoblots using 
125l conjugated antibody were visualized via Phosphorimager (Bio-Rad) and the 
radioactive bands were quantified using the Quantity One software (Bio-Rad).
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2.4.4 Whole cell labelling studies:
Metabolic [35S]-methionine, [32P]-orthophosphate labelling and immunoprecipitations: 
For metabolic labelling, COS-7 cells were washed twice with methionine-free DMEM 
or phosphate-free DMEM and incubated in methionine-free DMEM containing 0.5 
mCi [35S]-methionine or in phosphate free DMEM containing 0.5 mCi [32P]- 
orthophosphate for 4h at 37°C. After the incubation periods, cells were washed twice 
with Phosphate Buffer Saline (PBS) and lysed in 0.5 ml RIPA buffer (50 mM Tris-CI, 5 
mM EGTA, 5 mM EDTA, 50 mM NaF, 10 mM Na-Pyrophosphate, 1 mM Sodium 
Orthovanadate, 1% NP-40, 0.5% DOC, 0.1% SDS, 0.1% Phenylmethylsulfonyl 
fluoride, 10 mg/ml Leupeptin, 10 mg/ml Pepstatin, 10 mg/ml Antipain). Nuclei were 
removed from cell lysates by centrifugation at 22,000g for 5 min at 4°C in a 
microfuge. Cell lysates were preabsorbed with 25pl protein A- or protein G-
Sepharose, previously equilibrated in RIPA buffer, for 1 h at 4°C. Protein A/G-
Sepharose beads were then removed by centrifugation at 22,000g for 1 min at 4°C, 
and lysates were rotated with 5pg of antibodies for 1h at 4°C. Immune complexes 
were then precipitated with 25pl protein A/G-Sepharose for 1h at 4°C. Sepharose 
beads were washed twice in RIPA buffer containing 500mM NaCI and once in RIPA 
buffer containing 150mM NaCI. Immunoprecipitated proteins were eluted in 40pl of 
SDS-PAGE loading buffer, boiled for 3 min, resolved by SDS-PAGE and visualized 
by Phosphorimager, Bio-Rad (Hertfordshire, UK). Quantification of radioactive bands 
was performed using the Quantity One software (Bio-Rad).
2.4.5 GST-Fusion protein production
BL21 bacteria were transformed with pGEX constructs and plated onto LB Agar 
plates containing Ampicillin and Chloramphenicol. A 10ml LB Chlor/Amp culture was 
grown overnight at 37°C, and added to 11 LB Amp the following morning. This was
allowed to grow to an OD Aeoo of 0.5-0.7 (approx. 2.5 hours), after which
isopropylthio-b-D-galactoside (IPTG) was added to a final concentration of 0.5mM. 
Induction was carried out at room temperature, and allowed to continue for 3-4h. The 
bacteria were centrifuged at 4,000 rpm, and the resultant pellet washed in 10ml 
buffer A, re-centrifuged and the pellet was left overnight at -20°C at this stage. The 
following day the pellet was resuspended in 10ml 1xTE containing 100pM
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phenylmethylsulfonyl fluoride (PMSF) and 1 mg/ml each of antipain, leupeptin and 
pepstatin. Triton-X 100 was added to 1% and the mixture was sonicated at full power 
for 3 X 30s followed by addition of 25ml Buffer C + PMSF and the mixture centrifuged 
at 35,000 rpm for 30min. To the supernatant was added pre-swollen glutathione- 
Agarose beads (80mg dry unswollen mass), and the mixture left at 4°C rotating for 2h 
(Glutathione-Agarose beads were pre-swollen in Buffer C and then washed three 
times in Buffer C before use). After affinity-purification beads were washed five times 
with Buffer C + PMSF. GST-fusion proteins were then eluted from the beads in 70mM 
glutathione containing buffer C (pH adjusted to 7.4), or if fusion proteins were to be 
used in a kinase reaction, TE. Proteins were eluted in 1ml elutant solution for 15 
minutes on ice which was then removed and set aside. A further 1.5 ml of elutant was 
added for 15 more minutes which was then removed. The eluted proteins were then 
dialysed for a minimum of 24h @ 4°C in 1xTE or Buffer C depending upon the 
intended use. The concentration of dialysed protein was determined and then 
proteins were snap frozen in liquid nitrogen prior to storage at -80°C until required.
2.4.6 Affinity-purification ("pull-down") assays
GST-fusion proteins purified as described above were thawed on ice prior to use. 
Brain lysate was made by homogenising the tissue in a Down's Homogeniser in 
50mM HEPES pH 7.5, 150mM NaCI, 50 mM NaF, 10mM NaPyrophosphate, 1mM 
EDTA, 2mM EGTA, 0.5% Triton X-100 (or 1% NP-40, 0.5% DOC), plus protease 
inhibitors PMSF, leupeptin, antipain, pepstatin (10 pg/ml). This was then centrifuged 
at 50,000 rpm for 30min at 4#C. The supernatant was incubated with the GST-fusion 
proteins for 30min with rotation at 4CC prior to addition of glutathione agarose beads 
and incubation for a further 90min. 25pg fusion protein was used per assay and 5mg 
of brain lysate. After incubation beads were washed five times with 1ml ice-cold lysis 
buffer, and resuspended in 50pl 2X SDS-PAGE sample buffer. Proteins were 
separated by SDS-PAGE and detected by western blotting.
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2.4.7 In vitro kinase assays
10 |jg of GST fusion proteins or rod outer segments were mixed with purified GRK2, 
AMPK or PKA in kinase buffer (20 mM Tris-CI, pH 7.2, 5 mM MgCI2, 2 mM EDTA, 
1mM DTT. For GRK reactions the buffer was supplemented with Gpy and PIP2) in a 
final volume of 25 pi. Agarose beads were pre-warmed in kinase buffer for 1 min at 
37°C, ATP was then added to the reaction to a final concentration of 0.2 mM 
containing 1/10 vol of [32P]-yATP (10mCi/ml) and the reactions were continued for 15 
min at 37°C. Reactions were stopped by the addition of 12.5 pi of 3X SDS-PAGE 
loading buffer, boiled for 3 min, resolved by SDS-PAGE and visualized by 
Phosphorimager, Bio-Rad. Quantification of radioactive bands was performed using 
the Quantity One software (Bio-Rad).
2.4.8 Immunoprecipitation from brain membranes
Brain membranes were prepared as described previously (Couve et al., 2000). They 
were then solubilised for 2h at 4°C in buffer containing 2% CHAPS. After 
centrifugation, the lysate was precleared with 50pl of a 1:1 slurry of protein A beads 
(Pharmacia Biotech) in lysis buffer with 50pg rabbit non-immune IgG (Pierce) for 1h
at 4°C, rotating on a wheel. The beads were removed by centrifugation, and to the 
supernatant was added a further 50pl protein A (for polyclonal antibodies) plus the 
antibody of interest. Immunoprecipitations were carried out using 5-10 mg of antibody 
or an equivalent amount of IgG control. This was incubated at 4#C for 4h on a rotating 
wheel. The beads were then washed four times with 1ml ice-cold lysis buffer, and 
resuspended in 50pl 3X SDS-PAGE sample buffer. Proteins were separated by SDS- 
PAGE and detected by western blotting.
2.4.9 Biotinylation
5 DIV rat cortical neurones grown on poly-L-lysine coated dishes were incubated for 
1 h in culture media containing 100pg/ml leupeptin. Dishes were placed on ice and 
washed twice with ice-cold PBS/Ca2+/Mg2+ (PBS containing 1 mM CaCI2 and 0.5mM 
M gCI2). The biotin reagent was freshly dissolved at 1mg/ml in ice-cold 
PBS/Ca2+/Mg2+, if biotin was to be cleaved for internalization assays then EZ Link 
Sulfo-NHS-SS Biotin was used, otherwise Sulfo-NHS-biotin was used. Cultures were
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incubated with biotin solution for 12 min on ice which was then aspirated and the 
dishes were blocked by washing 3 x 5  min in PBS/Ca2+/Mg2+ containing 0.1% BSA 
and 2 x 5  min in ice cold PBS/Ca2+/Mg2+. Neurons were returned to the 37#C 
incubator for the appropriate periods of time (10min to 60h) in the presence of 
100pg/ml leupeptin. Dishes were placed on ice, the media removed and 2-5 ml of ice- 
cold cleaving buffer was added (50 mM Glutathione in 75 mM NaCI, 10 mM EDTA, 
1% BSA and 0.075 N NaOH). Dishes were incubated 2 x 1 5  min at 4°C with constant 
shaking. Finally neurons were washed twice in ice cold PBS/Ca2+/Mg2+, lysed in 300 
ml ice-cold RIPA buffer and solubilised by rotating 1h at 4eC. Nuclear and cellular 
debris were removed by centrifugation at 14,000 rpm x 5 min at 4°C and the 
supernatants were precipitated with 100 ml UltraLink NeutrAvidin slurry for 2 h at 
4°C. Beads were washed twice in RIPA buffer containing 500 mM NaCI and twice in 
RIPA buffer containing 150 mM NaCI (one low salt wash followed by two high salt 
washes and then a final low salt wash). Beads were resuspended in 60pl SDS- 
sample buffer and resolved on SDS-PAGE and transferred to Hybond-C membranes.
2.4.10 ELISA
Cells were cultured in poly-L-lysine coated six-well plates with each experiment being 
carried out in triplicate. Cells were removed from the incubator, rinsed twice in cold 
PBS and then fixed in 4% PFA.. Cells were then blocked using blocking buffer for 15 
minutes and then affinity-purified 9E10 antibody was applied for 1 h in blocking buffer 
at 10pg/ml. Cells were then washed extensively and exposed to hrp-conjugated anti­
mouse secondary (1 in 2000) in blocking buffer for 45min. Cells were again washed 
and then TMB was applied for 5 minutes or until significant colour change was noted. 
TMB was removed placed in cuvettes and read at 455nm using a spectrometer. 
Nonspecific binding was determined using mock-transfected cells.
2.4.11 Overlay assay
The bait protein of interest was resolved using SDS-PAGE followed by transfer to 
nitrocellulose membranes. Here a renaturation procedure was enacted incubating the 
membrane for 15 minutes in 6M guanidine hydrochloride, 50mM Tris pH 7.4, 150 mM 
NaCI and 0.5% BSA. Renaturation consisted of a halving of the concentration of
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guanidine present in the buffer every 15 minutes whilst keeping other solute 
concentrations fixed until the concentration of guanidine was >50mM, when it was all 
removed. The probing protein was phosphorylated with PKA for 30 minutes using 
32PyATP. Unincorporated ATP was removed from the probe by centrifugation in 
micro-spin chromatography columns (BioRad). Probe was then applied to 
nitocellulose membranes in 5% BSA/PBS 0.1% TWEEN overnight at 4#C with 
agitation. Membranes were then washed thoroughly in blocking solution followed by 
PBS/TWEEN alone. Membranes were dried and exposed to phosphorimager screen.
2.4.12 Phosphoamino acid analysis
Post-SDS-PAGE gels were fixed in 40% methanol, stained with Coomassie and 
dried. Post-autoradigroaph exposure bands were excised from gel and rehydrated. 
They were then digested in either trypsin or thermolysin (0.1 mg/ml) for >18h at 37°C. 
Digests were separated from gel and dryed down in a spin vacuum. They were then 
hydrolysed in 6N HCI for 2h at 95°C. The solution was redried and then dissolved in 
10pl H2O which was spotted on plastic backed cellulose chromatography paper. Also 
spotted were standards. Samples were electrophoresed at pH 1.9 (in formic acid, 
acetic acid, water (1:10:89) solution) and then at pH 3.5 (acetic acid, water). 
Standards were visualised with ninhydrin. Chromotography paper was then exposed 
to either phosphorimager screen or autoradiograph.
2.4.13 Peptide maps
Peptides were retrieved from gels as above and then centrally spotted onto cellulose 
chromatography paper along with phenol red and basic fuschin dyes. Samples were 
then separated using electrophoresis at pH 3.5. A second dimension was then run 
using ascending chromatography.
2.4.14 Production and Purification of phospho-specific antibodies
Peptides were conjugated using N-terminal cysteine residues onto maleimide reacted 
MCKL haemocyanin Imject kit (Pierce). They were then injected into rabbits at set 
dates following a standard protocol (Cocalbiochem, USA). Bleeds were regularly 
tested for immunoreactivity to peptides and when this was deemed to be sufficient
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purified over peptide conjugated Thiosepharose columns (Pharmacia), initially over a 
de-phospho peptide column, and then the elute was passed over a phospho-peptide 
column. After extensive washing in buffer containing 500mM NaCI columns were 
eluted with 0.1M glycine pH 2.8. Eluant was immediately added to 1M Tris pH8, to a 
final pH 7.4. Antibody was then dialysed, concentrated and had sodium azide added.
2.4.15 Purification of AMPK and Edman degradation
AMPK was kindly purified by David Carling as described previously (Carling et al. 
1989 ). Edman degradation was carried out as previously described.
2.5.0 Commonly Used Buffers
TAE (Tris-Acetate EDTA) 40mM Tris-acetate
1mM EDTA (pH 8.0)
TBE (Tris-Borate EDTA) 90mM Tris-borate
2mM EDTA
TE (Tris EDTA) usually pH 7.6 10mM Tris.HCI (pH 7.6) 
1mM EDTA (pH 8.0)
SDS-PAGE buffer (Sodium Dodecyl Sulphate 
Polyacrylamide Gel Electrophoresis Buffer)
25mM Tris
250mM glycine (pH 8.3) 
0.1% SDS
Western Blotting Transfer Buffer 50mM Tris
380mM glycine 
0.1% SDS 
20% methanol
Solution I (For mini-preparation of plasmid DNA) 50mM glucose 
25mM Tris pH 8.0 
10mM EDTA
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10mM EDTA
Solution II
Solution III
Buffer A (For GST fusion protein purification)
Buffer B
Buffer C
Phosphate Buffer pH 7.6
1% SDS 
200mM NaOH
5M potassium acetate 
(29ml glacial acetic, 50ml 
H20 + 10MKOH on ice 
pH4.8)
50mM Tris pH 8.0 
25% sucrose 
10mM EDTA
10mM Tris pH 7.6 
1mM EDTA
20mM HEPES pH 7.6 
100mM KCI 
1mM EDTA 
20% glycerol 
5mM DTT (Dithiotriol)
84.5mM Na2HP04 
15.5mM Na2HP04
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CHAPTER THREE
3.1 Introduction
In the introduction to this thesis I described what is understood with regards to the 
mechanisms of GPCR receptor desensitisation and subsequent endocytosis. The 
majority of GPCRs studied desensitise due to receptor phosphorylation; this can be 
homologous, i.e. triggered by agonist occupation, or heterologous through the activity 
of other second messenger kinases. Rapid agonist induced phosphorylation is 
normally carried out by GRKs (Pitcher et al., 1999). Phosphorylation uncouples 
receptors from G-proteins and promotes interaction with arrestins. Association with 
arrestins sterically prevents further G-protein coupling and facilitates receptor 
endocytosis via clathrin-coated pits (Luttrell & Lefkowitz 2002). Endocytosis leads to 
a decrease in the number of receptors at the cell surface and this is detectable within 
minutes of GPCR activation. Internalised receptors can be either returned to the 
surface in a de-phosphorylated and resensitised state, or degraded via late 
endosomes and lysosomes. Downregulation describes the permanent reduction in 
the number of receptors that is often observed after prolonged agonist exposure 
(Tsao et al., 2001). This is the least understood step in the process of GPCR 
desensitisation, but it is thought to involve degradation of receptor proteins 
concomitant with a reduction in receptor expression (Ferguson 2001, Lefkowitz 2001, 
von Zastrow 2001).The separate steps of GPCR desensitisation have been 
delineated using a small number of ‘model’ receptor proteins, most commonly the p2 
adrenergic receptor, expressed in recombinant systems. It has been subsequently 
demonstrated that a large number of other class A and class B GPCRs utilise similar 
systems to the p2 adrenergic receptor albeit with minor differences such as GRK 
specificity and arrestin preference (Zhang et al., 1998). Heterologous and 
homologous phosphorylation of members of the class C mGluR family is also 
important for desensitisation (Schaffhauser et al., 2000, Cai et al., 2001, Sorenson & 
Conn 2003). Although structurally quite dissimilar from class A and class B GPCRs, 
with much smaller intracellular loops and far larger extracellular N-terminal domains, 
mGluRs can interact with both GRKs and arrestins. In cerebellar Purkinje cells 
mGluRI activity is regulated by GRK4 (Sallese et al., 2000) and in HEK 293 cells
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GRK2 and GRK5 phosphorylate mGluRI in an agonist dependent manner (Dale et 
al., 2000, Kaur Dhami et al., 2002). mGluRI undergoes both constitutive and agonist 
induced endocytosis that is enhanced by overexpression of arrestin 2 (Dale et al., 
2001) but interestingly arrestin 3 has little effect. It has recently been demonstrated 
that GRKs can regulate mGluRI activity in a manner independent of phosphorylation, 
but instead dependent upon the RGS domains of the GRKs. GRK 2 and GRK 5 have 
also been shown to regulate the desensitisation of mGluR 5 (Sorenson & Conn 
2003).
Heterologous expression of receptors in cell lines such as HEK 293 leads to 
uniform expression over a cell surface. Neurones show a far higher degree of 
compartmentalisation and this may lead to variable ratios of receptors to GRKs and 
arrestins. It is therefore likely that the regulation of cell surface GPCRs is far more 
complex in neurones, and probably dependent upon the receptor location e.g. 
synaptic verses extra-synaptic receptors.
GABAb receptors are, as previously noted, members of the class C GPCRs. The 
control of GABAb receptor desensitisation and surface stability is poorly understood 
in comparison to other GPCRs. It has been established that GABAb(2) is a substrate 
for PKA, and that phosphorylation by PKA at serine 892 in the intracellular carboxy- 
terminal domain of GABAb(2) greatly delays the onset of GABAb desensitisation 
(Couve et al., 2001). This contrasts with the classical induction of desensitisation 
through phosphorylation observed with other receptors including those in class C. 
Chronic agonist activation decreases phosphorylation of GABAB(2) at serine 892 
(Couve et al., 2001), but it is not clear whether agonist affects the phosphorylation 
status of GABAB(i), or other sites within GABAb(2). A role in the desensitisation and 
control of cell surface stability of GABAb receptors for GRKs and arrestins has yet to 
be determined. It is possible that the heterodimeric nature of GABAb receptors 
precludes interactions with these proteins.
To further understand the mechanisms behind the control of GABAb cell surface 
stability I examined:
1) The effect of agonist on the phosphorylation state of both GABAB(i) and 
GABAB(2) in heterologous systems.
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2) The effects of overexpression of different GRKs upon agonist-induced 
phosphorylation.
3) The cell surface stability of GABAb receptors in heterologous systems with 
and without the overexpression of arrestins.
4) The endocytosis and surface stability of endogenous GABAb receptors in 
cultured neurones.
For the heterologous studies I chose to use COS-7 cells. These have no 
endogenous GABAb response but readily express both subunits in quantities 
amenable to biochemical analysis. Moreover, COS-7 cells have formed the basis for 
much of the current understanding of trafficking events of GABAb receptors (Margeta 
Mitrovic et al.,. 1999, Calver, et al.,. 1999). Another advantage of using COS-7 cells 
is that they express only low levels of endogenous GRK's and arrestins (Ferguson 
2001), allowing for the observation of larger effects upon their overexpression.
For endogenous studies I used embryonically derived cultured cortical and 
hippocampal neurones, both of which express GABAB(i) and GABAB(2).
73
3.2 Studies in recombinant systems
3.2.1 GABAB(i) and GABAB(2) are phosphorylated in mammalian cell lines
COS-7 cells were transiently transfected with myc-tagged GABAB(ia) and FLAG- 
tagged GABAB(2) either singly (10pg per transfection) or together in a ratio of 1:4 
GABAB(1a): GABAB(2) (20pg total). This had previously been determined to be the 
optimal ratio of DNA for maximal surface expression of the receptor complex (Couve 
et al., 2001) and was kept constant in all experiments unless otherwise stated.
To determine the optimal conditions for immunoprecipitation, cells expressing 
receptors were incubated in media containing 35S labelled methionine for 4h, 36-48h 
after transfection. Cells were then rinsed in PBS prior to solubilisation in RIPA buffer 
for 1h. Cell lysates were then prepared and pre-cleared with IgG and Protein G and 
receptors were then immunoprecipitated with appropriate antibodies for 2h. After 
extensive washing in high salt concentration RIPA, immunoprecipitates were 
resolved using 8% SDS-PAGE, gels dried and exposed to autoradiograph. When 
expressed in COS-7 cells, myc-tagged GABAB(ia) migrates at approximately 116 kDa, 
whilst flag-tagged GABAB(2) migrates around 105 kDa (fig.3). Although the use of 
RIPA as an extraction buffer allows for the maximal solubilisation of GABAb receptors 
(Benke et al., 1999) it disrupts the interaction between GABAB(ia) and GABAB(2). If 
receptor complexes were immunoprecipitated using an antibody to one subunit only, 
minimal amounts of the other subunit were co-immunoprecipitated; yet to analyse 
phosphorylation of the receptor it was important to maximise the amount of receptor 
immunoprecipitated and immunoprecipitate similar amounts of both subunits. 
Immunoprecipitation was therefore carried out with antibodies to both tagged 
subunits allowing analysis of similar amounts of both GABAB(ia) and GABAB(2) (fig.3a 
lane 4).
To determine whether receptor subunits were phosphorylated they were 
transfected singly or co-transfected into COS-7 cells. 36-48h post-transfection, cells 
were rinsed in phosphate-free media prior to incubation for 4h in phosphate free 
media to which was added 32P labelled orthophosphate (0.5mCi ml'1). Receptors 
were then immunoprecipitated and samples resolved on 8% SDS-PAGE. I observed 
that the bands derived from cells labelled with 32P are much broader, and it is more
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difficult to separate the individual subunits GABAB(ia) and GABAB(2). This is because 
of the much higher energy beta emission produced by the 32P isotope in comparison 
to 35S. It is apparent however that both GABAB(ia) and G A B A ^  are highly 
phosphorylated when expressed either singly or together, and that bands at this 
molecular weight are not observed to immunoprecipitate from untransfected cells with 
either flag or myc antibodies (fig. 3b,c).
The observation that both GABAB(i) and GABAb(2) are phosphorylated when 
expressed individually demonstrates that this covalent modification does not require 
receptor activity (because of receptor inactivity when subunits are expressed 
individually). It is also worthy of note that GABAB(i) is phosphorylated even when 
intracellularly retained.
3.2.2 Agonist does not enhance phosphorylation of either subunit
Agonist occupation of G-protein coupled receptors can trigger phosphorylation of 
the receptor. This can be through second messenger stimulated pathways such as 
PKA and PKC, or it can be through GRK’s. To determine whether the basal 
phosphorylation observed in GABAs receptors could be modulated by the activity of 
the receptors, whole cell labelling experiments were carried out to determine the 
phosphorylation state of both GABAb subunits pre- and post agonist. COS-7 cells 
were transiently transfected and then labelled with 32P as before. Thirty minutes 
before the end of 32P orthophosphate incubation plates were treated with 100pM 
baclofen, or designated untreated controls. Receptors were then immunoprecipitated 
and resolved using 8% SDS-PAGE.
Baclofen did not induce a significant enhancement in the phosphorylation levels 
of either GABAb(-|) or GABAB(2) (n=4) (fig 4a,b). The phosphorylation state of both 
subunits also did not increase after only 5 or 10 minutes of agonist application.
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Figure 3 GABAb receptors are basally phosphorylated
a) COS-7 cells transfected with myc-tagged GABAB(1) and flag-tagged GABAB(2) 
were incubated with 35S labelled methionine containing media for 4 hours prior 
to immunoprecipitation with myc, flag or both antibodies. R1 migrates at 
~116kDa whilst R2 migrates at 105 kDa.
b) Immunprecipitated GABAB(2) from 32P labelled COS-7 cells demonstrates 
basal phosphorylation.
c) GABAB(1) is also basally phosphorylated when expressed alone or with R2.
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Figure 4 Agonist does not enhance phosphorylation of either subunit
Application of baclofen does not enhance the phosphorylation of either subunit 
when co-expressed in 32P labelled COS-7 cells (n=4)
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3.2.3 GRK overexpression does not enhance agonist induced 
phosphorylation of GABAb receptors
It is possible that a kinase responsible for agonist induced phosphorylation in vivo 
would be underexpressed in comparison to the expression levels of GABAb in 
transfected cells. This would lead to difficulties in measuring agonist induced 
phosphorylation.
GRKs are responsible for homologous phosphorylation of receptors and 
overexpression of GRK 2 has been shown to enhance agonist-induced 
phosphorylation of a multitude of GPCRs including mGluRs. Because 
phylogenetically the GABAb receptor is closest to metabotropic glutamate receptors, I 
decided to determine whether GABAb receptor phosphorylation could be enhanced 
by the overexpression of GRK2. Whole cell labelling experiments were carried out as 
before, with the co-expression of GRK2. Transfection ratios were of 1:4:1 GABAB(1): 
GABAB(2):GRK2.
Initially I studied solely GABAB(2) phosphorylation in the presence of GRK2 
because it is GABAB{2) that is G-protein coupling subunit, and therefore most likely to 
be the target of uncoupling phosphorylation. GABAB(2) was immunoprecipitated from 
cells co-expressing GABAB(d and GRK2 after different exposure times to 100pM 
baclofen. However, agonist application did not elicit an increase in the 
phosphorylation of GABAB(2), but the converse (fig. 5a). This response was noted in 
the presence or absence of GRK2 and may be due to a decrease in PKA activity 
sequential to baclofen-mediated inhibition of adenylyl cyclase. GABAB(2) 
phosphorylation is returned to basal levels after 30 minutes, possibly reflecting the 
importance of GABAB(2) phosphorylation in preventing desensitisation. This rebound 
in phosphorylation can be explained by GABAb desensitisation, reducing the negative 
regulation of adenylyl cyclase and leading to increased PKA activity and a 
subsequent increase in GABAB(2) phosphorylation.
The effect of overexpression of GRK2 on total receptor phosphorylation by 
immunoprecipitating both GABAB(i) and GABAB(2) with and without agonist exposure 
was then analysed. Overexpression of GRK2 did not significantly affect the basal 
phosphorylation state of the whole receptor, neither the phosphorylation after agonist 
treatment (fig 5b). It is possible though that GRK2 does interact with the whole
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receptor, as is seen in figure 5b, where a band running at approximately 80kDa is 
only observed when GRK2 is over-expressed. Although this could be an interacting 
protein that is phosphorylated by GRK2, 80kDa is the molecular weight of GRK2. It 
may be that GRK2 interacts with GABAb in a manner not involving phosphorylation, 
but can modulate signalling through its RGS domains.
Concurrent to investigating the role of GRK2 in GABAb phosphorylation in vivo, 
an in vitro method was also employed. Recombinant GRK2, purified from an SF9 
insect cell line (a kind gift from Dr J.Pitcher), was incubated in tandem with G-protein 
Py subunits, PIP2 (both important for optimal GRK2 activity) and 32PyATP with 
purified GST-fusion proteins encompassing the carboxy-terminal domain of GABAB(i) 
or GABAb(2). Reactions were carried out in kinase buffer @ 30°C and terminated after 
15 minutes. GST alone was not a GRK substrate, and neither were the carboxy- 
terminal domains of GABAB(i ) or GABAs^) (fig. 5c). In vivo the receptor domains are 
believed to interact through coiled-coil motifs; and this may confer a different 
confirmation to when alone. To investigate the possibility that together the domains 
may present a substrate more similar to that in vivo, fusion proteins of GABAB(i) and 
GABAB(2) carboxy-terminal domains were pre-mixed and then incubated with GRK2. 
This was not the case though and again there was negligible phosphorylation (fig. 5c 
lane 4). The poor efficiency of GRK2 phosphorylation of GABAb subunits is illustrated 
when contrasted with the phosphorylation of GABAB(2) achieved by co-incubation with 
PKA (approximately 1 mole stoichiometry), or the phosphorylation observed of 
activated rhodopsin from purified rod outer segments by GRK2.
To explore the possibility that GABAb receptors are substrates for other GRKs 
similar whole cell labelling experiments were carried with the co-expression of both 
GABAb subunits and either GRK3, GRK5. Again, agonist application in the presence 
of each of these GRKs did not elicit an increase in the phosphorylation status of 
GABAb receptors (fig 5d,e).
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3.2.4 Influence of agonist upon stability of cell surface GABAb receptors in 
COS-7 cells
Although agonist did not enhance GABAb phosphorylation, the effect of agonist 
upon the surface stability of GABAb remained unknown. To investigate this COS-7 
cells were transiently transfected with GABAb receptors and seeded into 6 X 30mm 
well plates. Cells were exposed to agonist 36-48 hours post-transfection by addition 
of 100pM baclofen to the media for either 5,10,15 or 30 minutes whilst incubated at 
37°C. Cells were then fixed in paraformaldehyde and blocked in blocking solution. 
Whole cell ELISAs were carried out with surface myc-tagged GABA^i) probed for 
with affinity purified monoclonal anti-myc antibody. After extensive washing cells 
were exposed to secondary HRP conjugated donkey anti-mouse antibody. Cells were 
again washed and then incubated with the substrate TMB for 15 minutes. TMB is 
colourless upon application but exposure to HRP catalyses a colour change to blue. 
This colour change was quantitated with a photospectrometer set to read absorbance 
at 655nM. A cuvette containing unexposed TMB was used as a blank, and 
background antibody adherence to cells was quantitated by carrying out the ELISA 
on untransfected cells. All experiments were carried out in triplicate. Agonist 
appeared to cause a decrease in detectable receptors (fig. 6a), but this reduction is 
too small to be significant and, being similar at 5 minutes and 30 minutes, did not 
increase with time as would be expected with receptor internalisation. Typical 
reductions of 40% surface number are observed upon agonist application in similar 
experiments (Scott et ai, 2002). This is illustrated by comparing the GABAb response 
to the decrease in surface levels of the TRH receptor in the same system (fig. 6a).
To determine whether the small decrease in surface GABAb receptor number 
could be explained by receptor internalisation, or whether receptors were 
internalising and then rapidly recycling, biotinylation-cleavage assays were 
performed. These consisted of labelling GABAb transfected COS-7 cells that were 
pre-treated for 1 hour with the lysosomal inhibitor leupeptin (100pg/ml), with cell- 
impermeable, cleavable NHS-SS-biotin in PBS on ice. Post-biotinylation, cell media 
was returned and plates were replaced in the incubator at 37°C. Cells were then 
treated with 100pM baclofen, or left untreated. At 5, 10 or 30 minutes after the 
commencement of treatment, plates were placed back on ice. The remaining surface
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biotin was cleaved using glutathione containing cleavage buffer and cells were then 
solubilised in RIPA. Cell lysates were prepared and biotinylated proteins were 
precipitated on streptavidin-conjugated beads. After thorough washing, samples were 
examined using SDS-PAGE followed by western blotting. Streptavidin precipitates 
from only cells transfected with both GABAB(i) and GABAB(2) that had been kept on 
ice post-biotinylation and not cleaved showed myc-GABAB(i) at the surface, 
detectable as a broad band of approximately 115-130 kDa (fig. 6b lane 1). As a 
control to demonstrate the efficiency of cleavage, cells were kept on ice for 30 
minutes, preventing any internalisation, and then cleaved. These cells showed >95% 
decrease in GABAB(i) present in precipitates (fig. 6b lane 2), illustrating high cleavage 
efficiency. Precipitates from cells returned to the incubator prior to cleavage showed 
low myc-immunoreactivity, similar to that in observed in the cleavage control. This 
demonstrates that GABAb receptors are not subject to constitutive internalisation in 
recombinant systems. Application of baclofen did not cause an increase in detectable 
internalised receptors, demonstrating a lack of agonist induced GABAs receptor 
internalisation.
Although the data from cell-surface ELISA assays appears to contradict the 
biotinylation data, there are other explanations for the small reduction in signal seen 
after baclofen application. Baclofen binding to GABAb is thought to allosterically 
change the confirmation of the extracellular domain of GABAB(i) with the exposed 
extracellular domain closing in on itself. It is possible that upon fixation of cells with 
paraformaldehyde a proportion of the receptors are cross-linked in this confirmation 
leaving the N-terminal myc-tag marginally less accessible to antibody. Receptor 
number seems to be similar at all time points post baclofen addition, and does not 
decrease with time as would be expected with internalisation, supporting a change in 
affinity for anti-myc antibody.
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Figure 5 Analysis of effects of GRK over-expression upon GABAb receptor 
phosphorylation
a) Timecourse of GABAb(2) phosphorylation in COS-7 cells co-transfected with 
GABAB(1),GABAB(2), and GRK2 over 20 minutes after baclofen application.
b) GABAb(1) and GABAB(2) co-expressed with GRK 2 were immunoprecipitated 
from 32P radiolabelled COS-7 cells after exposure to 100pM baclofen for 30 
minutes.
c) GST-fusion proteins of the carboxy-terminal tails of GABAB(1) and GABAB(2) 
were incubated with purified GRK2 and 32PyATP in the presence of PIP2 and G- 
protein (W subunits. Phosphorylation was insignificant in comparison to 
rhodopsin from rod outer segments, or the phosphorylation of GABAb(2) by PKA.
d) e) Whole cell labelling experiments were carried out over-expressing GRK3 
and 5 to analyse whether the overexpression of these kinases lead to agonist 
induced phosphoryla tion. No s ign ifican t effect was observed.
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Figure 6 Surface GABAb receptors are highly stable in heterologous 
systems
a) COS-7 cells co-transfected with myc-GABAB(1) and flag-GABAB(2) were treated 
for between 5 and 30 minutes with 100pM baclofen before fixation and then 
assaying the number of surface receptors using a whole cell ELISA. Treatment 
had no significant effect upon surface G A B A b  levels, whilst treatment of cells 
transfected with TRHR with 30min 10pM TRH significantly reduced surface 
receptor levels.
b) COS-7 cells co-transfected with m yc-G ABA^) and flag-GABAB(2) were 
biotinylated with cleavable biotin, and then returned to the incubator for times 
upto 30 minutes in the presence of 100pM baclofen. Surface biotin was then 
cleaved and cells solubilised with labelled receptor purified on streptavidin 
beads. Total surface was assessed from plates left on ice (Control), and 
efficiency of cleavage was determined by cleaving plates not returned to the 
incubator but kept on ice (Cleave). Incubation in the presence or absence of 
baclofen did lead to receptor internalisation.
3.2.5 Analysis of the effect of arrestins upon GABAb receptors
The apparent stability of GABAb receptors upon activation could be because 
arrestin proteins, which are important for GPCR endocytosis, are not present in a 
stoichiometric ratio to GABAb receptors. Indeed COS-7 cells express low levels of 
arrestins in comparison to other cell lines such as HEK-293 (J.Pitcher, personal 
communication). Although GABAb phosphorylation does not appear to be mediated 
by GRKs, certain GPCRs can endocytose in an arrestin dependent manner 
irrespective of GRK phosphorylation. One such example is mGluRI, which is 
dependent upon arrestin 2 for both constitutive and agonist induced endocytosis 
(Dale et a!.,. 2001). The crystallisation of arrestin 1 demonstrated the presence of a 
phosphate sensor domain that specifically interacts with phosphorylated rhodopsin 
(Graznin et a!., 1998; Hirsch et al., 1999). That both GABA^-i) and GABAB(2) are 
basally phosphorylated also means that an interaction with arrestins could be 
possible, with agonist altering the confirmation of the cytosolic portion of the receptor 
exposing phosphorylated residues to arrestins.
Activation of GPCRs that interact with arrestins causes a characteristic change in 
the cellular localisation of arrestins. Prior to receptor activation, arrestins display a 
mainly cytosolic localisation, but upon receptor activation arrestin distribution is 
changed and arrestins translocate to the cell surface membrane and interact with 
with receptors (Luttrell & Lefkowitz 2002). This is rapidly followed by the clustering of 
receptor/arrestin complexes into clathrin-coated pits, where arrestins can be 
observed in punctate endosomal compartments. From this stage receptors can be 
divided into 2 different classes: those that continue to interact with arrestins and 
those that don’t (Oakley et al., 2000). If the arrestin receptor interaction is maintained 
then arrestins are observed to form large peri-nuclear clusters in tandem with the 
receptors, otherwise they gradually resume a more cytosolic localisation (Oakley et 
al., 2000).
An immunofluorescence based approach was utilised to investigate whether 
GABAb receptors can interact with arrestins, and also whether any such interaction 
can direct the internalisation of GABAb receptors. COS-7 cells were transiently 
transfected with GABAb receptors and an EGFP tagged arrestin 3 construct and 
seeded onto poly-L-lysine coated coverslips. Thyrotropin-releasing hormone
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receptors (TRHR) have previously been demonstrated to internalise in response to 
agonist in an arrestin dependent manner (Scott et al., 2002) and so VSV-tagged 
TRHRs were also co-expressed with EGFP arrestin 3 as a positive control. 
Coverslips were incubated at 4eC with antibodies to expressed receptors added to 
complete media (monoclonal anti-myc for GABAB(i> and monoclonal anti-VSV for 
TRHR). After thorough washing coverslips returned to the incubator in serum free 
media to which was added agonist complimentary to the receptor (100pM baclofen or 
10pM TRH). After 2, 5 or 30 minutes of incubation coverslips were removed and 
fixed. Receptors remaining at the surface were stained with Cy5 conjugated anti­
mouse antibody, cells were then permeabilised and internalised receptors stained 
with TRITC conjugated anti-mouse antibody.
Only low levels of TRITC staining were observed in cells expressing GABAb 
receptors that had been returned to the incubator, similar to the staining present in 
cells kept on ice (fig.7 images C,K,S); whilst Cy5 staining of surface receptors 
remained constant (fig.7 images B.J.R). This supported the data obtained in cell- 
surface biotinylation assays indicating a lack of agonist-induced internalisation of 
GABAb receptors. Furthermore, the localisation of co-expressed arrestin 3 was 
unchanged throughout agonist exposure (fig.7 images A.I.Q) signifying the lack of a 
role for arrestins in GABAb desensitisation. The response of arrestin 3 in cells 
expressing TRHR contrasts vividly with that seen in GABAb. Here a redistribution of 
receptor from the surface to an internal pool through an endosomal pathway in 
conjunction with a tight association of arrestin 3 is observed (fig.7 images D-G.M- 
P.U-X).
Although there is functional redundancy between arrestin 2 and 3 in regard to the 
endocytosis of many GPCRs (Luttrell 2002) with similar expression patterns of both, 
instances of receptor preference for one over the other exist, as is seen for mGluRI 
(Dale et al.,. 2001). Arrestin 2 was also over-expressed in conjunction with GABAb 
receptors to investigate whether it could interact with and direct GABAb receptor 
endocytosis. However, these experiments revealed that, similar to arrestin 3, arrestin 
2 had no observable effect upon the cell surface stability or internalisation of GABAb 
receptors (fig.8).
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3.2.6 Effects of agonist on the degradation of GABAb receptors in COS-7 cells
Post-internalisation, GPCRs are either degraded or recycled to the surface. 
Application of agonist enhances internalisation and therefore increases the 
probability that a receptor will be degraded. To determine whether chronic agonist 
treatment enhances degradation of surface GABAb receptors I used a biotinylation- 
degradation assay similar to that used by other experimenters in the study of GPCR 
degradation (e.g. Whistler et al., 2002). Cells co-transfected with GABAB(i) and 
GABAb(2) were labelled with the non-cleavable biotin derivative succimodobiotin 36- 
48h post-transfection. This does not have the disulphide group of NHS-SS-biotin, and 
so is stable even under reducing conditions, allowing for irreversible biotinylation. 
Post-biotinylation, plates were returned to the incubator to equilibrate for 6h before 
lysis in RIPA buffer of labelled plates for an initial time point, taken to be time Oh 
which was snap frozen in liquid N2. Plates were then treated with 100pM baclofen or 
left untreated and incubated for a further 20 hours prior to lysis of remaining plates. 
Lysates were then prepared from all cells and remaining biotinylated proteins purified 
with streptavidin-conjugated beads. Western blotting of SDS-PAGE subjected 
samples demonstrates that after 20h of incubation -40% of GABAb receptors are 
remaining (fig. 9a,b), equating to an approximate half life of surface GABAb in COS-7 
cells of 16 hours. This is significantly greater than the 10h half life of GABA^) 
measured by Couve et al.,. when expressed in COS-7 cells (Couve etal., 1999). This 
difference is probably attributable to co-expression of GABAb(2) in my study, allowing 
me to look purely at surface receptors.
Interestingly, treatment of the cells with baclofen did not significantly alter the 
receptor degradation rate. This again supports the lack of agonist-induced 
internalisation observed in this cell line.
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Figure 7 Overexpression of arrestin 3 does not alter GABAb heterodimer cell 
surface stability
COS cells were transfected with MYC-GABAB(ia) and FLAG-GABAB(2) plus 
arrestin 3-EGFP (a-d, i-l and q-t) or with TRHR plus arrestin 3-EGFP (e-h, m-p and 
u-x). Cells were stimulated with 100 pM baclofen for 5 min (i-l) or 30 min (q-t) or 
with 10 pM TRH for 5 min (m-p) or 30 min (u-x). Cells were then processed for 
immunofluorescence. Arrestin 3-EGFP is shown on the left panels. The surface 
receptor pool was detected using Cy5 conjugated secondary antibodies prior to 
permeabilisation (blue channel). The internalised receptor pool was detected 
using Texas-Red conjugated secondary antibodies following permeabilisation 
(red channel). Merged images are shown on the right hand 
panels.
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Figure 8: Overexpression of arrestin 2 does not alter GABAb heterodimer cell 
surface stability
COS-7 cells were transfected with myc-GABAB<ia) and flag-GABAB(2) plus EGFP- 
arrestin 2 (a-l). Cells were left untreated (a-d) or stimulated with 100 pM baclofen 
for 5 min (e-h) or 30 min (i-l). Cells were then processed for immunofluorescence. 
EGFP-arrestin 2 is shown on the left panels. The surface receptor pool was 
detected using Cy5 conjugated secondary antibodies prior to permeabilisation 
(blue channel). The internalised receptor pool was detected using Texas-Red 
conjugated secondary antibodies following permeabilisation (red channel). 
Merged images are shown on the right hand panels.
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Figure 9 Application of agonist does not enhance GABAb degradation in 
heterologous systems
a) COS-7 cells co-transfected with myc-GABAB(1) and flag-GABAB(2) were surface 
biotinylated and then either lysed (control) or returned to the incubator for 20h 
with or without 100pM baclofen. Cells were then lysed and biotinylated proteins 
were streptavidin purified. Samples were resolved by SDS-PAGE, transferred to 
nitrocellulose and immunoblotted with anti-myc antibody, follwed by [125l] 
labelled secondary.
b) Blots were quantitated using a phosphorimager. Application of baclofen had 
no effect upon amount of biotinylated GABAb remaining after 20h.
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3.3 Studies of endogenous receptors
3.3.1 GABAb receptors are highly stable at the cell surface in cortical 
neurones
Cortical neurones derived from E18 rat embryos were cultured on 10cm poly-L- 
lysine plates. At 5 DIV plates were pre-treated for 1 hour with the lysosomal inhibitor 
leupeptin (100pg/ml), biotinylated with cleavable biotin and then either left on ice or 
returned to the incubator for defined time periods in the presence or absence of 
100pM baclofen. This was to allow observation of GABAb receptor internalisation in 
the cultures, and also to determine whether internalisation is enhanced by agonist. 
After incubation surface biotin was cleaved using glutathione based cleavage buffer 
and cells were lysed in RIPA. Streptavidin coated beads were used to purify proteins 
that had been biotinylated and then endocytosed, thus protected from cleavage. The 
experiments in figure 10 were carried out with Dr A. Couve, and these demonstrate 
that both GABAbo) and GABAB(2) are present at the surface of cortical neurones after 
5 DIV. Moreover, they are not subject to significant levels of basal endocytosis and 
neither is there enhancement of endocytosis by treatment of agonist at 10 or 60 
minutes (60 min: control = 2.6 ±1.0%, baclofen = 3.5 ± 1.0%, n=3) (fig. 10a,b). Only 
when cultures are treated for 6h with baclofen is there a small enhancement of the 
internalisation of GABAB(i). This increase is relatively minor however, and the length 
of treatment required does not fit with the time course expected from classical agonist 
induced endocytosis of other GPCRs.
To demonstrate the validity of the system, membranes were immunoblotted for 
the AMPA receptor subunit GluR1. This has previously been demonstrated to 
internalise both constitutively and upon treatment with AMPA (Ehlers 2000). Over a 
60 minute timecourse in the presence of AMPA ~43% of GluR1 was recovered from 
an internal pool (fig. 10c).
To visually confirm the biotinylation data, 20 DIV hippocampal neurones grown on 
coverslips were treated with 100pM baclofen for either 15 minutes or 1 hour. Cultures 
were then fixed in paraformaldehyde in tandem with untreated controls, and co­
stained with antibodies against either GABAB(i) or GABAB(2) and a marker for early 
endosomes, EEA-1. Because AMPA receptors internalise rapidly into endosomes in
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a dynamin and agonist dependent manner (Carroll et al., 1999), I compared the 
endocytosis of AMPA receptors with that of GABAb. To do this I treated separate 
coverslips from the same culture with AMPA (100pM) for 15 minutes and then fixed, 
permeabilised and co-stained for GluR1 and EEA-1 in parallel with untreated 
coverslips.
Treatment of neurones with AMPA for 15 minutes caused a rapid change in the 
distribution of GluR1 containing receptors. Prior to treatment they exhibit a dendritic 
cell membrane distribution. AMPA treatment results in a re-distribution of receptors to 
the soma of the cell body where the appear very punctate. This occurred in tandem 
with a large increase in co-localisation of GluR1 and EEA1, indicative of trafficking to 
early endosomes (fig. 11a).
Antibodies to GABAB(2) show membranous distribution over the cell body and also 
along dendrites (fig. 11b). Receptors are not clustered, with staining appearing quite 
even throughout the neurones. In the basal state there is no co-localisation of 
GABAB(2) with EEA1 staining endosomes. Agonist treatment does not change the 
localisation of GABAB(2), with the same proportion remaining at the membrane. There 
is also no re-distribution of GABAB(2) to endosomes with there remaining a complete 
lack of co-localisation of GABAB(2) and EEA1 after both 15 minutes. Even when 
treated for 60 minutes with baclofen there was no observable change in staining.
GABAB(1) showed a notable absence of surface staining. Instead, staining was 
largely somatic with distribution also along the internal compartment of dendrites. 
This was reminiscent of an ER distribution and is similar to that observed by other 
experimenters (Vernon et al., 2001). The data obtained using biotin clearly 
demonstrates the presence of the GABAB(i) at the surface in neurones, and this is 
supported by an overwhelming wealth of electrophysiological data from other 
laboratories. The antibody used for immunocytochemistry was raised against a 
portion of the carboxy-terminal domain of GABAB(i). It is feasible that the epitope is 
masked when GABAB(d and GABAB(2) interact, thus explaining the lack of surface 
staining. Other antibodies available within the laboratory raised to the N-terminal of 
GABAB(i) were also used, but unfortunately these were not suitable for 
immunofluorescence.
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Figure 10: GABAB receptor cell surface stability in primary neuronal cultures.
a) Surface proteins in 5 DIV rat cortical neurons were labelled with 1 mg/ml biotin 
and left untreated (lanes 1-3) or exposed to 100 pM baclofen (lane 4) for the 
indicated periods of time. Dishes were incubated at 4°C (lanes 1 and 2) or 37°C 
(lanes 3 and 4). Surface biotin remaining after incubation periods was left 
uncleaved (lane 1) or removed by cleaving with glutathione (lanes 2-4). Lysates 
were precipitated with streptavidin beads and samples resolved by SDS-PAGE. 
Immunoblots were performed with anti-GABAB(1) antibodies and [125l]- 
conjugated secondary anti-rabbit antibody. The immunoblots were visualized 
using a phosphorimager.
b) Same as above using anti-GABAB(2) antibodies.
c) Same as above using 100 pM AMPA + 50 pM AP5 for 60 minutes (lane 4) and 
GluR1 antibodies.
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Figure 11 Immunofluorescence analysis of GABAb receptor surface stability
21 DIV hippocampal neurons were left untreated (a,b,c top panels) or stimulated 
with 100pM AMPA for 15 minutes (a) or 100pM baclofen for 15 minutes (b,c). Cells 
were fixed and treated for immunofuorescence using anti GluR1 antibodies (a) or 
anti GABAb antibodies (b,c) in combination with anti-EEA1 antibodies. FITC 
conjugated secondary antibodies were used to visualise the receptors and Texas 
Red-conjugated secondary antibodies were used to visualize EEA1. All panels 
correspond to merged images. Examples of colocalization of AMPA receptors 
and EEA1 are indicated by white arrows.
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The lack of observable GABAB(i) at the surface makes it difficult to draw any 
conclusions from GABAB(i) staining. It is possible to say though that although there is 
a degree of overlap of GABA^-i) and EEA1 staining, there is no accumulation of 
GABAB(i) within EEA1 staining endosomes. The GABAb(2) data though supports that 
obtained with biotinylation.
3.3.2 Agonist application enhances GABAb receptor degradation rate in 
neurones
Detection of an internalised pool of biotinylated GABAb receptors was difficult 
even six hours post-biotinylation. Any endocytosis that occurs is probably matched by 
the rate of degradation of endocytosed receptors, although the use of leupeptin 
excludes the possibility that this degradation is lysosomal. If GABAb receptors are not 
subject to appreciable levels of endocytosis they may be present at the surface 
membrane for a long period prior to removal. Alternatively, it is possible that they are 
subject to very rapid turnover rates, and that they are degraded in a non-lysosomal 
manner at a similar rate to which they are endocytosed. This could explain the lack of 
observable endocytosed receptors. Ascertaining the average length of time a GABAb 
receptor resides at the surface would allow me to make judgements as to the 
dynamism of the receptor in neuronal cultures. To do this I labelled surface receptors 
with non-cleavable biotin and calculated their half-life, i.e. the time taken for the 
number of receptors retrieved with streptdavidin to decrease by 50%. This technique 
has been used previously to calculate the cell surface half-life of neuronal AMPA 
receptors (Mammen etal., 1997; Archibald eta i, 1998).
GABAb receptors have a very slow turnover rate, with 63.1% (±3.8% s.e.m.) 
remaining 24 hours post-biotinylation (fig. 12a). At all sampled time points up to 24 
hours post-biotinylation the addition of baclofen elicited a small increase in the 
degradation of GABAs receptors, although this was outside the realms of statistical 
significance. However, after 60h of baclofen treatment there was a highly significant 
difference between the number of GABAb receptors retrieved from treated vs. 
untreated plates. From untreated cultures 24.3% (±0.4% s.e.m.) of receptors present 
at time zero were recovered. Treatment with baclofen reduced this to 14.8% (±0.5% 
s.e.m.) (n=7, p<0.0001) indicating enhanced degradation rates (fig. 12bi,c). To
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determine whether at 60h all receptors retrieved were still at the cell surface, a similar 
experiment was performed, but using cleavable baclofen. After 60h plates were 
cleaved prior to strpetdavidin precipitation and western blotting. When compared to 
an uncleaved control from the same experiment it can be seen that cleavage 
removes all GABAB(i) immunoreactivity, indicating that all labelled receptor recovered 
at this time remains at the surface (fig. 12bii) Baclofen did not alter the morphology of 
the neurones or cause an increase in cell death. To demonstrate that the effect of 
baclofen was specific to GABAb receptors, membranes were blotted for the GABAa 
receptor subunit (33. There was no difference in the amount of GABAa receptor p3 
remaining 60 hours post-biotinylation between treated and untreated samples 
(baclofen: 97.1 ± 3.3% control, n=6) (fig. 12c).
Plotting all data showed that GABAs receptor number decreased according to an 
exponential decay with t *  31.Oh. Application of baclofen decreased this surface half- 
life to 23.5h (fig. 13a,b).
3.3.3 Chronic agonist application causes a decrease in surface GABAb 
receptors but not downregulation
Although chronic agonist enhances the degradation of surface GABAb receptors, 
the total number of receptors at the cell surface may not alter. It could be that the 
enhanced degradation rate is matched by an increase in the rate of receptor 
insertion, leaving the net number of surface receptors unchanged. To examine 
whether the total number of receptors at the surface is modulated in response to 
agonist it was necessary to pre-treat the neurones for set time periods prior to 
biotinylation and quantification of the number of receptors present. Plates of cultured 
cortical neurones were prepared and then treated at 4.5 DIV for 60h with 100pM 
baclofen. At 7 DIV plates were biotinylated in tandem with the biotinylation of 
untreated control plates. Surface proteins were purified on streptavidin as before and 
examined by SDS-PAGE and western blotting. Using this technique I found 60h pre­
treatment significantly reduced the total number of GABAb receptors at the surface 
(baclofen: 75.7 ± 4.7% control p<0.05) (fig. 14).
Continual or repetitive activation of GPCRs leads to their downregulation. This is 
defined as a decrease in the total number of receptors present in cells or tissues
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(Tsao et al., 2001). Crude lysates were also prepared so that it could be determined 
whether chronic baclofen treatment affected the internal pool of GABAb receptors. I 
also analysed levels of neurofilament to determine whether the treatment per se was 
affecting the vitality of the neurones and having a non-specific effect on GABAb 
numbers. Interestingly, I did not observe a significant decrease in the levels of 
GABAB(i) in lysates from treated neurones, and neurofilament levels remained 
unchanged (fig. 14). This demonstrates that whilst surface GABAb receptor levels are 
altered by chronic baclofen, there is no large-scale downregulation of GABAb 
receptor protein synthesis. This indicates that the enhanced degradation rates 
caused by chronic baclofen can alter surface GABAb receptor numbers 
independently of changes in total receptor number.
3.3.4 Treatments that result in the enhancement or quiescence of neuronal 
activity do not effect GABAb degradation
The chronic application of baclofen is likely to lead to a continued state of 
enhanced neuronal inhibition through enhanced baclofen induced GIRK currents. I 
decided to investigate whether this enhanced inhibition per se was responsible for 
the increase in GABAb receptor degradation rate. The chronic treatment of cultures 
with the AMPA receptor antagonist CNQX in conjunction with the NMDA antagonist 
APV prevents spontaneous mEPSCs and elicits a decrease in synaptic activity in 
cultured neurones and is a well used pharmacological tool for inhibiting neuronal 
activity in cultures (Okabe et al., 1999, Watt et al., 2000, Ehlers 2003.) I biotinylated 
cultures as before and then returned them to the incubator in conditioned media and 
treated with CNQX(10pM) and D-AP5(50pM) for 60h, equivalent to approximately 2 
half lives of the receptor under basal conditions. I then retrieved remaining 
biotinylated protein and quantitated using western blotting. If the inhibition of neuronal 
activity by baclofen was responsible for enhanced GABAb degradation then I would 
expect to see a similar enhancement in degradation with CNQX+APV. This was not 
the case however, and this pharmacological treatment appeared to have no 
significant effect on the amount of biotinylated GABAb receptor protein remaining (fig.
15). I also investigated whether enhanced neuronal activity had an effect on the 
amount of biotinylated GABAb remaining. To do this I treated biotinylated cultures
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with the GABAa antagonist bicuculline (40pM). This prevents the firing of GABAa 
mediated mIPSCs thus increasing overall excitatory activity within cultures (Ehlers 
2003). This treatment again elicited no significant effect on the amount of biotinylated 
GABAb receptors retrieved. If cultures were treated with baclofen and bicuculline 
however then a similar baclofen induced degradation of GABAb receptors was 
observed to that seen in cultures treated with baclofen alone (fig. 15). This 
demonstrates again that it is not the effect of inhibiting neuronal activity that 
enhances GABAb receptor degradation, but an effect specific to GABAb receptor 
agonist.
3.3.5 Treatment with activators of cAMP dependent protein kinase pathways 
reduces GABAb degradation
Chronic activation of GABAb receptors will lead to chronic inhibition of adenylyl 
cyclase, causing a decrease in cAMP accumulation and thus PKA activity. A 
physiological response from the neurones to try and correct this perturbation in PKA 
activity could involve reducing the number of GABAb receptors at the surface by 
enhancing the rate of their degradation. If this is true then the concomitant treatment 
of activators of PKA and baclofen should reverse such a situation. To investigate this 
possibility I treated biotinylated neurones with baclofen in conjunction with PKA 
activator forskolin (500nM) and 8-Br-cAMP (10pM). These drugs both activate PKA 
but through different pathways. Typically forskolin is used at concentrations of 20- 
50pM to cause maximal activation of PKA (e.g Couve et al., 2001), whilst 8-Br-cAMP 
is also used at much higher concentrations (Ehlers 2000). I used sub-optimal 
concentrations of both because I wanted to subtly increase overall PKA activity over 
a long time period to counteract the effect of baclofen. Treatment with PKA activators 
alone caused an increase in GABAb retrieved over basal levels. This demonstrates 
that the surface stability of the receptor is controlled as a function of PKA activity. 
When cultures were treated with both PKA activators and baclofen there was a 
significant reduction in baclofen-induced degradation (baclofen: 65.1 ±3.5%, baclofen 
+ fsk/Br-cAMP: 95.0 ±8.8%, n= 4, p< 0.05 (fig. 16)) such that degradation was 
returned to near basal levels.
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Another method of increasing PKA activity is to activate endogenous pathways 
within the neurones. One such pathway is that through p-adrenoceptors which couple 
to the Gs class of G-protein, stimulating the activity of adenylyl cyclase and so 
increasing cAMP accumulation and PKA activity. To activate this pathway I co­
treated cultures with isoproterenol (10pM), a non-selective p-adrenergic agonist and 
baclofen. When cultures were treated with both there was a small but highly 
significant reduction in the degradation of GABAb, with more biotinylated R1 retrieved 
from cultures that had been treated with isoproterenol and baclofen than baclofen 
alone (baclofen: 65.1 ±3.5%, baclofen + isoproterenol: 83.2 ±4.6%, n= 7, p< 0.01 (fig.
16)). This demonstrates that activation of endogenous systems can influence GABAb 
surface stability through receptor cross-talk.
3.3.6 Protection from degradation correlates with increased GABAB(2) ser892 
phophorylation
As mentioned earlier, GABAB(2) forms a substrate for PKA where it is basally 
phosphorylated at residue ser892. This phosphorylation has been demonstrated to 
delay the onset of desensitisation of GABAb elicited inwardly rectifying potassium 
current (Couve et al., 2001). Chronic baclofen leads to a decrease in cAMP 
accumulation by the negative regulation of adenylyl cyclase by GABAb receptors. 
This in turn leads to a reduction in PKA activity and therefore a diminishment of the 
phosphorylation at ser892; and so increased desensitisation. I noted that stimulators 
of PKA activity could reduce the baclofen-enhanced degradation. I was interested to 
see whether this reduction in degradation correlated with protection from the 
baclofen-induced dephosphorylation at ser892. To investigate this I treated cultures 
of cortical neurones with 100pM baclofen, or with 100pM baclofen + PKA activators 
as before. After treatment, crude lysates of these cultures were prepared for western 
blotting where I probed for phosphorylated GABAB(2) by using an antibody raised to a 
peptide designed to mimic the phospho-892 epitope within GABAB(2) (Couve et al., 
2001). Lysates were also probed for GABAB(2) alone so that the signal from the 
phospho-specific antibody could be normalised to total GABAB(2) levels. The PKA 
activators had a significant effect upon the phosphorylation of GABAB(2), and there 
was a 30.0±2.3% increase compared to cultures treated with baclofen alone (fig 16b).
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Figure 12 Baclofen specifically enhances surface G A B A b removal
Cortical neurones were surface biotinylated and then incubated for varying 
times with or w ithout 100pM baclofen. Neurones were then solubilised and 
biotinylated proteins were purified on streptavidin beads. Samples were 
resolved using SDS-PAGE and immunoblotted for GABAB(1a) and GABAAp3. 
Baclofen had little effect upon the amount of biotinylated GABAb retrieved up to 
24h of treatment (a), but 60h treatment caused a significant reduction in retrieval 
of GABAB(1a) (b i). The use of cleavable biotin suggested that all biotinylated 
GABAB(1a) retrieved at th is  time was at the surface (b ii). 
Data from multiple experiments show that at 60h treatment causes a significant 
reduction in the amount of biotinylated GABAB(1a) retrieved (basal: 24.33 ± 0.4% 
n=7, baclofen: 14.75 ± 0.5%, n=7, p<0.0001), but no effect on the amount of 
GABAa|33 (c).
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Figure 13 Exponential decay of surface GABAb receptors
Plotting results from multiple experiments demonstrates that biotinylated 
surface receptor decreases exponentially with a half life of 31.Oh, and this is 
reduced to 23.5h in presence of 100/jM baclofen.
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Figure 14 Chronic baclofen reduces surface but not total GABAb receptor 
numbers
Total surface numbers of GABAb receptor in primary cultures of cortical neurons 
after prolonged agonist stimulation. 5 DIV cortical neurons were left untreated (-, 
black bars) or exposed to 100 pM baclofen (+, grey bars) for 60 h at 37°C. After 
agonist treatment neurones were labelled with 1 mg/ml biotin. Lysates were 
precipitated with streptavidin beads and samples separated by SDS-PAGE. 
Immunoblots of the biotin and total fractions were performed with anti-GABAB(ia) 
antibodies, anti-neurofilament and [125l]-conjugated secondary anti-rabbit 
antibodies. The immunoblots were exposed to phosphorimager and quantified. 
The data from multiple independent experiments are expressed as 
% control ± s.e.m. p= <0.05
Control CNQX+D-AP5 Bic. Bic.+Bac.
Figure 15 Effect of activators and inhibitors of synaptic activity
upon GABAb receptor degradation
Cortical neurones were surface biotinylated and then incubated for 60h in media 
alone, or with inhibitors of neuronal activity- either 10/jM CNQX + 50/iM D-AP5, or 
activators- 4QpM bicuculline. Plates were also incubated with 4QpM bicuculline + 
100pM baclofen. Neurones were then solubilised and biotinylated proteins were 
purified on streptavidin beads. Samples were resolved using SDS-PAGE and 
immunoblotted for GABAe(ia)- Both inhibitors (CNQX + D-AP5) and activators 
(bicuculline) of neuronal activity had no effect upon amount of GABAb receptor 
retrieved at 60h. However, the addition of baclofen to bicuculline caused a 
similar enhancement of degradation as seen previously.
104
Figure 16 Protection of GABAb receptor stability in primary cultures of cortical 
neurons by PKA activation.
a) 5 DIV rat cortical neurons were biotinylated and left untreated (lane 1) or 
treated with 500 nM forskolin/10pM Br-cAMP (lane 2), 100 pM baclofen (lane 3), 
100 pM baclofen + 500 nM forskolin/10pM Br-cAMP (lane 4) or with 100 pM 
baclofen + 500 nM isoproterenol (lane 5) for 60 h at 37°C. Lysates were 
precipitated with streptavidin beads and samples separated by SDS-PAGE. 
Immunoblots were performed with anti-GABAB(i) antibodies and [125l]-conjugated 
anti-rabbit secondary antibody. Blots were exposed to a 
phosphorimager.
b) Data collected from multiple experiments was quantified and normalized to 
surface anti-GABAB(1a) in control neurons. The data is expressed as % control ± 
s.e.m.
c) 5 DIV rat cortical neurons were treated with 100 pM baclofen (-, black bar9) or 
with 100 pM baclofen + 500 nM forskolin/10 pM Br-cAMP (+, grey bars) for 30 or 
60 h at 37°C. Lysates were separated by SDS-PAGE and immunobloted with anti- 
GABAB(2) antibodies (R2) or with phosphorylation site-specific antibodies (P- 
Ser892) and [125l]-conjugated secondary. Blots were exposed to a 
phosphorimager and quantified. Data collected from multiple experiments was 
averaged and expressed as % control (baclofen treatment) ± 
s.e.m.
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3.4 Discussion
The regulation of cell surface GABAb receptors is poorly understood at present. 
The data in this chapter suggests that the cell surface stability of GABAb receptors is 
unlikely to be regulated by either GRKs or the arrestin family. Agonist does not 
promote any GRK mediated phosphorylation of GABAb receptors, nor interaction 
between GABAb receptors and arrestins. Nevertheless, a role for GRKs in the 
regulation of GABAb receptor activity cannot be conclusively negated. This is 
because this study focussed upon the cell surface stability of GABAb receptors and 
not the coupling of receptors to G-proteins; and so it is possible that receptors are 
more rapidly desensitised in conjunction with overexpression of GRKs. During the 
writing of this thesis a study was published from an independent group containing 
similar initial observations to those made here (Perroy et ai, 2003). By using FRET 
this group demonstrated that GABAb receptors do not interact with arrestin 3 and do 
not internalise in HEK cells. Perroy et ai, observed a lack of desensitisation of 
GABAb receptors in HEK cells, correlating the surface stability with activity. However, 
desensitisation was observed in cerebellar granule cells though which, unlike HEK 
cells, express GRK4. Co-expression of GRK4 and GABAb receptors in HEK cells led 
to GABAb receptor desensitisation. Perroy et ai, showed that this GRK induced 
desensitisation was independent of phosphorylation but relied upon the presence of 
the RGS domains of GRK4. Although novel with respect to GABAb receptors, there is 
precedence for a role of GRKs in desensitisation not involving phosphorylation as 
observed in the desensitisation of follicle stimulating hormone receptors (Reiter et ai, 
2001) and mGluRI (Dhami et ai, 2002).
All GRKs possess RGS domains with very similar homology to one another 
(Pitcher et ai, 1998). Whether the RGS domains of other GRKs could mediate the 
GABAb receptor desensitising effects of the RGS domain of GRK4 has not been 
ascertained. Indeed, it has been shown that for mGluRI the RGS domains of both 
GRK2 and GRK5 can mediate desensitisation. Crucially, the expression profiles of 
GRK4 do not match those of GABAb receptors. I did not analyse GRK4 mediated 
phosphorylation of GABAb receptors because initial reports could demonstrate only 
significant expression of GRK4 in the testes (Ambrose et a i, 1992; Premont et ai, 
1996). A more recent study using PCR showed expression of mRNA transcript in
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cerebellar granule cells (Sallese et ai, 2000), but importantly demonstrated the lack 
of transcript in many other regions of the brain. Comparative sequence analysis of 
GRK4 shows a high degree of interspecies variation. Only 72% of GRK4 amino acids 
are identical between mouse and human and 90% between rat and mouse; whereas 
GRK2 and GRK6 show 96% identity between mouse and human, and GRK5 94% 
identity between mouse and human (Premont et ai, 1999). This large amount of 
variation indicates a lack of selective pressure that would otherwise prevent non­
specific, function interfering changes in the sequence over time. The differences 
between species in sequence means the importance of GRK4 is questionable, as is 
whether GRK4 serves the same function in rat as in human. I think it is therefore 
unlikely that GRK4 is the major determinant of GABAb receptor desensitisation in the 
cortex, hippocampus, striatum etc.
The scale of GABAb desensitisation in neurones is an unresolved issue. Earlier 
reports suggest that presynaptic GABAb receptor mediated effects do not desensitise 
(Mott & Lewis 1994). A more recent study demonstrates that postsynaptic GABAb 
responses decrease by ~50% after chronic incubation of neurones with 50pM 
baclofen for 2h, whereas presynaptic GABAb receptors responses are unaffected 
until the duration of treatment is greater than 48h (Wetherington & Lambert 2002). 
Repetitive baclofen can also greatly diminish GABAb receptor coupling to potassium 
channels within 1h (Couve et ai, 2001), which is a postsynaptic response (Liischer et 
ai, 1997). Perroy et ai, measured the ability of baclofen to stimulate GTP exchange, 
an indicator of G-protein coupling, and found that after 1h incubation with baclofen 
there was a 67.2 ± 4.8% reduction in coupling in cerebellar granule cells (Perroy et 
ai, 2003). It should be noted however that to trigger this reduction neurones were 
pre-treated with 1mM baclofen, a concentration more than an order of magnitude 
greater than that needed to elicit maximal GABAb responses.
The majority of studies of GRK and arrestin activity have assessed their activity 
against receptors at a monomeric level. It is possible that the formation of a 
heterodimer confers insensitivity to GRK phosphorylation and arrestin action upon 
GABAb receptors. Indeed, the intracellular domains of heterodimerised receptors 
probably form a markedly different topology to monomeric receptors. In this respect,
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the fate of other GPCRs that form functional heterodimers remains to be studied in 
detail.
The study presented in this chapter clearly differentiates GABAb receptors from 
other receptor subtypes in terms of the regulation of surface levels. The lack of 
agonist-induced internalisation is a remarkable feature of GABAb receptors and may 
have implications for their physiological role, being not confined to heterologously 
expressed receptors but also observed in endogenous receptors. This is of greater 
significance because in neurones other proteins that control GABAb surface stability 
are also likely to be expressed. The calculated surface half-life of receptors in 
cultured neurones was «31.0 h. Because after 60h an internal receptor pool was not 
detected, it suggests that GABAb receptors are not recycling during this period. This 
inherent stability may be a product of the extrasynaptic localisation of GABAb 
receptors (Fritschy et a i, 1999, Kulik et ai, 2002). Wetherington & Lambert 
demonstrated that the activity of pre-synaptic GABAb receptors remains unaffected 
after up to 48h of treatment (Wetherington & Lambert 2002). Only when neurones are 
treated for 72 hours or longer with baclofen is an apparent change in GABAb 
response noted. Although the chronic treatment of neurones with baclofen alters the 
half-life of GABAb receptors in my study, it is apparent that this decrease in half -life 
will not greatly effect total receptor number up to 48h after treatment. It may be that 
physiologically recordable desensitisation is not appreciable until 72h after 
initialisation of treatment, because it takes this long to change surface receptor 
numbers, again illustrating the lack of dynamism within the GABAb receptor. It is also 
a possibility that it requires prolonged agonist treatment to ‘switch on1 a special 
degradation pathway for GABAb receptors. The biotinylation of neurones pre-treated 
with 60h baclofen does demonstrate a reduction in surface GABAb receptor numbers, 
supporting the data from Wetherington & Lambert. This effect was only observed at 
the surface though, with the intracellular pool of GABAb receptors showing no 
significant reduction. This demonstrates that as well as being resistant to 
endocytosis, it appears that GABAb receptors do not undergo downregulation, at 
least over a 60h treatment.
Endocytosis plays a role in decreasing the response of a target tissue to agonist 
and refining a tissues response over time. However, most GPCRs that endocytose
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are not basally exposed to agonist, instead agonist is released intermittently. The |33 
adrenergic receptor is important in the regulation of thermogenesis and as such 
needs to be basally and continually activated. Interestingly the P3 adrenergic receptor 
is not phosphorylated or internalised in response to agonist (Liggett et ai, 1993). One 
can draw parallels between the importance of the basal activity of the |33 receptor and 
that of the GABAb receptor. GABAb receptors are tonically activated by GABA 
spillover (Scanziani 2000) having an important inhibitory effect on neuronal firing 
patterns. Maximal GABAb activation is likely to occur under conditions where 
GABAergic neurones are firing at high rates altering the GABA release to uptake ratio 
and enhancing spillover. It is precisely under these sort of conditions that GABAb 
receptor activity needs to be maximal. At GABAergic synapses it will limit further 
GABA release, whilst at excitatory synapses it will increase the threshold for neuronal 
firing. One can envisage that if the receptor were to endocytose under these 
conditions then it may have dramatic and deleterious effects on neuronal firing.
As mentioned in the introduction to this thesis, intrathecal administration of 
baclofen is used to treat intractable spasticity (Meyerthaler 1999). Using this 
treatment regime a regular bolus of baclofen supplied directly into the spinal cord can 
alleviate spasticity. Interestingly, a fixed dose of baclofen can be used for long 
periods (years) without seeing a diminshment in therapeutic properties. This 
contrasts with other classes of drugs acting at GPCRs e.g. opiates, where an 
escalation of dose to achieve the same results is often inescapable. The intrinsic 
stability and lack of downregulation of GABAb receptors observed in this study may 
also help to explain how this is possible
This study also suggests that GABAb receptors are degraded in a membrane- 
delimited manner, or at a rate that is equal to their internalisation. This is because an 
internalised pool of receptors was not observed. The endocytic pathway leads 
directly from early endosomes to late endosomes and then lysosomes. In a set of 
further experiments designed to examine the effect of inhibiting the lysosome on 
GABAb degradation rates I observed no effect of the lysosomal inhibitor leupeptin 
upon the degradation of surface biotinylated receptor in the presence or absence of 
agonist over a 25h period (basal plus leupeptin: 96.3 ± 7.8% control, n=3; baclofen 
plus leupeptin: 95.5 ± 8.5% baclofen, n=3). This suggests that degradation takes
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place in a non-lysosomal manner. The presence of either GABAb receptor subunit in 
compartments staining for EEA1 was never observed in confocal studies regardless 
of agonist exposure time. Both of these observations imply that direct surface 
regulation of GABAb receptors does not involve the endocytic pathway. It is possible 
that GABAb receptors are targeted directly to the proteasome from the surface, 
preventing the build-up of an internalised pool. However, 02 adrenoceptors are also 
subject to non-endocytic proteolysis that is insensitive to proteasomal inhibitors 
(Jockers et ah, 1999) and the vasopressin receptor can be degraded in a membrane- 
delimited manner via metalloproteases (Kojro & Fahrenholz 1995). Therefore other 
uncharacterised pathways for GPCR degradation exist through which GABAb 
receptors may be processed.
Lastly, it was observed that activating PKA directly or through cAMP producing 
pathways protected GABAb receptors from degradation. It is tempting to speculate 
that the degradation of GABAb receptors and their stabilisation depends solely on the 
cAMP levels in neurons. These results support this model with agonist occupancy 
lowering cellular cAMP, resulting in enhanced degradation of the surface population 
of receptors. Interestingly, GABAB(2) displays a high basal phosphorylation in its 
single phosphorylated serine residue that is a PKA substrate (Couve et ai, 2002). 
Thus, the high stoichiometry of receptor phosphorylation provides an explanation for 
the stability of the resting population of receptors in cortical neurons. My results show 
that phosphorylation at this residue is correlated with protection from degradation, 
highlighting the importance of this residue in GABAb function. Whether or not specific 
proteins associate with the receptor in a phosphorylation dependent manner and alter 
the receptor stability remains to be determined. A number of associated partners of 
the GABAb receptors have been described recently but their role in GABAb receptor 
function remain, for the most part, unexplored (Couve et a i, 2001; El Far & Betz, 
2002; Nehring e ta i, 2000; Vernon etal., 2001; White etal., 2000).
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CHAPTER FOUR GABAB(i) Phosphorylation
4.1.1 Introduction
Whole cell labelling assays performed to analyse GABAb phosphorylation 
demonstrated that both GABAb(i) and GABAB(2) are phosphoproteins. As covered in 
the previous chapter, phosphorylation of GABAB(2) is largely attributable to protein 
kinase A activity at serine 892 (Couve e ta l., 2002). However, the sites of 
phosphorylation within GABAB(i) and the kinases responsible for this phosphorylation 
remain unknown.
Utilising GST fusion proteins of the carboxy-terminal domain of GABAB(i) it was 
possible to demonstrate that an unknown kinase associated with and phosphorylated 
this domain from brain lysates. The use of different kinase inhibitors revealed that this 
unknown kinase did not fit the pharmacological profile of well-characterised second- 
messenger kinases. Particularly intriguing was the observation that heparin, normally 
a kinase inhibitor, robustly stimulated kinase activity.
I proposed to identify this unknown kinase by mapping the minimal region 
required for binding and phosphorylation. I then intended to use a truncated fusion 
protein encoding this region to affinity purify enough kinase for identification through 
mass spectrometry or Edman degradation techniques. However, prior to me carrying 
this approach out the a1 catalytic subunit of AMP activated protein kinase (AMPK) 
was isolated as an interacting protein with the GABAB(i) tail in yeast two-hybrid 
studies at GSK, Harlow. Subsequent to this I focussed on determining whether 
AMPK can phosphorylate GABAe receptors and the sites involved in phosphorylation.
4.1.2 5’AMP activated protein kinase: a regulator of metabolic activity
5’AMP activated protein kinase was initially identified as a kinase able to co-purify 
with and phosphorylate the cholesterol synthesising enzyme HMG-CoA reductase, 
which lead to it being called HMG-CoA reductase kinase (HRK). Phosphorylation 
reduced the activity of HMG-CoA reductase leading to a cessation in cholesterol 
synthesis. In terms of metabolism this can be envisaged as the switching off of an 
anabolic pathway so as to conserve energy. It was subsequently discovered that 
HRK phosphorylated a number of other substrates and that its activity was potently
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stimulated by the presence of 5’AMP. This lead to the kinase being fittingly renamed 
5’AMP activated protein kinase (AMPK) (Hardie etal., 1998).
ATP hydrolysis leads to the formation of inorganic phosphate ions and ADP. ADP 
rarely accumulates though because it is rapidly converted back to ATP under the 
action of adenylate kinase. This reaction also produces AMP which is formed in a 1:1 
ratio with every molecule of ATP. In the cell the ratio of ATP:AMP is normally -100:1 
(Hardie et al., 1998), but in metabolic stress ATP levels fall and ADP levels rise which 
leads to dramatic changes in the ratio of ATP:AMP (Hardie et al., 1998). AMPK is 
exquisitely sensitive to such changes because it is independently influenced by both 
falling ATP levels and rising AMP levels. Activation of AMPK depends upon the direct 
allosteric modulation of the kinase by AMP binding (Carling et al., 1989) and 
phosphorylation of the kinase by an upstream AMPK kinase (AMPKK) which is also 
activated by AMP (Weekes et al., 1994). ATP is thought to compete for the AMP 
binding site within AMPK and when bound leaves the kinase in an inactive state 
(Hardie et al., 1998). This means that when cellular ATP levels are normal AMPK is 
kept in an inactive state, but perturbations in the ratio between ATP and AMP can 
trigger rapid activation. Protein phosphatase dephosphorylation of AMPK leads to 
Inactivation, however when AMP levels are continually raised AMPK remains AMP 
bound and AMPK dephosphorylation is prevented (Davies etal., 1995).
The main effect of AMPK activation within the cellular environment is to conserve 
energy (Hardie et al., 1998). AMPK does this by ‘switching off7 anabolic biosynthetic 
processes that consume ATP and ‘switching on’ ATP producing catabolic pathways. 
A well studied example is the activity of AMPK against Acetyl-CoA carboxylase, 
where phosphorylation by AMPK on multiple residues within Acetyl-CoA carboxylase 
inhibits fatty acid synthesis and stimulates fatty acid oxidation (Hardie et al., 1998). In 
the heart AMPK has been shown to be important in initialising the Pasteur effect 
whereby anaerobic conditions stimulate glycolysis (Marsin et al., 2000), thus 
protecting cardiac myocytes in times of ischaemia by producing ATP.
Biochemical purification of AMPK revealed a heterotrimeric complex with a larger 
a subunit of approximately 63 kDa and two smaller p and y subunits of 38 and 35 kDa 
respectively. The subunits were subsequently cloned and it was demonstrated that 
there are 2 closely related a isoforms, two (3 and three y isoforms. The a subunits
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possess classical protein kinase active sites flanked by the amino acids Asp-Phe-Gly 
(DFG) and Ala -Pro-Glu (APE) and are responsible for the catalytic activity of the 
complex. The relevance of the different subunit isoforms is as yet poorly understood, 
although there have been reported differences in substrate preferences between the 
a1 and a2 catalytic subunits. Sequence comparisons with known yeast proteins 
showed a striking homology between the SNF (sucrose non-fermenting) proteins and 
AMPK subunits, with a1 AMPK showing 47% sequence identity to SNF1. This 
demonstrates the highly conserved nature of AMPK across phyla. The a subunit is 
responsible for AMPK catalytic activity whilst the (3 subunit is believed to act as a 
bridging molecule between the a and y subunits (Woods et a/., 1996). The precise 
roles of the |3 and y subunits remain unclear, however they are thought to be involved 
in both regulating kinase activity and modifying kinase localisation.
As mentioned previously, phosphorylation of AMPK takes place upon sites in the 
a and p subunits by an upstream AMPKK and is important for kinase activity. One 
well characterised critical site which must be phosphorylated prior to activation is 
found within the active site of the catalytic a subunits at threonine residue 172 
(Hawley et al., 1996; Stein et al., 2000). Antibodies that specifically recognise an 
epitope incorporating a phosphorylated threonine 172 are commercially available and 
provide a good indication of intracellular AMPK activation.
Although AMPK is expressed in neuronal tissue, relatively little is known about its 
activity in the brain. Reports have demonstrated that AMPK is basally active in 
cortical neurones and especially so in astrocytes, where it plays an important role in 
regulating ketogenesis (Bl£zquez et al., 1999). Ligation of the coronary arteries 
mimics a heart attack by causing myocardial ischaemia, with an increase in heart 
AMP levels coupled with ATP depletion activating AMPK (Kudo et al., 1995). In the 
brain the closest analogy to such an event is a ‘stroke’ whereby occlusion of an artery 
supplying the brain leads to ischaemia. Similar to in the heart, it is likely that such an 
event will cause rapid AMPK activation. AMPK is also activated by non-pathological 
events in tissues that have variable demands in energy consumption. The most 
obvious example of such a tissue is skeletal muscle which can remain unused for 
long durations and then subjected to intense activity. Indeed, studies have 
demonstrated that AMPK is significantly activated during muscle contraction (Hutber
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et al., 1997). Transgenic mice expressing a dominant negative AMPK construct 
specifically in muscle tissue have a ‘lazy’ phenotype and are reluctant to exercise, 
demonstrating a physiological role for AMPK in muscle contraction outside of 
pathological events (Mu et al., 2001). Neuronal tissue is also subject to extreme and 
rapid changes in activity patterns. LTP formation is thought to involve repetitive 
neuronal firing so as to depolarise postsynaptic neurones enough to release the Mg2+ 
block on NMDA receptors. These activity patterns may cause disturbances in the 
intracellular concentrations of Na+ and K+ ions, which will lead to increased Na+/K+ 
ATPase activity in attempt to rectify the perturbance. It is probable that increased 
Na+/K+ ATPase activity will also lead to transiently raised AMP levels that may 
activate AMPK. Pathologically it is likely that AMPK is even more readily activated in 
neural tissue than other tissues such as liver and muscle because of the inherently 
high metabolic demands of neurones coupled to their inability to store glucose in the 
form of glycogen.
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4.2.1 GABAB(i) carboxy-terminal domain forms a major kinase substrate
GPCR’s are phosphorylated at residues along the intracellular loops and the 
intracellular carboxy-terminal domain. Because family C GPCRs characteristically 
have relatively small intracellular loops, the carboxy-terminal domains are the most 
probable sites for phosphorylation. Sequence analysis of GABAB(d shows a total of 
26 serines and threonines within the putative intracellular loops and carboxy-terminal. 
Of these, 17 are found within the carboxy-terminal domain, making this the most 
likely site for phosphorylation. To investigate this further I labelled plates of COS-7 
cells transfected with a truncated ‘tail-less’ myc-tagged GABAB(i) (C') or full length 
myc-tagged GABAB(1) with either 35S labelled methionine or 32P orthophosphate. 
Subunits were immunoprecipitated and resolved using 8% SDS-PAGE with gels 
being dried and exposed to autoradiograph. Expression levels of 35S labelled 
GABAB(i) C  were several fold higher than wild type GABAb(i> (fig. 17a). This is 
probably because deletion of the carboxy-terminal domain results in the removal of 
the main ‘RSRR’ ER-retention motif at amino acids 922-925 (Margeta-Mitrovic et al., 
2000; Pagano et al., 2001). Without this motif the GABAB(d subunit is no longer 
retained within the ER when expressed alone, thus preventing ER accumulation 
which is probably a limiting factor on synthesis. When proteins are labelled with 32P 
however, the full length GABAB(i) subunit gives a much stronger signal, even though 
there is far less expressed (fig. 17b). This supports the supposition that the carboxy- 
terminal domain is the most highly phosphorylated region of the receptor.
4.2.2 A kinase associates with and phosphorylates GABAB(1) carboxy-terminal 
domain from brain lysates
In an attempt to isolate kinases that interact with the carboxy-terminal domain of 
GABAB(i) a GST-fusion protein of this domain was prepared (CR1). This was added 
as an eluted protein to lysates produced from rat brain homogenised in ‘pull-down’ 
buffer. 25 pg of fusion protein was incubated with 1 ml of lysate (5 mg/ml) for 90 
minutes with rotation at 4°C. A 50:50 slurry of glutathione agarose beads was then 
added for 30 minutes to bind the fusion proteins. This was then washed extensively 
for 30 minutes in low (150mM) and high salt (350mM) containing pull-down buffer. 
The beads were washed a further 5 times in kinase buffer to remove all traces of
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detergent and salt. Beads were then added to pre-warmed kinase buffer containing 
200pM cold ATP, spiked with 5pCi 32PyATP. Using this protocol a kinase was 
observed to specifically associate with and phosphorylate CR1 (fig. 18a). The kinase 
did not interact with GST alone, and importantly no kinase activity was registered if 
CR1 had not been pre-exposed to brain lysates. This ruled out the possibility that the 
associating kinase was bacterially derived and interacted during purification of the 
fusion protein.
In an attempt to identify the kinase the same experiment was repeated but to the 
kinase buffer inhibitors of either PKA (PKA peptide), PKC (PKC inhibitor peptide) or 
CamKII (KN-93) were added at concentrations in excess of the IC50. As an additional 
controls GTP and heparin (7pM) were also included. Heparin is a poly-anionic amino- 
glycan, synthesised in the liver and certain white blood cells. In addition to being a 
powerful anti-coagulant, heparin is a non-specific kinase inhibitor. GTP (2mM) was 
used because certain kinases such as casein kinase, are able to use GTP as a 
phosphate donor molecule in preference for ATP. The added GTP was not 
radioactively labelled and so if used as a phospho-donor it would appear to inhibit 
kinase activity. Inhibitors of PKA, CamKII and casein kinase had no effect on kinase 
activity and neither did GTP (fig. 18b). A small reduction in phosphorylation was 
noted when PKC inhibitors were used, but because this was used at a concentration 
in excess of predicted IC100, it was likely to be non-specific inhibition. Intriguingly, 
heparin caused a strong and reproducible stimulation of kinase activity. Searches of 
scientific literature revealed that only two identified kinases have been documented to 
be stimulated by heparin. These are GRK 6 (Hall et al., 1999) and heparan binding 
FGF receptor. The associated kinase was unlikely to be GRK 6 because previous 
studies (see Chapter 3) had indicated that GABAb receptors do not form GRK 
substrates. Heparan binding FGF receptors are tyrosine kinase receptors (Pellegrini 
2001). Interestingly, GABAB(i) possesses a single tyrosine residue in its intracellular 
domain (Y959) which follows a dileucine motif and is the penultimate amino acid 
within GABAB(i). Phosphorylation of this residue might be expected to have major 
effects upon protein-protein interactions. A phospho-amino acid analysis was 
performed to identify the amino acids that are phosphorylated by hydrolysing the 
phosphorylated fusion protein and then separating the hydrolysed amino acids using
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thin layer chromatography. These were run alongside phospho-threonine, phospho- 
serine and phospho-tyrosine control samples. Exposure of the chromatography plate 
to autoradiograph demonstrated which amino acid had incorporated the labelled 
phosphate group. This indicated that the associating kinase was phosphorylating 
exclusively serine residues (fig. 18c).
4.2.3 Sites of binding and phosphorylation map to amino acids 905-925
To further map the site of kinase binding and also narrow down possible sites of 
phosphorylation a similar pull-down with subsequent in vitro kinase assay was 
performed using fusion proteins comprising truncated regions of the GABAB(i) 
intracellular domain. The carboxy-terminal intracellular domain of GABAB(i) extends 
from the predicted end of the last transmembrane domain at amino acids 857 to the 
terminal amino acid 960. The putative coiled coil region lies from amino acids 876 to 
916 (Couve et al., 2001). The truncated fusion proteins used included fusion proteins 
of each half of the tail (82 aa:857-908,83 aa:909-960) and the coiled coil region alone 
(85 aa:876-917) (Couve et al, 2001). Out of seven truncations only 2 bound kinase 
and formed a substrate (fig 19). These were 83 and 87, which allowed me to infer that 
the minimum region required for kinase binding and phosphorylation was from amino 
acid 909 to 925. This region contains 3 possible sites of phosphorylation, S909, S917 
and S923. Previously this region has been reported to be responsible for mediating 
the binding between GABAB(i) and 14-3-3 proteins (Couve et al., 2001) and also 
partially overlaps the binding site of ATF4/CREB2 (Nehring et al., 2000; Vernon et al., 
2001; White et al, 2000). Interestingly when truncation 88 was used phosphorylation 
was not observed, although this construct is lacking only 4 amino acids present in 87 
922-925, the ER retention motif. This implies that the phosphorylating kinase must 
bind to these four amino acids, and/or phosphorylate S923.
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Figure 17 Removal of the carboxy-terminal domain greatly reduces GABAB(1) 
phosphorylation
a) COS-7 cells transfected with either myc-GABAB(1a) or a mutated version of the 
same construct lacking the carboxy-terminal intracellular domain were 
incubated in 35S labelled methione containing medium for 4h and then 
immunoprecipitated. Upon SDS-PAGE full length myc-GABAB(1a) migrated just 
above 116kDa, whilst the trucated subunit migrated at ~105kDa. Removal of the 
carboxy-terminal intracelluar domain greatly enhances the amount of subunit 
immunoprecipitated.
b) As a), but medium labelled with 32P orthophosphate instead cf 35S methionine. 
Although far higher amounts of 'tailess' receptor are precipitated, it appears that 
removal of the carboxy-terminal intracellular domain dramatically reduces the 
extent of subunit phosphorylation.
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Figure 18 Association of a kinase with the GABAb(1) intracellular carboxy- 
terminal domain from brain
a) Gst-fusion proteins of the G A B A ^  intracellular carboxy-terminal domain 
(CR1) were exposed to rat brain lysate, washed extensively and then incubated 
in kinase buffer @ 30°C with 32PyATP spiked ATP. A kinase associates with and is 
able to phosphorylate CR1. No phosphorylation is noted of either Gst nor CR1 
not previously exposed to brain.
b) CR1 exposed to brain was incubated in kinase buffer as before, but also 
added were inhibitors of different classical second messenger activated kinases. 
No significant effect was noted except for the addition of heparin.
c) A phospho-amino acid analysis was performed upon phosphorylated CR1. 
This demonstrated that the kinase that associates from brain phosphorylated 
CR1 solely at serine residues. (Signal above origin from incompletely hydrolysed 
amino acids)
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Figure 19 Mapping the region of phosphorylation within CR1
a) Gst fusion proteins of truncations of CR1 used to map phosphorylation sites. 
55 corresponds to the coiled coil region within the subunit.
b) Coomassie stained SDS-PAGE gel of fusion proteins.
c) Autoradiograph of SDS-PAGE resolved fusion proteins in same order as b) 
post-exposure to brain lysate and kinase assay. Full length CR1 is highly 
phosphorylated as is 53 and to a lesser extent 57.
d) Results from multiple experiments demonstrating that CR1,53 and 57 can all 
associate with and be phosphorylated by kinase(s) from brain.
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4.2.4 Isolation of AMPK as a potential interacting protein with GABAB(i)
At the start of this study I set up a yeast two-hybrid (Y2H) screen using the 
carboxy-terminal domain of GABAB(i) as a bait protein. However, this was abandoned 
when collaborators with our group at the Neurology Centre for Excellence in Drug 
Discovery, GlaxoSmithkline, Harlow kindly let us have access to data obtained during 
screens that they had carried out. At GlaxoSmithkline Dr Katie Freeman and her 
group had carried out Y2H screening with the intracellular carboxy-terminal domain of 
GABAB(i) on an industrial scale, isolating ~160 potential interacting proteins. Because 
the aim of their screen was to discover other unidentified GABAb subunits, other hits 
were by-products of little interest to industry but of major interest to us. One hit of 
particular interest was the a1 catalytic subunit of AMPK. The region of interaction 
involved the second half of the catalytic subunit from amino acids 289-550 (fig 20). 
The catalytic domain within the a1 subunit consists of the majority of the N-terminal 
half, and ends around amino acid 250, just upstream of the interacting portion. It has 
been established that the portion of the a1 subunit isolated from the Y2H with 
GABAB(i) interacts with the 3 and y subunits of AMPK (Woods et al., 1996, Crute et 
al., 1998); but although the precise amino acids necessary have not been mapped, 
the interaction is thought to be mediated by amino acids c-terminal to aa392 (Crute et 
ai, 1998).
4.2.5 AMPK robustly phosphorylates GABAB(i) carboxy-terminal domain
If AMPK interacted with GABAB(1) in yeast, it was plausible that GABAB(1) may 
form a substrate for AMPK. Because proving or disproving the veracity of yeast two- 
hybrid interactions can be a long and often fruitless process, I decided to primarily 
resolve whether AMPK could phosphorylate GABAb receptors.
In vitro kinase assays were carried out using immunopurified AMPK from rat liver 
(a kind gift from Dr David Carling, Imperial College London) and CR1 fusion protein. 
GST alone was also used in the assay to control for non-specific phosphorylation. 
Prior to in vitro kinase assays, fusion proteins were eluted and then extensively 
dialysed against 20mM Tris-EDTA pH 7.4 to remove all salts and impurities that could 
affect AMPK activity. To further control that any observed kinase activity was due to
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AMPK and not non-specifically immunopurified kinases I also used pre-immune IgG 
that had been exposed to the same lysates from which AMPK was purified.
Using this assay I observed that CR1 formed a specific AMPK substrate (fig 21 
a,b). Carrying out a similar experiment using truncated fusion proteins encoding 
either the first or second half of GABAb(-i) carboxy-terminal intracellular domain (82 
and 83) demonstrated that, in the same manner as the kinase associating from brain, 
the second half of GABAB(i) carboxy-terminal domain formed the AMPK substrate. 
AMPK showed no activity towards 82 (which includes 9 serine and threonine 
residues) indicating that AMPK does not just randomly phosphorylate any serine or 
threonine present but shows specificity to certain sites within CR1. Because the 
second half of CR1 was phosphorylated the sites of phosphorylation were narrowed 
down to between amino acids 905 and 960 (fig 21 c). The addition of heparin to the 
kinase assay at a concentration identical to that used in the kinase assays after 
exposure to brain lysates elicited a profound increase in AMPK phosphorylation of 
CR1 and 83. Multiple experiments revealed that the heparin stimulation was highly 
reproducible and increased phosphorylation of CR1 by ~250% over 30 minutes. This 
increase was identical to that observed with the kinase from brain (fig. 21 d). 
Stimulation of AMPK by heparin has not previously been documented in the 
literature, although one study (Ahmad etal., 1985) noted the stimulation of a ~70kDa 
kinase purified from rabbit muscle which phosphorylated glycogen synthase and was 
inhibited by of glycogen, both properties of AMPK, with heparin. Experiments 
performed using SAMS, an AMPK substrate peptide revealed that heparin increased 
the activity of AMPK against this by -30%. It therefore appears that the heparin 
stimulation is somewhat substrate specific. The presence of poly-anionic heparin may 
involve the stabilisation of CR1 into a confirmation more accessible for kinase 
activity, perhaps mimicking endogenous protein interactions.
To determine whether the kinase isolated from brain and AMPK phosphorylate 
the same residues I carried out two-dimensional peptide maps of tryptically digested, 
SDS-PAGE resolved CR1, phosphorylated (in the presence of radiolabelled ATP) 
either by the kinase associating from brain extracts or AMPK. Digested peptides were 
dried and then spotted onto cellulose chromatography plates where they were 
separated along a horizontal dimension according to their charge to mass ratio. The
123
second ascending dimension separated peptides according to their hydrophobicity. 
Chromatography plates were then dried and exposed to film, with only the 
radiolabelled peptides producing an image on the film. Peptide maps produced in this 
manner demonstrated very similar patterns produced from tryptically digested CR1 
phosphorylated by AMPK or the kinase associating from brain, indicating that both 
kinases phosphorylated the same residues (fig. 21 e).
4.2.6 Serine 917 is the primary site of AMPK activity
To gain an understanding into the possible role of GABAB(i) phosphorylation by 
AMPK it was necessary to identify the major site(s) of kinase activity within the fusion 
protein. To do this phosphorylated CR1 was digested with the proteases trypsin, 
chymotrypsin or thermolysin. Digested peptides were then separated on thin layer 
chromatography plates in two different dimensions according to their charge/mass 
ratio and also their hydrophobicity index. It was found that thermolysin gave the most 
efficient digestion of the phospho-protein, and when peptides were separated a 
single major phospho-peptide was present. This indicated that there was probably 
one major site of phosphorylation. I decided to mutate putative phosphorylation sites 
present in the second half of CR1 after amino acid 905 from serine to alanine. I then 
repeated the peptide mapping to see if I lost the major peptide. Using this 
methodology I observed that mutagenesis of the residue S917 lead to the removal of 
the major peptide within the map. This indicated that S917 was the major site for 
AMPK activity within the CR1 fusion protein. Somewhat more perplexing though was 
that the mutation S917A lead to only a very small decrease in CR1 phosphorylation 
(see 4.2.7 below). Analysis of the peptide map produced from peptides of CR1 
S917A demonstrates a large number of new peptides created that don’t exist, or are 
insignificant in maps from wild type CR1. Subsequent mutagenesis of the next serine 
S923 to an alanine within the CR1 S917A fusion protein to make a double mutant 
CR1 S917A.S923A removes the majority of these extra spots (fig. 22e). This loss is 
not observed if S909 is mutated in addition to S917 though (fig. 22d). The peptide 
maps suggest that S917 is the major site of phosphorylation within CR1, but that if 
this site is no longer present, ‘silent’ sites are revealed. The implications of this are 
somewhat uncertain, for CR1 S917A is an artificial protein and as such is an artificial 
substrate. Nonetheless, this data could also imply that if for some'reason S917 is
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masked by, for example, other proteins; S923 and other downstream residues to a 
lesser extent may serve as phosphate acceptors.
To further confirm the data obtained during from maps and mutagenesis, wild 
type CR1 was digested with chymotrypsin and subject to chromatography followed by 
Edman degradation. This experiment, conducted in conjunction with Dr D.Carling 
demonstrated that within wild type CR1 there is only one major site of 
phosphorylation and Edman degradation confirmed that this was S917 (fig 23).
4.2.7 In vitro phosphorylation of mutated CR1
Subsequent to experiments mapping the sites of phosphorylation within CR1, the 
efficiency with which AMPK could phosphorylate mutated CR1 fusion proteins was 
analysed. As well as the mutant fusion proteins previously used, a CR1 S917D 
mutant was also studied. Here the major site of phosphorylation is mutated to an 
aspartic acid residue, thus mimicking the negative charge conferred by the addition of 
a phosphate group. I hypothesised that if S917 was mutated in such a manner as to 
give the appearance of a phosphorylated residue, the kinase activity observed 
against a S917A mutant would no longer occur. All kinase reactions took place in the 
presence of heparin (7pM). In the control assay using IgG no phosphorylation of CR1 
was registered (fig 21c). As observed previously, there was robust phosphorylation of 
CR1, and this was decreased to -30% of wild type when S917 was substituted for 
either an alanine or an aspartic acid residue (fig 24). If S917 was mutated to an 
alanine in conjunction with mutation of S909 then there was no further decrease in 
total phosphorylation indicative that S909 was not a site of AMPK activity. Mutation of 
S923 in conjunction with S917 though significantly decreased phosphorylation. This 
observation in combination with the results from the peptide maps confirms that 
whilst S917 is indeed the major site of AMPK phosphorylation within CR1, S923 may 
form a secondary site or be of importance for interaction with AMPK. When both 
S917 and S923 are mutated to alanines there remains residual phosphorylation 
within CR1. The significance of this remaining phosphorylation is questionable 
because the rate of phosphorylation is very low and the peptide maps from this 
double mutant show no well defined peptides (fig. 22e). A stop codon at amino acid 
929 prevents further phosphorylation of S917,923A mutant showing any residual 
p h o s p h o ry la tio n  takes p lace at dow nstream  s ites .
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CR1 — +++
CR2 — —
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Catalytic domain Acid rich
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Binding site for 
AMPK ^ 47  subunits
392-550
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GABA^-i) interacting region
Figure 20 GABA^i) interacts with a1 AMPK in the yeast-two-hybrid system
a) Table showing interaction of a1 AMPK subunit with the carboxy-terminal 
domain of GABA^i) (CR1) in yeast Plasmid backbone is represented by control. 
Interaction was specific to CR1
b) Cartoon illustrating the specific region of at AMPK isolated using the yeast-2- 
hybrid screen.
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Figure 21 AMPK phosphorylates CR1
a+b) Tlmecourse of CR1 phosphorylation by AMPK. Note there Is no phosphorylation of 
Gst, whilst addition of heparin greatly enhances the rate of phosphorylation.
c) AMPK specifically and robustly phosphorylates the second half of the carboxy- 
terminal of R1 (53).
d) Comparison of the enhancement In phosphorylation achieved through the addition of 
heparin to the kinase buffer by AMPK and the kinase associating from brain.
e) Similar tryptic peptide maps of phosphorylated CR1 by I) Kinase from brain and II) 
AMPK suggest AMPK and kinase from brain phosphorylate the same residues.
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Figure 22 Peptide maps
Fusion proteins of wild type or serine to alanine mutants of the carboxy-terminal 
intracellular domain of GABAB(i) were phosphorylated by AMPK using 32P 
labelled ATP and then digested with thermoiysin. Peptides were separated using 
2D chromatography and then plates exposed to film, a) Wild type shows one 
major peptide, b) S917A mutation causes loss of major peptide revealing novel 
peptides.c) Superimposition of wild type peptide (red) upon S917A mutant 
map.d) Additional mutation of S909A has no major effect, whilst additional 
mutation of S923A (e) causes loss of all major peptides.
917,923S-^A
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Figure 23 Edman degradation of phosphorylated CR1
A GST fusion protein of the GABAb(1) carboxy-terminal intracellular domain (CR1) was 
phosphorylated with 32PyATP spiked ATP to saturation point by AMPK and then resolved 
using SDS-PAGE. Radiolabelled CR1 was excised from the gel and then digested with 
Chymotrypsin. Peptides were separated using a chromatography column. Edman 
degradation of the maximally radiolabelled peptide revealed the sequence RHQLQSRQQ, 
with the serine showing high levels of radiolabelling. This region corresponds to Ser917 
within the carboxy-terminal intracellular domain of GABAB(i)
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Figure 24 Analysis of mutant phosphorylation
i) Example time course phosphorylations of a)CR1, control IgG, b) CR1, c) CR1 
S917D, d) CR1 S917A, e) CR1 S909,917A and f) CR1 S917,923A
ii) Quantification of experiment, also shown is CR1 S917,923A with stop codon at 
929.
These experiments show that although peptide maps and Edman degradation 
show S917 is AMPK preferred substrate residues within CR1, in the absence of 
this site other downstream residues form substrates.
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4.3 Discussion
Proceeding with an in vitro kinase assay after a ‘pull-down’ is a convenient test as 
to whether your candidate protein: a) binds kinases, and b) forms a substrate. The 
use of radioactively labelled ATP allows for greater sensitivity than western blotting. 
However, this experiment is only a preliminary screen. The lack of phosphorylation of 
a candidate protein may mean kinases are unable to bind even if the protein forms an 
excellent substrate. Conversely a kinase may interact but if the protein does not form 
a substrate it will be impossible to ascertain. Other possible drawbacks include 
reduction of kinase activity by extraction conditions and incorrect folding of fusion 
proteins.
Notwithstanding these limitations, this technique has demonstrated that a kinase 
both associates with and phosphorylates CR1 from brain lysates. In conjunction with 
the data obtained from the whole cell labelling analysis this data indicates that the 
carboxy-terminal domain may form a substrate for kinase activity in the brain. 
Mapping of the kinase associating region demonstrates that the first half of the 
carboxy-terminal domain (82 aa 876-904), containing multiple serine and threonine 
residues and the majority of the coiled coil motif, is not phosphorylated by associated 
kinases from brain. Instead it is the distal portion of the carboxy-terminal domain that 
associates with kinases. The minimum region required to confer kinase activity from 
brain upon the CR1 fusion protein covers the amino acids 905-925. This stretch of 20 
amino acids contains the last 12 amino acids of the coiled coil and also the ER- 
retention motif RSRR. Removal of the RSRR region prevents association with 
kinases, indicating that this may form the major kinase binding site. The association 
of kinases with the end of the carboxy-terminal domain as opposed to the proximal 
portion probably reflects greater accessibility of this region to other proteins within the 
heterodimerised receptor because it projects away from the coiled coil. In the 
complete receptor the proximal portion of the carboxy-terminal domain is likely to be 
in closer association with the plasma membrane and GABAB(2).
The chief determinant in the interaction between a phosphorylation motif and 
kinase is the ability of the motif to fit into the substrate-binding pocket of the kinase, 
found in the kinase catalytic domain. A Y2H interaction between a bait protein and a 
kinase could conceivably take place between a consensus phosphorylation motif
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within the bait protein binding to the active site of the kinase. The interaction between 
AMPK and GABAS(i) though must involve regions outside the active site of AMPK 
because the non-catalytic carboxy-terminal half of alAMPK was isolated as the 
interacting region in the Y2H screen. The fact that AMPK also phosphorylates the 
carboxy-terminal tail of GABAB(i)Can therefore be viewed as additional support of an 
interaction, because it involves a separate domain of AMPK. Further characterisation 
of the interaction between GABAB(i) and a1 AMPK is provided in the next chapter.
The introduction of an S917A mutation did not elicit a dramatic reduction in the 
phosphorylation of CR1. However, the peptide maps in conjunction with the Edman 
degradation, clearly demonstrate that S917 is the main site (>90% of total 
phosphorylation is at this site in wild type). It could be that, as previously mentioned, 
mutation reveals silent sites that would be phosphorylated if S917 were to be 
obscured. As discussed in the introduction to this chapter, the consensus sequence 
for AMPK phosphorylation is poorly defined (Hardie et al., 1998). However, studies 
using synthetic peptides and of known AMPK phosphorylation sites have 
demonstrated that three or four sites are conserved between substrates (Weekes et 
at., 1993, Hardie et al., 1998). The conserved sites being hydrophobic residues at P- 
5 and P+4, with a basic residue found at either P-3 or P-4. Also, often noted is the 
presence of a basic residue at P-6. Although none of the possible serine and 
threonine residues within the second half of the carboxy-terminal domain of GABAB(1) 
forms a perfect AMPK consensus phosphorylation site, S917 satisfies a number of 
the determinants. Crucially at P+4 the residue is a leucine fulfilling the requirement 
for a hydrophobic residue at this position. A histidine is found 4 amino acids upstream 
of serine 917, meeting the requirement for a basic amino acid at position P-3. Most 
AMPK substrates have a hydrophobic residue at P-5, but in the case of S917 a 
hydrophobic residue (leucine) is found at P-6. Although this differs from classical 
AMPK phosphorylation sites, it should be kept in mind that this particular stretch of 
residues putatively forms a coiled coil ending at S917. It is probable that the tertiary 
structure imposed by the coiled coil allows for a hydrophobic residue at P-6 instead of 
P-5. The additional mutation S923A reduces the phosphorylation by a much greater 
amount than S917A alone, and this is not observed when S909 is mutated in addition 
to S917. This implies that S923 is a secondary site, but another explanation is that
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the area around S923 is important for interaction with AMPK, and this mutation 
affects the binding of the kinase and subsequent phosphorylation of other serines. 
Indeed, the addition of a stop codon at amino acid 929 truncates CR1 and removes 
all further phosphorylation in a S917A, S923A mutant, indicating that any other 
phosphorylation occurs downstream of these sites. Although the relevance of 
consensus sites for kinase activity is questionable, it is clear that S923 does not 
appear to be an optimal AMPK phosphorylation site, and indeed the most likely other 
site within CR1 is at S953, although this lacks a basic residue at P-3/4. It is possible 
that an S917A mutant containing S923 but no further serines would demonstrate 
whether S923 is a true AMPK site. This though would also be a substrate much 
removed from the wild-type CR1, where clearly only one site serves as an AMPK 
substrate.
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CHAPTER FIVE
5.1 Introduction
Having established that GABAB(i) is an in vitro substrate for AMPK it was 
important to further investigate the interaction between GABAB(i) and AMPK and 
determine whether AMPK could associate with as well as phosphorylate GABAB(i). I 
also wanted to further investigate the role of phosphorylation of GABAB(i) by AMPK. 
Although serine 917 is a substrate for AMPK in vitro it remained unproven as to 
whether serine 917 forms a substrate in vivo. One approach to ascertaining whether 
serine 917 is an in vivo kinase substrate was to raise a phospho-specific antibody to 
this site and then use it to blot brain lysates. This would allow me to determine 
whether phosphorylation occurs in vivo.
The addition of a negatively charged phosphate group to a protein affects the net 
charge of a protein as well as the distribution of charge within a protein. An additional 
phosphate group can also result in the creation of motifs responsible for protein- 
protein interactions. Phosphorylation of GPCRs is normally associated with 
desensitisation and internalisation events. However, as shown in chapter 3 of this 
thesis, the phosphorylation of GABAB(i) does not increase upon agonist exposure, 
making an involvement in desensitisation events unlikely. I therefore focussed upon 
other possible consequences of GABAB(i) phosphorylation. Phosphorylation of 
residues within the intracellular carboxy-terminal domain of GABAB(i) might be 
expected to have an effect on the trafficking of the receptor due to the presence of 
the ER retention motif in this region, in addition to the coiled coil domain. Primarily I 
decided to study the effect of mimicking or inhibiting the phosphorylation of GABAB(i) 
upon cell surface trafficking of the receptor through the site-directed mutagenesis of 
putative phosphorylation sites to either alanines or aspartates. I then assayed the 
ability of these mutant receptors to traffic to the cell surface in COS-7 cells using 
ELISA. Subsequently the effect of treating cortical neurones with activators of AMPK 
upon the cell surface levels of GABAB(i) was analysed.
The other area investigated was the ability of phosphorylated GABAB(i) to interact 
with other proteins. Rather than trying to find novel binding partners to 
phosphorylated GABAB(i), which would be a long process outside the realms of this
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investigation, I concentrated upon two proteins that had been previously shown to 
interact, namely GABAB(2) and the transcription factor CREB2.
5.2.1 Confirmation that AMPK associates with CR1 from brain
To confirm that the kinase co-purifying from brain lysates with CR1 was indeed 
AMPK it was important to immunoblot pull-downs from brain lysates that had been 
transferred to nitrocellulose membranes. It was empirically determined that AMPK 
from brain was far more soluble in buffer containing the detergents NP-40 (1%) and 
de-oxycholic acid (DOC) (0.5%) than in Triton X-100 containing buffers. Highly 
efficient solubilisation of AMPK from muscle and liver is obtained in buffers containing 
0.5% Triton X-100 (D.Carling, personal communication), and so this differing 
solubility could be indicative of differences in the nature of AMPK found in brain 
compared to that observed in muscle. Pull-downs using 25pg of eluted CR1 fusion 
protein or GST were carried out in lysate (5mg protein) from rat brain homogenised in 
a buffer that allowed maximal solubilisation of AMPK. After incubation with rotation 
for 90 minutes at 4'C, a 50:50 slurry of glutathione agarose beads was added and 
lysates were incubated for a further 30 minutes. Beads were then washed 4 times in 
pull down buffer with 5 minutes of rotation per wash. To determine the stringency of 
the interaction the experiment was also carried out using pull-down buffer containing 
350mM salt for bead washing. Loading buffer was added to the samples which were 
then boiled followed by resolution using 12% SDS-PAGE. Following electrotransfer of 
gels to nitrocellulose, membranes were probed with an antibody that specifically 
recognised the catalytic subunit of AMPK when phosphorylated at threonine 172. As 
previously mentioned, phosphorylation at this site is imperative for the catalytic 
activity of AMPK. Activated AMPK was observed to associate with CR1 (figure 25a), 
and this association was not attenuated by 350mM salt washes signifying the 
interaction was of high affinity. To confirm that the kinase associating in these 
conditions could phosphorylate CR1 pulldowns were washed extensively in kinase 
buffer and then incubated with ATP spiked with 3*yATP to which was also added 
200pM 5’AMP. CR1 was robustly phosphorylated in these conditions and this 
phosphorylation was significantly stimulated by the addition of 5’AMP (fig 25b).
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Figure 25: The intracellular carboxy-terminal domain of GABAB(i) associates 
with AMPK catalytic subunit
a) GST-CR1 or GST alone were exposed to brain lysate. After extensive washing 
in low (150mM) or high (350mM) salt buffer, bound material was resolved by 
SDS-PAGE and analysed by immunoblotting with an anti a1/2 Phospho-Thr172 
antibody. Binding was detected under both wash conditions to GST-CR1 but not 
GST alone.
b)i) GST-CR1 exposed to brain as above was then incubated with ATP (200pM) 
spiked with 32PyATP, with or w ithout 5'AMP (200pM) for 20 minutes. Samples 
were then resolved using SDS-PAGE and exposed to phospho-imager for 
quantification.
ii) Inclusion of 5'AMP significantly enhanced phosphorylation (* = p<0.05)
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5.2.2 Immunofluoresence
Few studies detailing the subcellular localisation of AMPK exist in the literature, 
and those have been performed are in cell lines. Although it is known that both 
catalytic subunits of AMPK are expressed in neurones (Culmsee et al., 2001), the 
precise neuronal localisation of the kinase has never been ascertained. For the 
interaction between GABAB(i) and AMPK subunits to be of physiological relevance 
both GABAB(i) and AMPK are must be co-expressed in the same subcellular 
compartments. To analyse the distribution of AMPK relative to GABAb receptors, 
neurones were doubly immunolabelled with antibodies specific to both GABAb 
subunits and also to antibodies raised to the catalytic subunit of AMPK. 21 DIV 
cultured hippocampal neurones were fixed and blocked in blocking solution 
containing 0.2% Triton X-100 to allow cell permeabilisation. They were then stained 
for the catalytic subunit of AMPK using a rabbit polyclonal anti a1/2 subunit AMPK 
antibody (gift from Dr D. Carling) or the activated AMPK recognising Thr172 
phospho-specific a1/2 antibody.
a1/2 AMPK exhibits a somatodenditic staining pattern, with the majority of 
dendrites and the axon strongly staining for a1/2 AMPK whilst the cell soma shows 
diffuse AMPK staining throughout, with the occasional aggregate. There is a small 
amount of nuclear staining. As noted in chapter 3, the commercially available 
GABAB(1)used in this study shows very little GABAB(i) staining at the surface, possibly 
because the antigenic epitope is obscured in the complete receptor. Use of this 
antibody shows intracellular GABAB(1) staining that is most probably ER resident. 
Comparisons of this intracellular GABAB(i) pattern and the staining obtained with the 
anti a1/2 subunit AMPK antibody show a high degree of colocalisation throughout the 
internal bodies of neuronal dendrites, with certain dendrites showing almost complete 
overlap of staining (example staining fig 26 a-c). Within the soma of the neurone 
pockets of colocalisation do exist but overall it is much lower. Because intracellularly 
retained GABAB(i)is unlikely to represent the complete receptor, this staining pattern 
indicates that AMPK is found in similar intracellular regions to GABAB(i) and may 
associate with the non-dimerised subunit in vivo.
As mentioned in chapter 3, the staining pattern obtained with an 
antibody raised to GABAB(2) is quite different to that seen with GABAB(i). Use of this
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antibody gives very strong surface staining although no clustering of the subunit is 
evident. GABAb(2) immunoreactivity is probably representative of the complete 
receptor because of the extremely high degree of interaction between the two 
subunits in vivo (Benke et at., 1999). When comparing co-distribution of AMPK and 
GABAB(2) it is apparent that, similar to GABAB(i), there is a large degree of 
colocalisation between the two proteins especially in the dendrites of the neurone. 
Within the dendrites there is strong staining just beneath the membrane suggesting 
that AMPK may be able to phosphorylate surface receptors (fig. 26 b1-b6).
Immunolabelling of active AMPK with the phospho-specific thrl 72 antibody gives 
a similar staining pattern to the pan a subunit antibody in the neuronal soma although 
nuclear staining is increased. However the dendritic labelling is quite different with 
most dendrites being only weakly immunoreactive for activated AMPK, where it is 
observed in punctate clusters, possibly at synapses. However, many neurones 
analysed do appear to posess one strongly non-punctate staining dendrite (fig. 26 
c,d). This is most probably the axon and suggests that in this region AMPK is active 
under basal conditions. When comparing the co-staining of activated AMPK with 
GABAB(2) there appears to be a far lower degree of colocalisation. The staining 
patterns observed in this study may be interpreted to indicate that under basal 
conditions AMPK is situated in close proximity to GABAb receptors but is not 
activated and so will not phosphorylate the receptor. The fact that the two strongly 
colocalise though suggests that upon activation of AMPK, phosphorylation of the 
receptor may occur rapidly.
5.2.3 AMPK co-immunoprecipitates with GABAB(2)
To further qualify the nature of the interaction between GABAb(i) and AMPK, the 
possibility that the two proteins could co-immunoprecipitate was investigated. This 
has the advantage of demonstrating an interaction between complete proteins, and 
strongly suggests that the proteins interact in vivo. Unknown motifs within the 
carboxy-terminal half of AMPK a subunits limit their heterologous expression of this 
subunit (Crute et al., 1998). High expression levels are only possible when 
transfecting an a subunit truncated at amino acid 312 (Crute et al., 1998). Because 
the carboxy-terminal half of AMPK was isolated as an interacting protein from the
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yeast two-hybrid system it was not feasible to use a truncated a subunit. Therefore 
efforts were focussed upon trying to demonstrate a direct interaction between native 
AMPK and native GABAB(i) from brain. Initially, experiments were conducted utilising 
available antibodies to either immunoprecipitate GABAB(i> and blot for a AMPK or vice 
versa. Unfortunately this technique elicited extremely high levels of background 
antibody cross reactivity such that autoradiographs of western blots ‘blacked out’ 
making it impossible to discern whether the two proteins co-immunoprecipitated.
Interestingly, immunoprecipitations using pan a AMPK antibodies from solubilised 
rat brain membrane fractions were immunopositive for GABAB{2) when blots were 
probed with a monoclonal mouse anti-GABAs^) antibody (fig. 27). No signal was 
noted in the control rabbit IgG. Because in yeast GABAB(2) is unable to interact 
directly with the a1 AMPK subunit, coupled to the fact that almost all GABAB(2) is 
bound to GABAB(i) in brain membranes, the co-immunoprecipitation of GABAB(2) with 
AMPK suggests that it is probably the complete receptor that is co- 
immunoprecipitating with AMPK. It may be that GABAB(i) is acting as a bridging 
protein interacting with both AMPK and GABAB(2) concurrently.
5.2.4 Site-directed mutagenesis of GABAB(i) carboxy-terminal
Because S917 is close to the RSR ER retention motif of GABAB(i) and S923 is in 
the middle of this motif, investigations were undertaken to determine whether the 
mutation of these sites could effect the cell surface trafficking of either the single 
subunit or the heterodimerised receptor. Serines 909, 917 and 923 were mutated to 
either alanine or aspartate residues and used either individually or in permutations. 
Mutant constructs were sequenced prior to experimentation. Determination of the 
efficiency of cell surface trafficking was carried out using whole cell ELISAs in COS-7 
cells. Mutant GABAB(d was transfected alone initially to determine whether the 
mutation allowed cell surface trafficking. Mutated GABAB(i } was then co-transfected 
with GABAB(2). For maximal efficiency of receptor surface trafficking, co-transfections 
of the two subunits are carried out in a ratio of GABAB(i) to GABAB(2) that is 1:4. In 
these experiments though a submaximal ratio of GABAB(i) to GABAB(2) at 1:2 was 
used so that any enhancement in the trafficking efficiency was more apparent.
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Figure 26 Co-localisation of GABAb and AMPK in neurones
21 DIV hippocampal neurones were stained for GABAb receptor subunits 
and AMPK in neurones. Neurones were then visualised using confocal 
microscopy. Scale = 10/iM
a) 1) pan a -AMPK staining, 2) GABA^) staining, 3) merge. Areas of strong 
colocalisation are highlighted with arrows.
b) 1) pan a -AMPK staining, 2) GABA^g staining, 3) merge, 4-6 close up of 
of arrowed area in 3.
c) +d) 1) phospho-AMPK staining, 2) GABA^) staining, 3) merge. Note single 
dendrite per neurone strongly stains for phospho(active) AMPK (arrowed). 
There is less co-localisation of active AMPK and GABA^g than total AMPK
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Figure 27 GABAb(2) co-immunoprecipitates with the catalytic subunit of AMPK
Crude brain membranes were prepared and then detergent solubilised in buffer 
containing 2% CHAPS. From this solution extracts were immunoprecipitated 
using a rabbit anti AMPK a1/2 subunit specific antibody, or control rabbit IgG. As 
a positive control a goat GABA^ib) subunit specific antibody or goat IgG were 
also used in immunoprecipitations. Antibody protein complexes were purifed on 
Protein A agarose and, after extensive washing, were resolved on SDS-PAGE 
and analysed by immunoblotting with a mouse anti GABAb<2) antibody. 
GABAb(2) subunit was observed to immunoprecipitate with antibodies to either 
GABAe(ib) or a1/2 AMPK, but not control IgG.
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Mutations S909A, S917A and S923A did not significantly effect surface trafficking of 
the receptor. Mutations of serines to aspartates mimicking the phosphorylation at 
these sites were also tested. The mutation S917D alone had no detectable effect on 
the trafficking of either GABAB(i) or the complete receptor, but the mutation S917D 
S923D caused an increase in the surface trafficking of the GABAB(i) in the presence 
of GABAB(2) and also allowed ER exit of GABAB(1) alone (fig. 28).
5.2.5 Effect of activators of AMPK on neuronal surface numbers of GABAB(i)
The data obtained from mutating residues within the intracellular carboxy-terminal 
of GABAB(i) suggested that the sequential phosphorylation of S917 and S923 may 
alter the surface trafficking of the receptor and possibly allow the ER exit of 
monomeric GABAB(1) subunit. To investigate whether compounds known to activate 
AMPK could alter the surface receptor number in neurones, experiments were 
carried out treating neurones with oligomycin and metformin. Oligomycin has been 
demonstrated to potently activate AMPK in many different cell types (Marsin et at.,
2000) and is thought to work by uncoupling oxidative phosphorylation and thus 
depleting intracellular ATP. Because of the mechanism of action it rapidly depletes 
ATP, but is toxic over longer periods. 5 DIV cultured cortical neurones were treated 
for up to 80 minutes with 200nM oligomycin at 37°C in tandem with an untreated 
control. Cells were then placed on ice where they were biotinylated prior to 
solubilisation in RIPA. Biotinylated proteins were streptavidin precipitated and then 
resolved using 8% SDS-PAGE. Proteins were electrotransferred to nitrocellulose and 
then immunoblotted with anti-GABAB(ia) antibodies. A secondary 125l labelled anti­
rabbit antibody was then used and proteins were quantitated using a 
phosphorimager. Twenty minute treatment with oligomycin caused a -65% increase 
in the amount of surface GABAb receptor, however this fell outside the boundaries of 
statistical significance. Other time points also showed a general trend towards an 
increase in surface levels of the receptor but at no time point was this increase 
significant even when n=9. This variability was probably attributable to the inherent 
toxicity of oligomycin.
The majority of other AMPK activators also have a high degree of toxicity except 
for the anti-diabetic agent metformin. Metformin has recently been demonstrated to
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activate AMPK (Zhou et ai., 2001) in a manner independent of changes to AMP:ATP 
ratios (Fryer et ai, 2002; Hawley et ai, 2002) and has far lower toxicity than other 
AMPK activators. Metformin is slower to activate AMPK than the metabolic poisons, 
probably because it is very hydrophilic and thus takes a long time to cross the cell 
membrane and accumulate intracellularly to an optimal concentration. Neurones 
were treated with 2mM metformin, this concentration previously being demonstrated 
to be the optimal for rapid AMPK activation (Zhou et a i, 2001). Biotinylation 
experiments were carried out as with oligomycin, but at 3 and 5h after commencing 
treatment. Multiple experiments demonstrated that 5h treatment with metformin 
significantly increased surface GABAB(i) by 50.7±14.7% (p<0.05) (fig. 29). Western 
blotting of lysates from treated neurones for activated AMPK and quantitation with 125l 
labelled secondary demonstrated an increase in signal that was maximal 4h after 
commencement of treatment. This showed that AMPK is activated in neurones by 
metformin (example experiment is shown in fig. 29).
5.2.6 Purification of an antibody specific to phosphorylated GABAB(i>
To confirm whether S917 is phosphorylated in vivo an antibody (UCL-89) was 
raised to a phospho-peptide designed around the S917 (fig. 30). Peptides were 
designed with an N-terminal Cysteine so that they could be coupled via a suiphydryl 
group to maleimide activated keyhole limpet haemocyanin. Rabbits were immunised 
with peptide conjugated carrier protein and then re-immunised until significant 
immunoreactivity with peptide was noted using dot-blots of peptide. After the final 
bleed had been taken antibodies were purified by initially running serum over 
thiopropyl-sepharose columns to which a non-phosphorylated form of the antigenic 
peptide had been coupled. This was to minimise the purification of antibodies that 
recognised epitopes within the antigenic peptide that did not include the phospho- 
serine. The serum was then purified over columns to which had been conjugated the 
immunising phospho-peptide and antibody was eluted with glycine pH 2.5.
5.2.7 UCL-89 specifically recognises phosphorylated CR1
Initial experiments were conducted to determine whether UCL-89 could cross- 
react with GST fusion proteins of the carboxy-terminal domain of GABAB(d (CR1)
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Figure 28 Mutations of phosphorylation sites affect surface
trafficking
A+B GABAb(i ) was mutated at S909, S917 and S923 to either alanines or 
aspartate residues. Constructs were then transfected into COS cells and 
assayed for surface trafficking using whole ceil ELISA.
C Confocal microscopy confirms that whilst GABAb(i> wild tye (a) and S917D 
mutant (b) do not traffick to surface, constructs with both S917D and S923D 
mutations are efficiently trafficked and can be visualised using anti-myc (c i,ii)
145
A)
R1
R1R2
R1S917A 
R1S917AR2 
R1S923AR2 
R1 S909,923aR2  
R1S909,917(923AR2
B)
R1
R1R2
R1S917D
R 1 s 917d R 2
R1S917D»S923D
R1S917D»S923DR2
20 40 60 80 100 120 % Surface 
Expression
80 100 120
% Surface 
Expression
C)
a) b)
c ii)
146
Figure 29 Effect of activators of AMPK on neuronal surface
numbers of GABAsfi)
a) Cortical neurones were treated with the AMPK activating toxin oligomycin 
(200nM) for times between 0 and 80 minutes. They were then biotinylated
and surface receptors streptavidin purified prior to resolution using SDS-PAGE 
and western blotting. 1125 secondary was used to allow quantification of 
bands. Although oligomycin appears to enhance surface receptor numbers this 
is not significant (n=9).
b) Neurones were treated with the less potent but non-toxic AMPK activator, 
metformin (2mM) prior to biotinylation and purification using streptavidin 
beads. Metformin caused a consistent increase in phospho-AMPK levels 
highest approximately 4h after treatment began (i). There was a significant 
increase in surface GABAb receptors 5h post metformin (5h vs. cont = 
150.7±14.7% (p<0.05))
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when phosphorylated. Preliminary investigations determined that optimal UCL-89 
reactivity occurred when membranes had been blocked in 5% BSA, 1xTBS and 
immunoblotting was carried out overnight at 4°C. CR1 was co-incubated with AMPK 
at 30°C in the presence or absence of ATP. Kinase reactions were terminated by the 
addition of SDS loading buffer. 50ng of fusion protein was then loaded per lane and 
resolved using 12% SDS-PAGE. Proteins were electrotransferred and membranes 
immunoblotted with UCL-89 (5pg/ml). UCL-89 was observed to cross reacted with 
CR1 post AMPK phosphorylation and did not recognise GST (fig. 30). There was a 
small amount of cross-reactivity with unphosphorylated CR1 but this was trivial in 
comparison to the enhancement in signal achieved through phosphorylation. To 
conclusively demonstrate that UCL-89 was recognising S917 phosphorylation 
peptide blocking assays were performed. These showed that addition of even 50ng 
of phospho-peptide to the antibody containing solution dramatically reduced UCL-89 
recognition of phosphorylated CR1, whereas addition of up to 1pg of 
dephosphorylated peptide had little effect upon immunoreactivity.
5.2.8 UCL-89 cross reacts with a ~110-120kDa doublet from rat brain
membranes
To investigate whether S917 is phosphorylated in vivo rat brain membranes were 
prepared including the phosphatase inhibitors sodium fluoride (50mM) and sodium 
pyrophosphate (10mM) in all buffers. 200pg of membranes were then boiled per 
sample in SDS loading buffer for 5 minutes prior to resolution using 8% SDS-PAGE. 
Proteins were electrotransferred and membranes were immunoblotted with UCL-89 
in the presence or absence of 100ng phospho-peptide. A doublet band was detected 
at between 110kDa and 120kDa that was completely blocked by co-incubation of the 
antibody with 100ng phospho-peptide. These bands correspond with the predicted 
molecular weights of GABAB(ia) and GABAB(ib) respectively.
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5.2.9 Other effects of phosphorylation
S917 forms the final amino acid of the coiled coil motif within the receptor. It was 
therefore tempting to speculate that phosphorylation of this residue might alter the 
binding properties of the coil and thus the subunit. To determine whether this might 
occur I analysed the effect that phosphorylation had upon the interaction of GABAB(d 
with GABAB(2). To do this overlay assays were performed where 10pg of either GST, 
AMPK phosphorylated or mock-phosphorylated CR1 or CR1 with a phosphorylation 
mimicking S917D mutation were resolved on a 12% SDS-PAGE gel. Proteins were 
then eiectrotransferred to nitrocellulose and re-natured in the presence of decreasing 
concentrations of guanidine hydrochloride. A GST fusion protein of the carboxy- 
terminal of GABAB(2) (CR2) was then phosphorylated with PKA using 32PyATP spiked 
ATP and used to probe the membranes in an overlay assay. After extensive washing 
the membrane was exposed to phosphorimager and binding between the different 
preparations of CR1 and CR2 was quantitated. The GST control showed no 
detectable binding but the intracellular domains strongly bound to one another. 
Interestingly there was no significant change in the affinity of the domains for one 
another irrespective of either phosphorylation or mutation of S917 (fig. 31). This 
suggests that phosphorylation at this residue has little effect upon the interaction 
between GABAB(i) and GABAB(2).
CREB 2 /ATF 4 is a transcription factor that has been demonstrated to strongly 
interact with the carboxy-terminal domain of GABAB(i) by several independent groups 
(Nehring et al., 2000; Vernon et a!., 2001; White et a/., 2000). The precise function of 
this interaction is as yet undetermined as is a mechanism by which the interaction is 
regulated. The site of interaction has been thoroughly mapped in yeast and involves 
the coiled coil of GABAB(i). To determine whether phosphorylation of S917 could alter 
the binding of GABAB(i} to CREB2 pulldowns were carried out using either GST or 
CR1 that had been either phosphorylated or not by AMPK. To ensure that the effect 
of phosphorylation on the fusion protein and not the actual kinase assay per se 
(30min incubation in kinase buffer at 30°C) was being tested the negative control 
involved carrying out the same kinase assay in the presence of AMPK but the 
absence of ATP. Fusion proteins were then removed from the kinase assay and 
added to brain lysates prepared according to Vernon et al., (Vernon et al., 2001).
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Pulldown assays were performed and fusion purifying proteins resolved using 12% 
SDS-PAGE. Gels were electrotransferred and probed with an antibody specific to 
CREB2 (Santa Cruz). CREB2 was observed to strongly associate with CR1 alone 
and not with GST. Phosphorylation of CR1 by AMPK prevented the interaction 
between CREB2 and GABAB(i) (fig. 31b).
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Figure 30 Purification of phospho-specific antibody to S917
a) Immunising peptide
b) UCL-89 specificallly recognises CR1 after AMPK phosphorylation
c+d) Immunoreactivity is blocked by phospho-peptlde but not de-phospho peptide 
demonstrating phospho-specificity of UCL-89
e) Preliminary blots from brain membranes show doublet of immunoreactivity at 115kDa 
blocked only by phospho-peptlde
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Figure 31 Other effects of phosphorylation
a) Overlay assay was performed against Gst, CR1, CR1 post-ampk 
phosphorylation and CR1 S917D, probing with CR2.
Phosphorylation by AMPK or mutation of S917 to aspartate did not 
affect binding of CR2 (replicative experiment)
b)Pulldown assays were performed from brain lysates with CR1 that 
had previously been either mock-phosphorylated or phosphorylated 
by AMPK. Proteins were resolved using SDS-PAGE and transferred to 
nitrocellose membranes. These were then blotted with a-CREB2 
antibody. CREB2 was observed to run as a dimer and associated 
exclusively with non-phosphorylated CR1 (replicative experiment).
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5.3 Discussion
The yeast two-hybrid interaction between a1 AMPK and the carboxy-terminal tail 
of GABAb(1) involved the carboxy-terminal half of the a1 subunit. Further delineation 
of putative interaction site using in vitro translated a1 AMPK as a bait was carried 
out, but significant binding between the fusion protein and the translation product was 
unachievable. This was observed over a range of different conditions using a variety 
of buffers. However, as demonstrated above, active AMPK strongly associates with 
the carboxy-terminal tail of GABAB(i) from brain. This indicates that other factors not 
present in the translation reaction help to confer binding. It could be that post- 
translational modifications of a1 AMPK are important to determine the correct folding 
and therefore binding to GABAB(i). Another possibility is that AMPK only binds to 
GABAB(1) when activated, i.e. phosphorylated at threonine 172, and other possible 
sites. Activation is unlikely to occur in reticulocyte lysates, for not only is the presence 
of the upstream AMPKK unknown in this lysate, but also reticulocyte contains an 
ATP-regenerating system that would maintain AMPK in its inactive state (Woods et 
ai., 1996). Whether the entire heterotrimeric AMPK complex binds to GABAB(1) is not 
clear, but varying expression patterns of different subunits suggest that AMPK may 
exist in confirmations other than the heterotrimeric form (Woods et al., 1996). 
Because the molecular weight of the p subunit of AMPK is 38kDa I was able to probe 
the same transferred membranes from pull-downs that had shown an association 
with the a subunit. However, I was unable to obtain a signal from pull-down lanes, 
and moreover the signal present from lysates itself was very weak. Empirically I 
observed strong p AMPK subunit immunoreactivity in western blots from crude brain 
membranes when loading a similar amount of protein to that in the lysates. This 
indicates differences in the solubility of the p subunit, which can be myristoylated at 
its N-terminus (Mitchelhill et al., 1997) and the a subunit, and allows for the possibility 
of an a subunit fraction not bound to p subunit. This would not be entirely without 
precedent, for within skeletal muscle the amount of a subunit greatly exceeds that 
present for either pand y, denoting a large proportion of the a subunit is not 
complexed with p and y. It does not appear that the presence of the p and y subunits 
are essential for catalytic activity, but instead they act as modulators of both activity 
and cellular localisation. Because the binding sites on a AMPK of GABAB(i) and p
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AMPK subunit overlap it may be that the binding of either p AMPK or GABAB(d is 
mutally exclusive to a AMPK. Unfortunately time did not allow for further investigation 
of this possibility.
A further controlling experiment to analyse the specificity of UCL-89 would be to 
blot brain homogenates obtained from GABAB(i) knockout mice. There should be no 
cross-reactivity with proteins in these homogenates, verifying that the bands 
observed in wild type brain are from GABAb receptors.
Throughout this study on the activity I have been hampered by the lack of a non­
toxic method by which to manipulate the activity of AMPK. Unlike PKA specific 
activators of AMPK do not as yet exist. I experimented with several toxic activators 
including oligomycin, but it is difficult to tell whether effects observed are due to 
AMPK activation. Metformin however is non-toxic even at relatively high 
concentrations is non-toxic. However it is not as potent as the metabolic poisons 
(Zhou et al., 2001; Fryer et al., 2002), and in neurones I did not record an increase in 
phosphorylation of more than -80% at T172. This increase in T172 phosphorylation 
was prolonged over several hours (fig. 29) and was great enough to have an 
apparent effect. Although time considerations meant that investigations into the 
physiological effects of activating AMPK were of a preliminary nature metformin 
significantly increases the surface levels of GABAb receptors probably through the 
insertion of new receptors. Similar to in COS cells where the mimicry of 
phosphorylation of both S917 and S923 enhanced trafficking of the receptor, it may 
be that phosphorylation in neurones helps overcome ER retention and may more 
efficient trafficking of the complete receptor. Further work of an electrophysiological 
nature is needed to confirm that these additional receptors are functional. If inserted 
receptors are functional however, this may represent a novel mechanism for 
modulating neuronal function in the onset of metabolic stress. An enhancement in 
GABAb activity might be expected to lead to a decrease in neuronal firing, and thus 
decrease the metabolic demand. Analogous to this possible mechanism, it has been 
previously demonstrated that phosphorylation of NMDA receptors channels can 
enhance surface delivery, most probably by helping to overcome ER retention (Scott 
et al., 2001).
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Ideally the most appropriate experiments to carry out to determine whether AMPK 
has an effect upon GABAb receptor surface level and signalling would be to carry out 
cell surface studies and electrophysiology in neurones from mice deficient in the 
catalytic subunit of AMPK. Recently data has been reported from mice deficient in the 
a2 catalytic subunit of AMPK (Viollet et al., 2003). Although the study concentrated 
on measuring the metabolic function of these mice, it was noted that they had altered 
autonomic responses consistent with enhanced catecholamine release. This was 
proposed to be due to a central defect in the control of sympathetic activty, (Viollet et 
al., 2003) indicating AMPK activity may modulate the sympathetic nervous system.
The observation that CREB-2 no longer associates with phosphorylated CR1 was 
interesting and may provide a possible mechanism controlling this interaction. The 
fact that phosphorylation did not affect the affinity of CR1 for CR2 shows that this site 
may be phosphorylated within the complete receptor. This, in combination with the 
immunoprecipitation data suggests that as well as possibly regulating receptor 
trafficking, it is feasible that AMPK may interact with and regulate the function of the 
heterodimerised receptor in response to cell stress.
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CHAPTER SIX Final Discussion
6.1 Summary
Regulation of GPCR signalling is crucially important in controlling neuronal 
activity. An intricate system involving kinase activation and subsequent arrestin 
mediated receptor sequestration has evolved to allow the desensitisation of activated 
GPCRs (Pierce et al., 2002). Much of this mechanism has been delineated in 
recombinant expression systems, but the use of knockout animals has confirmed its 
importance in the control of GPCR activity in neurones (Luttrell & Lefkowitz 2001). 
This thesis describes work undertaken to identify pathways that can control the 
surface number and hence the signalling of GABAb receptors in heterologous and 
native systems. In addition I have also undertaken the preliminary characterisation of 
a novel interaction between the stress activated kinase AMPK and GABAB(i). This 
interaction may have importance in governing surface GABAb receptor numbers and 
activity.
Initial studies in COS-7 cells demonstrated that both GABAb receptor subunits are 
basally phosphorylated and that, surprisingly, agonist has no effect upon the level of 
this phosphorylation. Overexpression of several different GRK constructs did not 
confer an agonist-induced phosphorylation upon GABAb receptors and this 
suggested that the classical agonist-induced increase in phosphorylation observed in 
a large number of GPCRs was not relevant to GABAb receptor signalling. In support 
of this I noted no interaction between the arrestin proteins and GABAb receptors, 
regardless of agonist application, and no significant internalisation of the receptor in 
COS-7 cells.
Further studies in cultured neurones showed that the lack of internalisation 
observed in a recombinant system was replicated with native receptors. 
Furthermore, it was demonstrated that surface GABAb receptors have an unusually 
long half-life, in excess of 30h. Application of the agonist baclofen significantly and 
specifically reduced the half-life of surface GABAb receptors but this was only 
observed over long time periods. Interestingly the presence of lysosomal inhibitors 
did not alter degradation rates, and coupled to the lack of a detectable internalised
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pool, it is probably that GABAb receptors are either degraded at the surface 
membrane or are rapidly degraded upon internalisation so as to prevent the 
accumulation of an internalised pool.
Modulation of baclofen induced degradation was achieved by activating PKA or 
pathways leading to PKA activation. Activation of GABAb receptors negatively 
regulates adenylyl cyclase activity and so leads to a decrease in intracellular cAMP 
and hence a reduction in PKA activity. Thus stimulation of PKA by the application of 
exogenous activators would be expected to compensate for the effect of baclofen. 
Analysis of the phosphorylation state of S892 in GABAB(2) has previously shown that 
chronic baclofen can reduce phosphorylation at this site (Couve et al., 2002). In the 
study presented here it was possible to correlate the protective effect of PKA 
activation with increased phosphorylation at S892. This strongly infers that 
phosphorylation at S892 is not only important in the relatively short-term control of 
desensitisation events, but also in the long-term modulation of surface receptor 
number. In concordance with the increase in degradation rate elicited by baclofen, it 
was found that chronic baclofen treatment decreased the number of GABAb 
receptors at the neuronal surface. Interestingly though, chronic baclofen treatment 
did not trigger downregulation as measured by total protein levels of GABAb receptor. 
It thus appears that insensitivity to agonist-induced downregulation is another 
distinguishing feature of GABAb receptors. This is in agreement with the fact that 
GPCR endocytosis is an important preliminary step to downregulation (Tsao et al.,
2001). This lack of downregulation helps to explain why, in the clinical context of 
treating spasticity, GABAb receptors remain sensitive to baclofen after years of 
administration (Meyerthalereta!., 2001).
The remainder of this thesis focussed upon studying the phosphorylation of 
GABAb(i ) subunit. GABAB(i) is phosphorylated to a high degree in COS-7 cells and 
this phosphorylation appears confined to the intracellular carboxy-terminal domain. I 
then observed that fusion proteins encoding the carboxy-terminal domain of GABAB(i) 
provide a substrate to a kinase associating from brain homogenates. This kinase 
appeared insensitive to inhibitors of classical second-messenger activated kinases, 
but was unexpectedly robustly activated by heparin. Yeast two-hybrid screens carried 
out by collaborators at GlaxoSmithline identified the catalytic subunit of AMPK as a
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putative interacting protein with the carboxy-terminal domain of GABAB(i). In this 
thesis I have confirmed that GABAB(i) can form an in vitro substrate for AMPK. 
Intriguingly the AMPK phosphorylation of GABAB(i) was also stimulated by heparin to 
a similar degree to the kinase associating from brain suggesting they are one and the 
same. Use of site-directed mutagenesis allowed me to map the major site of AMPK 
phosphorylation to S917 within the carboxy-terminal domain, although there 
appeared to be residual phosphorylation at other sites, most probably S923.
Pull-down assays performed from brain lysates demonstrated that as well as 
interacting in yeast, AMPK was able to interact with GABAB(i) in brain. Western 
blotting demonstrated that specifically the activated a subunit of AMPK was able to 
associate with GABAB(i). Kinase assays performed after pulldowns demonstrated an 
enhancement in GABAb(1) phosphorylation upon the addition of 5’AMP, confirming the 
kinase was in an active state. Immunoprecipitations confirmed that AMPK can 
associate with GABAB(2) in brain. Because these two proteins are unable to interact in 
yeast, coupled to the fact that almost all GABAb(2) is heterodimerised with GABAB(i) in 
brain (Benke etai., 1999), the co-immunoprecipitation of the two proteins is coherent 
with AMPK interacting with the complete GABAs receptor. It is notable that this is the 
first reported yeast 2-hybrid hit with GABAB(i) that probably associates with the 
dimerised receptor.
Aspartate mutations of GABAB(i) S917 and S923 suggest that sequential 
phosphorylation of both S917 and S923 can enhance surface delivery of the 
dimerised receptor, implicating phosphorylation in GABAb trafficking events. It was 
also noted that mutation of both these residues permits the ER exit of GABAB(i) in the 
absence of GABAb(2) co-expression. I then went on to affinity purify an antibody 
specific to phospho-S917 -  UCL-89. UCL-89 strongly cross-reacted with the carboxy- 
terminal domain of GABAB(i) but only after phosphorylation by AMPK. Preliminary 
investigations using UCL-89 suggested that GABAB(i) is phosphorylated at S917 site 
in vivo. Early data also indicates that activators of AMPK can influence the surface 
receptor complement of neurones.
Phosphorylation of GABAB(1) by AMPK has no effect upon the interaction of 
GABAb(i ) with GABAe^ ), but it does prevent the interaction of GABAB(i) with CREB2. 
The lack of effect upon the interaction between GABAB(i) and GABAb(2) by
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phosphorylation suggests that this residue can be phosphorylated in the complete 
receptor implying that phosphorylation of S917 may affect receptor activity. The 
demonstration that CREB2 is no longer able to Interact from brain with 
phosphorylated GABAB(i) points towards a mechanism controlling the interaction 
between these two proteins. It is highly probable that the position of S917 at the end 
of the coiled coil allows phosphorylation at this site to regulate other protein 
interactions through the coiled coil.
6.2 Implications of GABAb receptor surface stability
Recent work demonstrates that GABAa receptors are highly dynamic and that 
their surface number is tightly regulated by endocytotic pathways (Kittler et al., 2000; 
Kittler & Moss 2003). This means that changes in receptor number can rapidly and 
critically influence synaptic efficacy, leading to continual variations in IPSPA. The 
inhibitory response provided by GABAb receptor activation is markedly different both 
in onset and duration from that of GABAa inhibitory activity. The role of GABAb 
receptors coupling to inwardly rectifying potassium channels is to provide an 
inhibitory current that is longer lasting than that provided by GABAa receptors. The 
inherent stability of GABAb receptors observed gives a molecular basis for this 
physiological action. It is conceivable that if GABAb receptors were rapidly trafficked 
in a manner akin to other GPCRs upon activation then the receptors would be unable 
to provide the prolonged inhibitory IPSPB. It is plausible that the heterodimeric 
configuration of GABAb receptors precludes interactions with GRKs and arrestins that 
may otherwise occur. An interesting hypothesis is that GABAb receptors have 
evolved a heterodimeric nature precisely for this reason.
Although this study demonstrated an inherent surface stability of GABAb 
receptors, I did note increases in their degradation in response to chronic agonist 
application. This identifies a novel mechanism by which neurones can tailor the 
complement of GABAb receptors over longer time periods. The observation that 
activation of PKA or PKA stimulating pathways in the form of p adrenoceptors 
reduces degradation suggests baclofen triggered degradation is allied to prolonged 
dampening of PKA activity elicited through baclofen application. It could be argued 
that the increase in GABAb degradation and the concomitant decrease in surface
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GABAb receptors should be viewed as a cellular attempt to rectify this perturbation. 
Interestingly, the protective effect of PKA activation was correlated to an increase in 
the phosphorylation of S892 in GABAB(2), which otherwise is reduced in response to 
chronic agonist (CoBtfeg/ 2002). Previously it had been proposed that 
phosphorylation of S892 prevented the internalisation of the receptor (Couve et al.,
2002). However, the results presented in this thesis and by other groups show that 
GABAb receptors do not readily internalise. It is more likely that phosphorylation of 
S892 prevents other post-receptor activation sequelae occurring, thus leading to 
delayed desensitisation in tandem with protection from surface degradation over 
chronic periods. S892 phosphorylation may be controlled as function of total PKA 
activity. A large number of drugs used to treat psychiatric conditions such as 
depression and anxiety act either directly or indirectly at p- adrenoceptors which 
activate adenylyl cyclase. It is likely that they have downstream effects upon GABAb 
receptor degradation, possibly by influencing the phosphorylation at S892. In 
agreement with this possibility it has been recently been shown that chronic cocaine 
greatly decreases GABAB(2) receptor phosphorylation and is correlated to reduced 
GABAb receptor activity (Xi et al., 2003).
6.3 Regulation of GABAb receptor function in response to metabolic 
demands
Immunolabelling studies of GABAb localisation demonstrate that in the cerebellum 
GABAB(i) stains in a zebrin (aldolase-C) like pattern (Fritschy et al., 1999). Aldolase-C 
is a marker of metabolic acitivity and this implies that GABAb receptor expression can 
be regulated as a function of metabolic activity. The interaction between GABAB(i) 
and AMPK is particularly exciting because it provides additional evidence that events 
affecting the neuronal metabolic status may have downstream effects upon inhibitory 
neurotransmission. The data presented suggests that AMPK is able to associate with 
dimerised GABAb receptors, and therefore it is likely that AMPK phosphorylates sites 
is able to act to modify receptor G-protein coupling. Mutagenesis studies indicate that 
phosphorylation at S917 and S923 may affect trafficking of the receptor. This is most 
probably due to change of charge at S923 interupting the RSRR ER retention motif 
which it lies in. Metformin causes an increase in surface GABAb receptor number in
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neurones. This is unlikely to be due to an effect on protein synthesis because 
activators of AMPK have catabolic as opposed to anabolic activities. Whether this 
increase correlates with phosphorylation requires further investigation. UCL-89 was 
raised to monitor the phosphorylation state of GABAb(1) in the face of metabolic stress 
but unfortunately time-constraints meant that this study could not be contained within 
this thesis.
6.4 Future Directions
It is apparent that surface GABAb receptors are exceptionally stable, but 
eventually they are degraded in a non-lysosomal manner. The mechanism behind 
GABAb degradation requires further clarification; receptors may be degraded by 
membrane associated proteases or they may internalise (albeit extremely slowly) and 
be rapidly cleaved so that an intracellular pool is not observed. The protective effect 
of phosphorylation also needs further analysis. It could be due to the promotion of 
interactions of GABAb(2) with anchoring molecules or by targeting GABAb receptors to 
less dynamic regions of the cell. Further work will be useful to clarify the precise role 
of phosphorylation at serine 892 and to screen for proteins that interact with this 
region.
Mechanisms regulating AMPK function in neurones have not been investigated 
and little is known about how neuronal AMP levels are regulated. Future work should 
determine whether other neuronal phenomena such as LTP formation can activate 
AMPK in vivo. It is also conceivable that a downstream effect of cAMP accumulation 
is an increase in AMP levels due to the action of phosphodiesterases. Because it is 
very difficult to pharmacologically manipulate AMPK function without causing non­
specific effects, future studies of AMPK regulation of GABAb activity could ideally 
take place in neurones from AMPK knockout mice using electrophysiological and cell 
biology techniques. It is possible that the charge change through phosphorylation 
may also alter receptor to G protein coupling and this could be studied using mutants 
and FLIPR assays. The intracellular domains of GABAb receptor subunits may 
interact directly with G proteins in a phospho-dependent manner as observed in 
mGluR receptors (El Fae & Betz 2002) and this could be investigated with binding 
studies.
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